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Aims of the thesis 
Protein aggregates and particles are an important instability product in 
formulations of therapeutic proteins, such as monoclonal antibodies, and need to 
be analyzed in formulation development, production, and for release. This is 
required by the authorities due to the potential loss of activity, increasing 
concerns about the immunogenicity, and to gain the broadest possible knowledge 
of product properties to ensure product quality. In particular the analysis of 
visible and subvisible particles (i.e. in the lower µm range) is currently a hot topic 
in the development of therapeutic protein formulations which constantly gains 
more importance by novel findings, additional available techniques, and new 
regulatory requirements. 
The overall goal of this thesis is to identify and evaluate critical factors for protein 
particle analysis and to apply this knowledge for the development of novel 
standardized protein-like particles. This is crucial because up to now the analysis 
of particles in therapeutic protein formulations relies on the calibration of the 
instruments with polystyrene standards which differ clearly from protein particles 
in their properties. 
Various techniques for protein particle analysis are available on the market and 
additional techniques are constantly under development. Thus, the first main 
objective of this thesis is to comparatively evaluate existing and novel techniques 
for quantification and characterization of particles in therapeutic protein 
formulations. This includes a comprehensive research on the state of the art of 
available techniques, as well as scientific applications and literature on these 
methods (Chapter 1). 
As a second step, techniques with novel measurement principles or from different 
application fields which are not yet state of the art for protein particle analysis 
should be experimentally evaluated for their suitability to characterize 
proteinaceous particles (Chapter 2). This should lead to a guideline which method 
is suitable for which purpose and which obstacles are to be considered in the 
data evaluation. 
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Additionally, for selected techniques, the focus is set on specific critical topics of 
scientific interest for the development of protein pharmaceuticals: the 
differentiation of silicone oil droplets and protein particles, which is currently 
highly relevant due to the trend of protein formulation in prefilled syringes 
(Chapter 3), and evaluation of the performance of different flow imaging 
microscopy instruments, which is crucial for correct data interpretation    
(Chapter 4). 
The second main objective of this thesis is the identification of typical and crucial 
properties of protein particles to enable the development of more proteinaceous 
particle standards. Additionally, these factors should provide the scientific basis 
for a better interpretation of particle analysis data generated by different 
measurement principles. A material screening based on the optical particle 
properties shape and transparency should be performed to identify potential 
materials and preparation methods for novel standardized protein-like particles 
(Chapter 5). 
Furthermore, novel methods to determine the critical protein particle properties 
density and refractive index, which are not well characterized up to now, are to 
be developed (Chapter 5 and Chapter 6). Understanding these properties and 
their relevance for protein particle analysis should support the development of 
standardized protein-like particles. Additionally, potential applications of those 
novel standards for protein particle analysis should be evaluated. Finally, general 
recommendations for protein particle analysis in the future are derived    
(Chapter 6). 
 
           Chapter 1
           
Introduction: Particles in therapeutic protein 
formulations – overview of analytical methods 
 
Abstract 
The presence of particles is a major issue during therapeutic protein formulation 
development. Both proteinaceous and non-proteinaceous particles need to be 
analyzed not only due to the requirements of the Pharmacopeias, but also to 
monitor the stability of the protein formulation. Increasing concerns about the 
immunogenic potential together with new developments in particle analysis make 
a comparative description of established and novel analytical methods useful. 
Our review aims to provide a comprehensive overview on analytical methods for 
the detection and characterization of visible and subvisible particles in 
therapeutic protein formulations. We describe the underlying theory, benefits, 
shortcomings, and illustrative examples for quantification techniques, as well as 
characterization techniques for particle shape, morphology, structure and 
identity. 
 
The following chapter was published in a slightly modified version as a review article in the Journal 
of Pharmaceutical Sciences and appears in this thesis with the journal’s permission: 
S. Zölls, R. Tantipolphan, M. Wiggenhorn, G. Winter, W. Jiskoot, W. Friess, A. Hawe: “Particles in 
therapeutic protein formulations, part 1:oOverview of analytical methods”; J Pharm Sci 
101(3):914-935 (2012) 
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1 General introduction 
Approximately half of all new drugs approved by the FDA in the last few years 
are biopharmaceuticals,1 mainly therapeutic proteins and especially monoclonal 
antibodies.2 A major challenge during formulation development of these products 
is overcoming their limited stability. Among the various degradation mechanisms 
a protein can undergo,3,4 the formation of protein aggregates and particles is a 
particular concern.5 Aggregates are generally defined as assemblies of protein 
monomers and can vary in many aspects such as size, reversibility, and 
structure. For instance, their size can range from dimers in the nm range to large 
aggregates of hundreds of microns which are visible to the human eye. These 
larger aggregates are often also designated as particles.6,7 However, not only 
proteinaceous particles, but also non-proteinaceous particles, e.g. originating 
from packaging material or excipients, can influence product quality and 
therefore need to be analyzed.8,9 
Our review aims to give an overview on methods for both quantification and 
characterization of visible and subvisible particles in therapeutic protein 
formulations. On the basis of the current classification of protein aggregates and 
particles,10 for this article particles are defined as material with a size above 
0.1 µm and are further classified into subvisible (0.1 – 100 µm) and visible 
particles (above 100 µm); submicron particles (0.1 – 1 µm) are a subgroup of 
subvisible particles. 
Whereas particles above 10 µm have received attention in the development of 
therapeutic protein products already for a long time due to the requirements of 
the Pharmacopoeias for parenteral products,11-13 the detection and 
characterization of subvisible particles below 10 µm has only recently gained 
more importance. This is due to increasing concerns about the potential 
immunogenicity of subvisible particles – both proteinaceous particles,14 non-
proteinaceous particles,15 and non-proteinaceous particles with adsorbed 
protein.16,17 Moreover, new techniques for the analysis of subvisible particles 
have emerged in the last few years, enabling a more detailed characterization of 
these impurities or contaminants.8,9 Several reviews summarizing methods for 
the quantitative analysis of protein aggregates and particles6,18,19 and one 
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describing analytical methods for protein particles down to 2 µm20 are available. 
Our review includes not only particle quantification techniques, but also analytical 
characterization methods that provide information about particle characteristics 
such as shape, morphology, structure and identity. Moreover, we discuss new 
developments in particle analysis. We provide a comprehensive overview of 
particle analysis for pharmaceutical protein products with the presented methods 
summarized in Table 1-1 and Table 1-2. The sections describing the individual 
analytical methods are sorted according to measurement principle and cover the 
underlying theory, advantages, shortcomings, and illustrative examples. 
Analytical techniques for nanometer protein aggregates with a very limited use 
for subvisible and visible particles such as size-exclusion chromatography and 
analytical ultracentrifugation are explained only briefly. For the pharmaceutical 
application of the described methods in development and production of 
therapeutic proteins, the reader is referred to Part II “Applications in the 
Pharmaceutical Industry” of the review article by Narhi et al.21 
  
INTRODUCTION                           PARTICLES IN THERAPEUTIC PROTEIN FORMULATIONS 
6 
 
Table 1-1: Overview of analytical methods for (protein) particle analysis, optical 
quantification methods. 
Principle Method Destructive 
Isolation of 
particles 
required 
Further 
information 
Visual 
inspection 
Human or 
automated visual 
inspection 
No No 
Detects only 
presence of visible 
particles 
Microscopic 
methods 
Light microscopy Yes Yes 
Manual data 
acquisition required 
Fluorescence 
microscopy 
Yes Yes/no a 
Manual data 
acquisition required 
Flow Particle Image 
Analyzer  
(Sysmex FPIA-3000) 
Yes No - 
FlowCAM Yes No - 
Micro-Flow Imaging Yes No - 
Electron microscopy Yes Yes - 
Atomic force 
microscopy 
Yes Yes - 
Light 
absorption / 
blockage 
Light obscuration Yes No - 
Nephelometry / 
turbidimetry 
No No 
Detects only 
presence of particles 
/ aggregates 
Light 
scattering 
Dynamic light 
scattering 
No No - 
Nanoparticle 
tracking analysis 
No No - 
Static light 
scattering  
No No - 
 a Yes/no = isolation possible, but not required; b ECD = equivalent circular diameter; - = no or 
very limited information provided 
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(continued from previous page) 
Provided information 
Size 
Size 
distribution 
Shape Structure Identity 
 
- 
 
- - - - 
Actual size Yes 
Different 
shape 
factors 
- - 
Actual size Yes 
Different 
shape 
factors 
Hydrophobic 
regions by 
selective 
fluorescent dyes 
Limited 
Different 
diameters (e.g. 
ECD b; Feret 
diameter) 
Limited 
Aspect 
ratio; 
circularity 
- - 
Different 
diameters (e.g. 
ECD b; Feret 
diameter) 
Yes 
Aspect 
ratio; 
circularity 
Transparency 
related values 
Fluorescence option: 
distinction of protein 
vs. non-protein 
material by selective 
fluorescent dyes 
Different 
diameters (e.g. 
ECD b; Feret 
diameter) 
Yes 
Aspect 
ratio; 
circularity 
Transparency 
related values 
Limited (distinction 
by software filters 
based on optical 
properties) 
Limited - Limited 
Surface 
morphology 
- 
Limited - Limited 
Surface 
morphology 
- 
ECD b Yes - - - 
- - - - - 
Hydrodynamic 
diameter 
Limited - - - 
Hydrodynamic 
diameter 
Limited - - - 
Molecular weight Limited - - - 
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Table 1-2: Overview of analytical methods for (protein) particle analysis, non-optical 
quantification methods, separation methods and spectroscopic methods. 
Principle Method Destructive 
Isolation of 
particles 
required 
Further 
information 
Electrical 
sensing zone 
Coulter counter Yes No 
Sufficient buffer 
conductivity 
required 
Resonant 
mass 
measurement 
Archimedes Yes No 
Density information 
for liquid and 
particles required 
for correct size 
determination 
Separation 
methods 
Size exclusion 
chromatography 
Yes No 
Detects indirectly 
fraction of insoluble 
particles 
Analytical 
ultracentrifugation 
Yes No 
Very limited 
applicability for 
particles 
Disk centrifugation Yes No - 
Asymmetrical flow 
field flow 
fractionation 
No No 
Applicability for 
particle analysis not 
fully established 
Fluorescence 
activated particle 
sorting 
No No 
Preparative 
separation possible; 
applicability for 
particle analysis not 
fully established 
Spectroscopic 
methods 
Circular dichroism No No - 
FT-IR  
spectroscopy / 
microscopy 
No Yes/no a - 
Raman 
spectroscopy / 
microscopy 
No Yes/no a - 
Intrinsic 
fluorescence 
No No - 
Extrinsic 
fluorescent dyes 
Yes Yes/no a - 
Energy dispersive 
X-ray spectroscopy 
Yes Yes - 
a Yes/no = isolation possible, but not required; b ESD = equivalent spherical diameter; - = no or 
very limited information provided  
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(continued from previous page) 
Provided information 
Size 
Size 
distribution 
Shape Structure Identity 
ESD b Yes - - - 
ESD b Yes - - 
Differentiation 
between positively 
and negatively 
buoyant particles 
(e.g. silicone oil 
droplets and 
protein particles) 
Hydrodynamic 
size 
- - - - 
Molecular 
weight 
Yes - - - 
Hydrodynamic 
size 
Yes - - - 
Hydrodynamic 
size; molecular 
weight if 
coupled with 
MALLS detector 
- - - - 
Hydrodynamic 
size 
Yes - - 
Separation of 
protein vs. non-
protein material by 
selective 
fluorescent dyes 
- - - 
Secondary, 
tertiary structure 
- 
Only in IR 
microscopy 
Limited, only 
in IR 
microscopy 
Limited, only 
in IR 
microscopy 
Secondary 
structure 
By comparison 
with database 
Only in Raman 
microscopy 
Limited, only 
in Raman 
microscopy 
Limited, only 
in Raman 
microscopy 
Secondary 
structure 
By comparison 
with database 
- - - 
Conformational 
changes 
- 
- - - 
Conformational 
changes 
Limited 
- - - - 
Atomic 
composition 
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2 Goals and challenges associated with 
particle analysis 
The tolerated amount of visible and subvisible particles in parenteral therapeutic 
protein products is restricted by regulations as described in the 
Pharmacopoeias,11-13,22 which makes quantification of protein particles essential 
in development and production of therapeutic proteins. The size of visible 
particles is not specified in the Pharmacopoeias, as the detection of particles by 
the human eye depends amongst others on personal eyesight, light conditions, 
and used test settings. However, the specifications for subvisible particles include 
particle sizes ≥ 10 µm and ≥ 25 µm,11,13 which makes also size determination of 
the counted particles necessary. 
Although the identification of particles present in parenteral protein products is 
not required by the Pharmacopoeias, a distinction between non-proteinaceous 
and proteinaceous particles is relevant in case of protein therapeutics. Non-
proteinaceous material, e.g. particles shed from pumps or primary packaging 
material (including silicone oil droplets in prefilled syringes) or particles formed 
by degradation of excipients (e.g. polysorbate),23 can trigger protein aggregation 
by heterogeneous nucleation and might be related to increased 
immunogenicity.16,24,25 Root cause analysis to determine the source of the 
particles is an important part of any investigation and can result in minimizing 
the occurrence of non-proteinaceous particles. In addition, false positive 
“particles” such as air bubbles need to be distinguished from real particles for a 
correct evaluation of the particle load in the analytical characterization. However, 
only few techniques are able to discriminate between proteinaceous and non-
proteinaceous particles, e.g. Raman spectroscopy/microscopy,26 IR 
spectroscopy/microscopy,27 and to a certain extent also methods involving 
fluorescent dyes28 and flow imaging microscopy methods29,30 (Table 1-1, Table 
1-2). 
For proteinaceous particles, it can be helpful during formulation development to 
further discriminate the particles with respect to e.g. size, shape or structure 
(Table 1-3). Depending on the (stress) conditions the protein had been exposed 
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to, several types of aggregates and particles can be detected allowing 
conclusions about the susceptibility of the protein to distinct stress conditions 
and the identification of means to prevent this instability.31 
Table 1-3: Overview of measurable particle properties. 
Property Reported as 
Size 
Hydrodynamic diameter 
Equivalent circular diameter (ECD) 
Equivalent spherical diameter (ESD) 
Feret diameter 
Molecular weight 
Concentration 
Total particle concentration 
Size distribution 
Shape 
Aspect ratio 
Circularity 
Optical properties 
Transparency 
Refractive index 
Identity 
Chemical identity  
(proteinaceous vs. non-proteinaceous) 
Further characterization of proteinaceous 
particles (secondary/tertiary structure) 
 
Many analytical methods for (protein) particles are based on the interaction of 
particles with light (Figure 1-1). Methods based on light scattering require a 
substantial difference in refractive index of the particles and the surrounding 
liquid. However, protein particles are often translucent with a supposed refractive 
index between 1.33 and 1.4.29 This value is close to that of aqueous buffers and 
highly-concentrated protein solutions, thereby hampering the detection by light-
based systems.29,32 However, to our knowledge the refractive index of protein 
particles has not been analyzed up to now. It likely depends on the type of 
particle, e.g. degree of protein unfolding and packing, so the values described in 
the literature are only assumptions. Light-based systems for particle analysis rely 
on the calibration with standards, usually polystyrene beads of a clearly higher 
refractive index compared to protein particles. Therefore, the results obtained 
from these systems for protein particles need to be evaluated carefully and 
standards that resemble the proteinaceous nature of the particles more closely 
would be very helpful for data interpretation.9 When comparing particle size 
results from several analytical techniques algorithms for size determination need 
to be considered as particle size can be provided as various parameters (Table 
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1-3). A further challenge lies in the often dynamic, heterogeneous and transient 
nature of particles, as size and number of particles can change when larger 
particles dissociate into smaller ones and vice versa.24,33 
 
Figure 1-1: Schematic classification of analytical methods based on the interaction of 
particles with light. NTA, nanoparticle tracking analysis; DLS, dynamic light scattering; 
SLS, static light scattering; FAPS, fluorescence activated particle sorting; LO, light 
obscuration; CD, circular dichroism; FTIR, Fourier transform infrared spectroscopy; EDS, 
energy dispersive X-ray spectroscopy. 
 
In general, several analytical methods with different underlying principles should 
be combined for each sample to overcome the limitations of a single method in 
terms of size range (Figure 1-2), concentration range or delivered parameters. 
This comes along with comprehensive and challenging data analysis as unequal 
results may be obtained for the same parameter if different measurement 
principles are applied. Therefore, results may not always be directly comparable 
and need to be evaluated considering the underlying theory. One possibility is to 
assess the sample with several orthogonal methods to understand the limitations 
and then select one or two methods for sample to sample comparison to look for 
trends rather than focusing on actual numbers obtained. 
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Figure 1-2: Depiction of the approximate size range of analytical methods for size 
determination of subvisible and visible (protein) particles. 
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3 Methods for particle analysis 
3.1 Visual inspection 
Visual inspection by definition describes the examination of particles detectable 
by the human eye without any auxiliary equipment. The absence of visible 
particles as requirement for parenterals was originally introduced because of 
foreign particles in pharmaceutical products, e.g. dissolved from packaging 
material or introduced during production, filling and packaging processes. 
However, as protein itself can form visible particles, the significance of this 
requirement has been controversially discussed. The USP requires parenteral 
preparations to be “essentially free from visible particulates”,22 but does not 
describe a specific analytical method for visual inspection. According to the 
Ph.Eur., injections need to be “practically free from particles”, which is to be 
evaluated by eye while gently swirling the formulation in its original container for 
5 seconds in front of a white background and 5 seconds in front of a black 
background with specified light conditions.12 Depending on the individual 
eyesight, experience of the operator and experimental conditions, particles larger 
than 50 µm6 to 100 µm8 can be detected by this manual method. Furthermore, 
intensive training of the operators, e.g. with particle test kits, is required to 
obtain reliable results. Due to the dependency on the operator’s ability and 
judgment, semi-automated and fully-automated visual inspection methods have 
been developed to improve and standardize the inspection process (e.g. from 
Seidenader GmbH, Markt Schwaben, Germany or Eisai Machinery GmbH, Tokyo, 
Japan). Semi-automated systems relieve the human operator from holding and 
swirling the container and standardize thereby the sample preparation process. 
Furthermore, auxiliary devices such as light from the bottom or a magnifying 
lens in front of the analyzed container alleviate particle detection. However, the 
detection process and the evaluation itself still need to be performed personally 
by the examiner involving again the operator’s ability and judgment. In contrast, 
fully-automated systems detect particles by light reflection and transmission with 
subsequent image analysis to distinguish particles from container defects. The 
threshold for vial rejection and automated sorting is set based on Knapp 
testing,34 a validation procedure for fully-automated visual inspection systems 
showing that it is still a probabilistic and not an absolute method. As a major 
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benefit, both human and automated visual inspection allows 100% non-
destructive inspection of the complete production volume. As a limitation, visual 
inspection originally only distinguishes between absence and presence of visible 
particles and does not provide information about particle properties such as 
number, structure or origin. Though, human inspectors can be trained with a set 
of standards to distinguish air bubbles, cellulose fibers, and colored particles from 
protein particles. For a rough estimation of the amount of visible particles, the 
evaluation scale provided in the “Deutscher Arzneimittel Codex” (DAC), which 
describes the presence of visible particles in scores from 0 (no particles visible 
within 5 seconds) to 10 (particles visible immediately and clearly in great 
quantities), can be useful.35 Semi-automated visual inspection has been used to 
roughly detect differences in protein particles generated by several stress types 
in terms of number and size, thereby complementing light obscuration and 
turbidity results.33 Furthermore, additional phenomena such as foam formation, 
turbidity or particle floating can be observed by visual inspection, supplementing 
information from other analytical methods.36 
3.2 Microscopic methods 
Microscopic methods enable the visualization of particles with a resolution 
ranging from 1 µm (optical microscopy, fluorescence microscopy and flow 
imaging microscopy) down to 0.1-1 nm (electron microscopy and atomic force 
microscopy) (Figure 1-2). Those methods add an important aspect to results 
obtained from pure counting or sizing techniques. Raman microscopy and FT-IR 
microscopy combine microscopic and spectroscopic information. A disadvantage 
of all microscopic techniques is that they only analyze a small fraction of the 
sample which may not necessarily be representative for the complete sample. 
3.2.1 Optical microscopy 
Optical microscopy allows visualization, counting and sizing of particles in the 
range of 1 µm to several mm. The method is listed in the Ph.Eur.11 and USP13 for 
the analysis of subvisible particles next to light obscuration with the same 
shortcoming of a large required volume of 25 mL. The compendial method 
requires a light microscope and includes a filtration step to isolate the protein 
particles onto a filter membrane. The maximum particle counts for parenteral 
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products are specified in the Ph.Eur.11 and the USP13 as follows: For a total 
volume of 100 mL or less, the maximum particle count is specified as 
3000 particles ≥ 10 µm and 300 particles ≥ 25 µm, each per container. For a 
total volume larger than 100 mL, the maximum particle count is 12 particles 
≥ 10 µm and 2 particles ≥ 25 µm, each per mL. 
Optical microscopy is rarely used as a single technique due to potential influences 
on sample properties by the initial filtration step and a very time-consuming 
manual evaluation of particle size and number. Thus, it is mostly combined with 
other techniques, e.g. it is used to get a first impression on the particle load on 
the filter prior to analysis by FT-IR microscopy or SEM-EDS (see below)27 or 
applied to analyze particles observed by visual inspection (see above) in more 
detail, which can be done directly in solution without a filtration step.36 However, 
microscopic evaluation of unstained particles can be difficult as translucent 
protein particles are hard to detect. Furthermore, it is not easy to distinguish 
proteinaceous from non-proteinaceous particles. Staining of the particles by 
protein-reactive dyes, e.g. the “reversible protein detection kit” (Sigma, St. 
Louis, MO), can in some cases improve the detectability and at the same time 
help to distinguish proteinaceous from non-proteinaceous particles by optical 
microscopy.37 
3.2.2 Fluorescence microscopy 
Fluorescence microscopy comprises visualization, counting and sizing of particles 
stained by fluorescent dyes such as Nile Red, Congo Red, Thioflavine T or SYPRO 
orange38 (see below), using a fluorescence microscope or a confocal microscope. 
The technique enables visualization of protein particles larger than ca. 0.5 µm, 
either immobilized on a filter or even without a filtration step as the stained 
sample can be placed directly on a microscopic slide. Conventional fluorescence 
microscopes are equipped with a light source (usually a xenon or mercury lamp), 
excitation filters and emission filters which allow the emitted light to pass to the 
detector, but at the same time mask any reflected excitation light.38 In confocal 
microscopy, only a small spot of the sample is illuminated by a laser beam, and 
the detection of emitted light is restricted to the same spot. Major advantages of 
confocal over conventional fluorescence microscopy include (1) three-
dimensional information about the complete sample and (2) an increased 
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resolution by a factor of 1.4 compared to conventional fluorescence microscopy 
due the arrangement of the optics avoiding background fluorescence.39,40  
A benefit of fluorescence microscopy in general is a high sensitivity for the 
detection of protein particles. This was for example shown for monoclonal 
antibodies stained by Nile Red which allowed an earlier detection of protein 
particles compared to UV absorbance or light microscopy and also permitted 
sizing and counting of the particles.38,41 The specificity of fluorescent dyes such 
as Nile Red for hydrophobic binding regions allows the distinction of hydrophobic 
versus hydrophilic material, e.g. particles of unfolded protein versus native 
protein or non-proteinaceous particles. Other dyes, such as Thioflavine T or 
Congo Red selectively bind to amyloid structures.38 However, binding of these 
and other fluorescent dyes to non-proteinaceous hydrophobic material cannot be 
excluded. A major shortcoming of this approach is the possibility that staining of 
the sample may change particle properties.42-44 
3.2.3 Flow imaging microscopy 
Flow imaging techniques allow analyzing particles without isolation. The particles 
pass an imaging field where they are illuminated by a light source and imaged by 
a charge-coupled device (CCD) camera. Subsequent automated image analysis 
provides information about size and number in a size range from ca. 1 to 
400 µm; information about shape and different parameters connected to 
transparency or compactness of the particles can be obtained for particles from 
ca. 5 to 400 µm.45 
Three major flow imaging systems currently on the market are: Sysmex FPIA-
3000 (Flow Particle Image Analyzer, Malvern Instruments, Herrenberg, 
Germany), FlowCAM (Fluid Imaging Technologies, Yarmouth, ME) and Micro-Flow 
Imaging (MFI, ProteinSimple, Santa Clara, CA). FPIA differs from the other 
techniques in mainly two aspects: (1) The particle suspension is analyzed 
“sandwiched” between “particle sheath liquid” which causes all particles in the 
imaging field to be orientated with their largest side perpendicular to the light 
beam.46 A direct contact between “particle sheath liquid” and analyte during the 
measurement could potentially cause changes in the sample properties. In 
contrast, FlowCAM and MFI use glass flow cells of 50 to 400 µm depth as imaging 
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field. The imaging field allows analysis of larger sample volumes and eliminates 
the use of particle sheath liquid as in FPIA.29,47 However, protein particles can 
stick to the glass surface in FlowCAM and MFI and thereby disturb the analysis. 
(2) FPIA applies stroboscopic sample illumination potentially missing particles 
between the illumination intervals. In contrast, FlowCAM and MFI use an image 
capture rate which is balanced with the flow rate to pick up nearly all particles 
passing by the analysis window of the flow cell.  
All imaging techniques are suitable to analyze particle properties such as size, 
shape, and transparency and allow the application of software filters in the data 
analysis to classify particles upon different properties. In addition, FlowCAM and 
MFI provide information about particle concentration (up to about 
5,000 particles/mL for FlowCAM and 1,200,000 particles/mL for MFI, according to 
the manufacturer), whereas FPIA is less suitable to determine the particle 
concentration due to the stroboscopic illumination and the small imaging field. In 
return, FPIA delivers the highest image quality among the flow imaging 
techniques.20 FPIA analyzes only a very small amount of the applied sample 
volume (less than 1%) whereas MFI and FlowCAM can achieve a higher efficiency 
of 60-80% depending on the used instrument. 
A general benefit of all flow imaging techniques is the digital visualization of 
particles enabling profound analysis of size, shape, transparency, and related 
parameters. This can for example enable a differentiation between silicone oil 
droplets and protein particles, as shown for MFI.29,30 As a general shortcoming, 
dilution of the sample can be required if particle count limits are reached, 
thereby potentially changing sample properties.32 Furthermore, as a light-based 
technique, flow imaging microscopy relies on sufficient differences in refractive 
index between particle and solvent. As this is not always the case, especially not 
for highly-concentrated protein solutions or formulations containing high 
concentrations of excipients such as sugars, particle number and/or size could be 
underestimated.32 
Especially MFI has been recently used for the characterization of particles in 
therapeutic protein products. The technique has been shown to detect aggregate 
and particle formation earlier compared to size-exclusion chromatography or 
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turbidity measurements48 and to detect higher particle counts as compared to 
light obscuration.27,49  
3.2.4 Electron microscopy 
In electron microscopy, the isolated particles of the samples are illuminated by 
an electron beam enabling qualitative evaluation of the surface morphology down 
to 1 nm resolution. Information about number, size and shape is limited due to 
the small imaged area in the mm range. The most important electron microscopy 
methods for protein particle analysis are scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM). SEM provides three-dimensional images 
of the particle. It requires drying and coating of the particles with a conductive 
layer, e.g. gold or carbon, which can influence the original sample properties and 
surfaces. Environmental SEM applies lower vacuum, i.e. higher pressures, 
thereby enabling analysis of hydrated samples,50,51 often in combination with 
energy dispersive X-ray spectroscopy27 (see below). TEM does not require 
coating, but the electron beam itself can change the original sample structure. In 
addition, the sample needs to be fixed, e.g. by filtration, and stained which can 
also change sample properties. An alternative option is cryo-TEM where rapid 
freezing of the sample allows analysis in a state similar to the hydrated state in 
the original solution.52 The major advantage of both, SEM and TEM, is the high 
resolution, enabling detailed information about particle structure as shown by 
TEM for monoclonal antibody aggregates53 and by both techniques for HSA 
aggregates.54 Although both examples describe the analysis of relatively small 
protein aggregates, the techniques should in principle be applicable also for 
protein particles. As a major shortcoming in addition to the caveats mentioned 
above, both methods are not suitable for high-throughput analysis due to 
expensive equipment and time-consuming measurements.6 
3.2.5 Atomic force microscopy 
In atomic force microscopy (AFM), the sample surface is scanned mechanically 
using a cantilever. The principle of AFM including application examples is 
presented in the literature.55-57 As a major benefit, AFM provides three-
dimensional images down to 0.1 nm resolution under ambient conditions without 
sample preparation by filtration or coating, i.e. the samples can be measured air-
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dried or in liquid. The high resolution is not only beneficial for the early detection 
of protein aggregation,58 but also for the evaluation of shape and surface 
structure of aggregates and particles. This was shown for heat induced 
aggregates of a monoclonal antibody57 and HSA59 in the nanometer range. It 
should be possible to transfer the technique to larger protein particles, but the 
image area in AFM is limited to µm dimensions strongly constraining information 
about particle number, size and shape.55 A technical difficulty of this technique is 
the need to find conditions where the cantilever tip does not draw the analyzed 
material with is as it moves across the surface.57 Further shortcomings include 
expensive equipment and time-consuming measurements similar to TEM and 
SEM. 
3.3 Light absorption/blockage methods 
3.3.1 Light obscuration 
Light obscuration is a compendial method for the quantification of subvisible 
particles within parenteral solutions. Depending on the system, size and number 
of particles between 1 µm and 600 µm can be quantified. A large sample volume 
of 25 mL is required by both Ph.Eur.11 and USP13 for the analysis of low volume 
parenterals (volume smaller than 100 mL), which is often not feasible in the case 
of therapeutic protein products.21 Approaches to reduce the volume for light 
obscuration measurements of pharmaceutical products have been made to 
overcome this drawback.60,61 Small volumes may come along with increased data 
variability,7 but allow at the same time the detection of vial-to-vial variations 
which are missed if the vials are pooled to obtain a larger measurement volume. 
The maximum particle counts are defined in the Ph.Eur.11 and the USP13 as 
follows: For a total volume of 100 mL or less, the maximum particle count is 
specified as 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm, each per 
container. For a total volume larger than 100 mL, the maximum particle count is 
25 particles ≥ 10 µm and 3 particles ≥ 25 µm, each per mL. The discussion on 
the significance of these numbers for therapeutic protein formulations is 
ongoing.7-9,61 The USP is in the process of developing a biologics-specific chapter 
for particle analysis in the µm range, which will include appropriate sample 
handling and analysis of small volumes, and is also going to develop an 
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instructional chapter discussing some of the other technologies for this size 
range. 
In light obscuration, particles passing a laser beam block a certain amount of 
light proportional to their cross-sectional area, which is recorded by a photo 
diode detector. Light obscuration instruments are typically calibrated with 
polystyrene standards and based on this calibration the equivalent circular 
diameter (ECD) of the analyzed particles is obtained. However, for the 
interpretation of the results it has to be considered that the physico-chemical 
properties of protein particles, with respect to shape, transparency, and 
refractive index, are highly different from standard beads.29,62 Therefore, there is 
a need for standard particles that better represent the properties of protein 
particles.9,27,62 The simple measurement principle is certainly an advantage of 
light obscuration methods leading to straightforward and fast measurements. 
Nevertheless, this simplicity comes along with some restrictions: the particles 
have to pass the laser beam individually to avoid overloading and coincidence, 
i.e. two particles being detected as one larger particle. Therefore, the particle 
concentration must not exceed a certain limit depending on the system. The 
following light obscuration systems are mainly used for the analysis of protein 
products: HIAC HRLD by Hach® (Loveland, CO)32,62,63 with a linear range up to 
18,000 particles per mL, SVSS by PAMAS GmbH (Rutesheim, Germany)64-66 with 
a linear range up to 200,000 particles per mL and AccuSizer 780 by Particle 
Sizing Systems (Port Richey, FL)67 for particle concentrations up to 15,000 
particles per mL. Further available systems are APSS2000/LiQuilaz® by Particle 
Measuring Systems (Boulder, CO) and Syringe® by Klotz GmbH (Bad Liebenzell, 
Germany). 
Light obscuration cannot differentiate between proteinaceous particles and 
particles of other origin. Moreover, the technique is sensitive to air bubbles, 
which could be introduced during sample preparation or analysis. On this 
account, sample preparation, e.g. reconstitution of lyophilized products and 
handling of highly concentrated solutions of high viscosity, can have great 
influence on the result.20 Therefore, degassing of the sample is often performed 
prior to measurement, however, this procedure can also change sample 
properties.61 Furthermore, translucent protein particles could be underestimated 
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in number and size as more light passes through such particles as compared to 
the polystyrene standards used for calibration.27,49 Similar to flow imaging 
microscopy, analysis of highly-concentrated protein solutions or formulations 
containing high concentrations of excipients such as sugars can be challenging 
due to low differences in refractive index between particle and solvent; thus, 
particle number and/or size could be underestimated.32 Despite these 
restrictions, light obscuration has been routinely used for lot release and has 
enabled the manufacturing and release of drugs that are safe and efficacious.9 It 
is also regularly used for the monitoring of subvisible particle counts in 
therapeutic protein formulations to compare various formulations or stress 
conditions.63,64,66,68 
3.3.2 Nephelometry / turbidimetry 
Nephelometry and turbidimetry are both light scattering-based methods that are 
listed in the Ph.Eur.69 and in the USP.70 Nephelometry is defined as the 
measurement of light scattered by the sample solution compared to a formazin 
reference suspension. The scattered light is measured in a nephelometer at a 
high wavelength, typically 850 or 860 nm, at a scattering angle of 90°. In 
contrast, turbidimetry is defined as the measurement of light transmitted 
through the sample solution compared to a formazin reference suspension. The 
transmitted light can be measured in a UV spectrophotometer at a wavelength 
where proteins do not absorb light, i.e. in the range of 320-800 nm. Ratio 
turbidimetry measures both light scattering and light transmission and thereby 
determines the ratio of scattered light to transmitted light typically at 860 nm. 
Ratio turbidimetry is recommended by the Pharmacopeias for colored solutions 
as it compensates for the reduction of the transmitted light by absorption. 
These measurements are simple and useful for a non-specific comparison of 
samples as limited sample preparation is required and the methods are non-
destructive. The results are given in various synonymous units, e.g. NTU 
(nephelometric turbidity units), FNU (formazine nephelometric units) or FTU 
(formazine turbidity units). Although nephelometry and turbidimetry do not 
provide information about size, concentration or nature of protein aggregates or 
particles, the methods are often used to detect relative changes in the aggregate 
status.33,36,68 However, high turbidity values can also originate from other factors 
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such as high protein concentration and do not necessarily reflect the presence of 
aggregates or particles.71  
3.4 Light scattering techniques 
3.4.1 Principles of light scattering 
Light scattering techniques play a central role in particle characterization. Light 
scattering can be seen as a very fast sequence of photon absorption upon 
illumination of a sample with light and almost instantaneous emission of another 
photon.72 Photon absorption in light scattering techniques shifts electrons in the 
molecule for a short time to a higher virtual (=physically non-existing) state, 
from which photons are immediately re-emitted. In contrast, photon absorption 
in spectroscopic techniques such as UV/VIS spectroscopy, IR spectroscopy and 
fluorescence spectroscopy shifts electrons in the molecule for a longer time to a 
higher electronic or vibrational state. 
During light scattering, the absorbed energy can be released from the virtual 
state as photons in two different ways: (1) The scattered photon has the same 
energy/frequency as the absorbed photon (elastic light scattering). This process 
occurs for nearly all scattered photons and is called Rayleigh scattering for 
scatterers smaller than the wavelength of the incident light and Mie scattering for 
scatterers in the range of the wavelength of the incident light and above. (2) The 
scattered photon has an energy/frequency different from that of the absorbed 
photon, which occurs only for 10-3 of all scattered photons (inelastic or Raman 
scattering).  
Rayleigh/Mie scattering (1) is used for dynamic light scattering (DLS), 
nanoparticle tracking analysis (NTA) and static light scattering (SLS). Raman 
scattering (2) is the basis for Raman spectroscopy. 
3.4.2 Dynamic light scattering 
Dynamic light scattering (DLS), also referred to as photon correlation 
spectroscopy or quasielastic light scattering, is used to determine the 
hydrodynamic size of native proteins, as well as aggregates and particles thereof 
from 1 nm to about 10 µm (size limit depending on sample properties and 
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measurement conditions).73 The technique is based on intensity fluctuations of 
laser light scattered by the analyte, which is moving in Brownian motion.74 
Intensity fluctuations are quantified via an autocorrelation function which 
compares the initial scattering intensity to the intensity after specified time 
periods. A slow decay in the autocorrelation function is caused by slow 
fluctuations in intensity indicating the presence of slowly moving large particles; 
a fast decay is due to fast fluctuations indicating the presence of fast moving 
small particles. From the measured decay the diffusion coefficient D can be 
obtained, which is directly proportional to the inverse radius of the particles via 
the Stokes-Einstein equation.75,76 An important assumption for the validity of 
Stokes-Einstein is that the analyzed molecules or particles are spherical and not 
interacting with each other. Provided that temperature and viscosity of the 
solution are known, the hydrodynamic diameter – usually reported as Z-average 
diameter, i.e. the mean diameter – is obtained from DLS measurements. 
Especially the viscosity, which affects the diffusion coefficient, plays an important 
role in the analysis of therapeutic protein formulations as many excipients, in 
particular sugars, increase the viscosity.32,71 Therefore, the viscosity needs to be 
individually determined for the respective formulation. As protein aggregates and 
particles are mostly not spherical but of various shapes, the delivered 
hydrodynamic diameter for protein particles needs to be evaluated carefully. In 
addition, for polydisperse samples, indicated by a high polydispersity index (PdI), 
Z-average values do not necessarily reflect the different sizes present in the 
samples. Furthermore, DLS can only distinguish two populations in the sample if 
they theoretically differ in size at least by a factor of two77 or three.78 Particle 
populations with a lower difference in size appear as one broader population 
reflecting the average distribution. 
DLS measurements provide intensity-based size distributions. However, this is 
not the best way for characterization of polydisperse samples as the scattering 
intensity I depends on the diameter d to the power of six in the Rayleigh 
approximation (Equation 1-1). 
6
dI   
Equation 1-1 
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The resulting size distribution by intensity is therefore biased to larger sizes. This 
can be an advantage if small amounts of larger aggregates shall be detected in 
the presence of monomeric protein. However, in most cases it is disturbing, as a 
few large aggregates/particles present in the sample can impede the 
measurement of many small molecules, e.g. protein monomer. Using volume, 
weight or number based size distributions may be a better estimation of the 
composition of the sample in some cases.79,80 Volume or weight based size 
distributions are still biased to larger sizes, but less than intensity based size 
distributions.73,81 For a direct comparison of particle counts of different sizes, a 
number based size distribution can be suitable. However, it should be noted that 
an inaccurate intensity distribution as obtained from DLS data will result in 
significant errors in the derived volume, weight or number distribution. 
Another challenge lies in high particle concentrations in the sample which can 
lead to multiple scattering effects. A technical possibility to reduce confounding 
influences of very large particles or to deal with high sample concentrations is 
the use of laser light backscatter detection, which detects the scattered light not 
in the commonly used 90° angle, but at a higher angle, e.g 173° (Zetasizer Nano 
S and Nano ZS by Malvern Instruments Ltd, Worcestershire, UK)82 or 153° 
(FOQELS by Brookhaven Instruments Corporation, Holtsville, NY).83 In this case, 
the laser light does not need to pass far into the sample as the scattered light is 
detected close to the cuvette wall thereby circumventing multiple scattering 
effects. 
Nevertheless, despite this improvement in the measurement of large particles, 
DLS is in particular suitable for the analysis of protein monomer and small 
aggregates in the nanometer range81,84-86 and less suitable for particles in the µm 
size range. As an advantage of DLS, measurements in plate reader-based 
systems can save time and material.87 As a further benefit, the method is not 
destructive and requires limited sample preparation. However, sufficient protein 
concentration is necessary for DLS to obtain reliable signals and the results are 
not quantitative as no absolute values for monomer content or aggregate 
concentration are provided.  
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Taylor dispersion analysis (TDA) is a novel method for the analysis of protein 
aggregates and particles which also determines the hydrodynamic size based on 
the diffusion coefficient. In contrast to DLS, the diffusion coefficient is not based 
on light scattering fluctuations, but on band broadening of the UV signal of the 
sample analyzed in a cylindrical tube under laminar Poiseuille flow, which passes 
a detector twice. TDA was shown to accurately size monomers of BSA and IgG 
antibodies and should in principle also be applicable for protein particles.88 
3.4.3 Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) was developed by NanoSight Ltd in 2006 for 
the characterization of analytes in the nanometer size range. In NTA samples are 
illuminated by a laser (405 nm, 532 nm or 638 nm), particle movement is 
recorded via light scattering by a CCD camera and a software tracks the particles 
as light-scattering centers moving under Brownian motion. This visualization 
adds the value of microscopic imaging of the sample next to the particle size and 
concentration information based on light scattering. In contrast to DLS, where 
intensity changes are measured as bulk technique for the complete sample, 
particles in NTA are tracked individually, which facilitates distinction of particle 
subpopulations. As the particles are tracked only in two dimensions in the 
measuring cell, a modified Stokes-Einstein equation89 (Equation 1-2) is applied to 
calculate the particle size with (x,y)² as the mean-squared particle path in two 
dimensions, kB as the Boltzmann’s constant, T as the absolute temperature, t as 
the measurement time, η as the viscosity and r as the hydrodynamic radius. 
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A comprehensive comparison of NTA with DLS is given by Filipe et al.90 An 
important advantage of NTA compared to DLS is the better peak resolution. 
Particles with diameters of only 1.5 fold difference can be distinguished in NTA90 
compared to the at least 2-3 fold difference required for DLS (see above). The 
lower size limit of NTA depends on the particle refractive index and can be as 
small as 10 nm for high refractive index particles such as gold particles, but is 
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usually 40 to 50 nm for low refractive index particles such as protein particles;91 
the upper size limit is about 1000 nm.89 
Another benefit of NTA is the visualization of the particles as light-scattering 
centers providing additional information about the sample, e.g. the degree of 
heterogeneity. Moreover, disturbing large particles in the µm size range can 
immediately be seen and excluded from the analysis. Alternatively, such particles 
could be removed prior to analysis, e.g. by filtration or centrifugation as shown 
for monoclonal antibody aggregates.31 However, one needs to consider that the 
subsequent analysis of the pretreated samples then displays only a selected 
fraction of the sample.  
In addition to the particle size, NTA provides semi-quantitative information about 
the particle concentration. The optimal concentration for a proper NTA 
measurement is between 107 and 109 particles/mL, which often requires dilution 
of aggregated protein samples which can potentially change the sample 
properties.90 Furthermore, highly concentrated protein solutions also need to be 
diluted in cases when high monomer amounts confound the analysis.  
NTA requires a trained operator in order to obtain reliable, reproducible results, 
as the adjustment of the instrument settings to the needs of the sample requires 
experience. If used properly NTA can be a powerful technique to gain better 
insight into the size distribution of the sample as shown for PEGylated vs. non-
PEGylated insulin92 or for HSA and IgG particles.31,93  
3.4.4 Static light scattering / multi-angle laser light scattering 
Static light scattering (SLS) can provide information about the size (molecular 
weight) of the analyte in the measured solution. In SLS, the time-averaged 
intensity of scattered laser light at a certain angle is measured as the excess 
scattering intensity compared to the scattering intensity of the solvent, also 
called excess Rayleigh’s ratio. SLS is suitable for smaller analytes, i.e. molecules 
with a radius of gyration smaller than 1/20 of the incident wavelength, as these 
molecules scatter light roughly isotropically. This holds true for molecules up to a 
radius of gyration up to about 30 nm, which includes protein monomers, as laser 
wavelengths in the range of 600 to 700 nm are mostly used.94 
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In multi-angle laser light scattering (MALLS), scattered light is measured at 
multiple angles to obtain more detailed information especially for higher 
molecular weight aggregates, whose scattering type is no longer isotropic.95 The 
Zimm-equation96 is used to calculate the radius of gyration and the molecular 
weight of the analyzed species from the angle-dependent light scattering 
intensities, which also depend on the concentration and the refractive index 
difference between analyte and solution. 
When using SLS as a stand-alone method for heterogeneous samples, e.g. 
aggregated protein solutions, one has to be aware that only a Z-average value 
for the molar mass of all species present in the solution is obtained.97 Therefore, 
in protein aggregation analytics, SLS and MALLS are mostly used as a detector 
for size exclusion chromatography (SEC)95,97,98 or asymmetrical flow field flow 
fractionation (AF4)66,98,99 in combination with UV and/or refractive index detection 
(to measure the concentration that is needed to calculate the molecular 
weight).97,100 The major benefit of SLS/MALLS in combination with separation 
techniques is the possibility to calculate the molecular weight and size of the 
individually eluting species. This makes the use of molecular weight standards, 
e.g. for SEC column calibration, dispensable101 and misinterpretation of 
aggregate sizes based on different elution behavior of standards and analytes 
can be avoided.80,102 Furthermore, the (Z-average) molecular weight of species 
eluting in the void volume of SEC can be determined by MALLS.97 Consequently, 
the combination of MALLS with SEC or AF4 is the static light scattering method of 
choice for the analysis of protein aggregates and particles as shown as AF4-
MALLS for monoclonal antibodies66,103 or SEC-MALLS for alpha-
chymotrypsinogen97 and monoclonal antibodies.102 
3.4.5 Fluorescence activated particle sorting 
Fluorescence activated particle sorting (FAPS) is a method similar to fluorescence 
activated cell sorting (FACS) based on the principle of flow cytometry.67 FAPS is 
able to size labeled and unlabeled particles from 100 nm to 5 µm by light 
scattering, but should in theory also be applicable to a size range up to 100 µm 
as FACS was originally developed for eukaryotic cells. Fluorescence labeling 
enables separation of differently labeled and/or unlabeled particles, i.e. of protein 
from non-protein particles in case of a protein-specific dye such as SYPRO 
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Orange.104 Furthermore, the characterization of particles in complex media, e.g. 
serum, should be possible as shown for nanoparticles analyzed by fluorescence 
single particle tracking.93 Size determination is also possible with unlabeled 
material based on sideward scatter (SSC) quantification and calibration with size 
standards. The size standards need to have a refractive index similar to the 
sample material which poses a challenge for protein particles as most size 
standards such as polystyrene beads show refractive indices much higher than 
protein particles. Size determination of labeled material is also possible based on 
the pulse width of the fluorescence signal after calibration with fluorescent size 
standards.105 Compared to other light scattering techniques such as DLS or SLS, 
FAPS analyzes particles individually and therefore shows size distributions of 
higher resolution.67 FAPS offers the possibility of miniaturization as only 100-
200 µL sample volumes are required and measurements can be performed using 
a microplate autosampler.104 A benefit of FAPS as a preparative separation 
method (based on analytical data) is that particles can be used for further 
processing afterwards. However, the particles are highly diluted during the 
measurement, so they may need to tolerate concentration procedures to be 
reused. 
FAPS was used for size determination of polyethyleneimine (PEI) polyplexes,67 
liposomes from 100 nm to 1 µm,106 protein particles from 1 to 5 µm104 as well as 
for mixtures of protein particles and silicone oil droplets in the lower µm range.107 
Overall, the method is not yet well established for the analysis of protein 
particles and needs further method development. 
3.5 Non-optical counting and sizing methods 
3.5.1 Electrical sensing zone / Coulter counter method 
The electrical sensing zone method is based on the increase in the electric 
resistance by particles passing an electrical sensing zone. The particles need to 
be suspended in a conductive electrolyte solution that enables an electric current 
in the measuring container between two electrodes separated by a small 
aperture. Each particle passing the electrical sensing zone around this aperture 
causes a change in the electric current that is proportional to its volume, 
following the so called Coulter principle. By calibration with size standards the 
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equivalent spherical diameter (ESD), i.e. the diameter of a sphere of the same 
volume as the particle, can be calculated.108 Furthermore, quantification of 
particles is also possible by the electrical sensing zone method which is therefore 
also designated as Coulter counter method. Providing size and number 
information for particles from 0.5 to 1000 µm with concentration limits of 40,000 
to 340,000 particles/mL, both depending on the aperture size, the Coulter 
counter method can be compared to light obscuration and flow imaging 
techniques. However, multiple apertures are needed to achieve this dynamic 
range and morphological parameters such as shape, aspect ratio or circularity 
are not provided by the Coulter counter method. The major benefit of a Coulter 
counter is the absolute and direct determination of the particle size which does 
not depend on optical properties such as transparency, shape or compactness – 
parameters that are critical for light-based methods, e.g. light obscuration or 
flow imaging techniques.25,109,110 The Coulter counter is therefore more suitable 
than light-based methods for the detection of particles in highly-concentrated 
protein solutions leading to high viscosity and low contrast between particles and 
solution.32 The major shortcoming of the Coulter counter method is the required 
suspension of the particles in an electrolyte solution if the formulation buffer 
itself does not show sufficient conductivity, which can trigger particle formation 
or disaggregation.20 Higher conductivity (in the range of 150 mM NaCl) is needed 
for the analysis of smaller particles from 0.5 to 20 µm, whereas lower 
conductivity (down to 20 mM) is sufficient for the analysis of larger particles from 
1 to 1000 µm (according to Beckman Coulter, the manufacturer of the Coulter 
counter) or for highly concentrated protein solutions as the proteins themselves 
can act as electrolytes. The application of the Coulter counter method for the 
quantification of subvisible particles in therapeutic protein formulations is 
relatively new. Only few examples show the successful detection of subvisible 
particles such as IgG particles25,32,111 and BSA particles.109 
3.5.2 Resonant mass measurement / Archimedes 
Resonant mass measurement is a novel technique developed by Affinity 
Biosensors which is based on the Archimedes principle: the upward buoyant force 
acting on an object in a fluid is equal to the weight of the fluid displaced by the 
object.112 In the Archimedes system, the sample solution is flushed through a 
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suspended microchannel resonator (SMR) or microcantilever which changes its 
resonance frequency depending on the buoyant mass of the particles passing the 
channel.113 Analysis of the peaks in the frequency trace enables (1) 
differentiation of particles into positively buoyant particles (e.g. silicone oil 
droplets) and negatively buoyant particles (e.g. protein particles) by the peak 
direction, (2) determination of the particle/droplet concentration by quantifying 
the number of peaks, and (3) determination of the particle/droplet size as the 
equivalent spherical diameter (ESD) by quantifying the height of the peak.114 
Particles/droplets from about 50 nm to about 6 µm (depending on the sensor and 
the particle type) can be analyzed by RMM in a concentration range from about 
105 to 107 particles/mL (depending on the applied measurement time). The 
major benefit of RMM is the straightforward measurement principle enabling the 
differentiation of silicone oil droplets and protein particles. Furthermore, particles 
are analyzed individually and the coincidence rate (if two peaks are located too 
closely together) is indicated by the system in case of high concentrations 
enabling corrective actions such as sample dilution. This is in contrast to optical 
methods where the coincidence of two particles is not noticed during the 
measurement and the user needs to trust the results as long as the 
concentration is within the specified range. The major shortcoming of RMM is the 
very low flow rate of the system (around 15 nL/min) leading to a very low 
sampling efficiency. This in turn requires extended measurement times (up to 
several hours) especially for low concentration samples if sufficient particle 
numbers should be counted to achieve statistically sound results.113 As a further 
limitation, the calculation of the particle/droplet size requires the density of the 
fluid and of the particles/droplets as input parameters although the density of 
protein particles is often not known. The limited experience with this novel 
technique represents a further challenge. In the available studies, RMM was 
applied for the characterization of various microspheres, silicone oil droplets and 
protein particles in a technical evaluation of the system113 and the differentiation 
of droplets and particles in pharmaceutical products.115 
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3.6 Separation methods 
3.6.1 Size exclusion chromatography 
In size exclusion chromatography (SEC) proteins are separated by their 
hydrodynamic volume. SEC is usually used to quantify protein monomer, 
fragments, oligomers, and small soluble aggregates.100,103 Large aggregates and 
particles either elute with the void volume or accumulate at the column top or 
pre-column. For the analysis of protein particles by SEC, there are in principle 
two possibilities: (1) SEC can be used to indirectly estimate the fraction of 
insoluble aggregates and protein particles as a loss in the total peak area36,48 or 
(2) SEC columns of higher cut-off up to 200,000 kDa (e.g. Tosoh Bioscience, 
Tokyo, Japan) can be used to analyze particles. The latter method comes along 
with low resolution between fragments, monomer and smaller aggregates. UV, 
fluorescence or refractive index detectors are typically used to monitor the 
elution process and estimate the protein content; light scattering detectors can 
be used to determine the molecular weight of the protein monomer and 
aggregates. Shortcomings of SEC are changes of the analyte properties by 
dilution in the mobile phase or interaction with the column material, which is 
especially the case for hydrophobic proteins and/or aggregates.116,117 Low 
required sample volumes and high sensitivity and robustness represent major 
benefits of SEC. However, for the analysis of protein particles, SEC is mostly 
used as an indirect method to correlate the loss of the total peak area with the 
amount of particles as mentioned above.36,48 
3.6.2 Centrifugation 
Centrifugation techniques use sedimentation to separate solid matter in a 
suspension according to particle size or density. Following Stokes’ law,118 the 
sedimentation velocity v depends on the density difference of particle and fluid 
(ρp – ρf), the hydrodynamic radius of the particle r and the viscosity of the fluid η 
with g being the gravitational force (Equation 1-3). 
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Thus, centrifugation methods are suitable to determine the size of particles in a 
suspension. The most commonly used centrifugation method for the analysis of 
protein particles is disk centrifugation. Analytical ultracentrifugation (AUC) is 
described only briefly here for the sake of completeness and is reviewed in detail 
in the literature.119-121 It has only been reported for small protein aggregates in 
the size range up to 2000 kDa121 and seems to be not suitable for particles larger 
100 nm6 due to scattering effects and rapid sedimentation of large particles 
hampering the detection. Approaches with reduced centrifugation speed to 
analyze protein particles are currently under development. 
Disk centrifugation, also called differential centrifugal sedimentation (DCS), 
applies rotation speeds up to 24000 rpm. The centrifuge in the form of a disk, 
filled with a density gradient fluid, e.g. sucrose or glycerin solutions, is orientated 
in a vertical direction for analytical purposes.122 The sample is diluted in a fluid of 
a lower density and injected into the disk center. Thereby, sample fluid and disk 
fluid are not mixed and only the particles sediment from the disk center to the 
edge where they are detected by a light extinction/scattering detector allowing 
concentration determination by Mie theory. This detection principle leads to a 
wider size range of DCS compared to AUC where light absorption is measured. 
The size of the particles is calculated following Stokes’ Law which requires 
knowledge (or at least an estimate) of the particle density. Depending on the 
used instrument particles from 5 nm to 75 µm (Chemical Process Specialists, 
Gorham, ME) or 10 nm to 30 µm (BI-DCP Disk Centrifuge Particle Size Analyzer, 
Brookhaven Instruments Corporation, Holtsville, NY) can be analyzed. However, 
suspension of the particles in the density gradient fluid can change sample 
properties. Particle size determination by DCS is not absolute, so external or 
internal calibration standards are required.123 DCS was used to analyze size 
distributions of particles in cytokine-HSA formulations,68 but is mainly found as 
analytical method to characterize nanoparticles, e.g. interacting with protein.124  
3.6.3 Asymmetrical flow field flow fractionation 
Asymmetrical flow field flow fractionation (AF4), like SEC and centrifugation 
methods, separates protein aggregates and particles by hydrodynamic size.125 
For a detailed description of the technique including application examples the 
reader is referred to the literature.99,126-132 In brief, the sample is injected into a 
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channel of a height in the µm range and transported by a mobile phase in the 
direction of the channel. Simultaneously, a cross flow perpendicular to the 
channel flow is induced, which transports the particles towards a semipermeable 
membrane. Due to the parabolic flow shape in the channel direction, smaller 
particles, diffusing faster back to the channel center than larger particles, will 
elute earlier than larger particles which will stay closer to the membrane where 
the channel flow is slower. The elution of the particles is monitored by similar 
detectors as used for SEC, i.e. UV, fluorescence, refractive index, and/or light 
scattering detectors. 
Major advantages of particle characterization by AF4 compared to SEC are the 
lack of a stationary phase that could interact with the sample, as well as the 
larger separation range from 1 nm up to 100 µm, depending on the channel 
diameter and measurement settings.6,125 Little sample preparation and low 
sample amounts are further benefits of the technique.128 However, dilution and 
concentration effects during the measurement, as well as solution viscosity due 
to high protein concentration and potential interactions of the analyte with the 
membrane can influence the separation. Parameters such as membrane material, 
molecular weight cut-off and the interplay between channel flow and cross flow 
rate need to be chosen carefully. Considering these factors, AF4 can typically 
provide complementary results to AUC and SEC. In some cases AF4 was even 
more suitable for the analysis of protein particles than AUC or SEC, as shown for 
submicron antibody particles.99,103 However, while the technique is well 
established for nanoparticles and smaller protein aggregates,130-132 further 
method development is needed for the analysis of protein particles. These 
particles follow the principle of steric elution, elute directly after the focusing step 
is finished, and can in most cases be evaluated only qualitatively. 
3.7 Spectroscopic methods 
Spectroscopic methods provide qualitative insight into particle structure, 
conformation and/or identity. 
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3.7.1 Circular dichroism spectroscopy 
Circular dichroism (CD) describes the unequal absorption of right-handed and 
left-handed circularly polarized light by chiral molecules.133 The underlying 
principles of CD spectroscopy are outlined in detail within the literature.134-136 
Far-UV CD spectroscopy operates in a wavelength range of ca. 170-250 nm and 
provides information about the secondary structure of a protein,137 near-UV CD 
spectroscopy covers a wavelength range of ca. 250-350 nm and allows 
assessments of the tertiary structure.138 The technique is especially sensitive to 
α-helix determination and is therefore complementary to the β-sheet sensitive 
technique of FT-IR spectroscopy (see below). The major shortcoming of CD 
spectroscopy is its limitation to only monomeric and oligomeric protein and 
aggregates, as sedimentation and light scattering of protein particles disturbs the 
analysis.6 Currently, methods enabling CD spectroscopy of protein immobilized 
on particles are under development which use a rotating cylindrical sample cell to 
avoid sedimentation and a small distance between sample cell and detector to 
minimize light scattering.139 This approach may also be suitable for the 
characterization of particles in protein formulations. 
3.7.2 Fourier-transform infrared spectroscopy 
Infrared (IR) spectroscopy measures the absorption of light due to vibrations of 
the molecule in the wavelength range from 0.8 µm to 1000 µm (described as 
wavenumbers from 12500 cm-1 to 10 cm-1). MIR (middle infrared spectroscopy, 
4000 – 400 cm-1) is mostly used to analyze protein secondary structure as 
vibrations of functional groups such as amide groups are observed in this 
region.140 Detailed information about the application of IR spectroscopy for 
proteins is reviewed in the literature.140,141 
As a main benefit, FT-IR spectroscopy can be applied both on liquid samples 
(solutions and dispersions) and on solid samples (e.g. lyophilizates).142 Also the 
analysis of highly aggregated protein formulations and particle containing protein 
formulations is possible. For this purpose mainly attenuated total reflectance 
(ATR) FT-IR spectroscopy is used, where the incoming light is reflected several 
times at the interface between an IR transparent crystal and the sample thereby 
generating an evanescent wave at the reflection points. The interaction of this 
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evanescent wave with the sample reduces the amount of reflected light reaching 
the detector and provides the IR spectroscopic information of the sample.140,141 
As a challenge of FT-IR spectroscopy, the amide I band of protein often appears 
in the spectrum as a broad peak which contains multiple underlying peaks 
originating from intramolecular secondary structures, but also intermolecular 
β-sheets.143 To extract secondary structure information from the amide I band, 
spectral processing, e.g. by performing the 2nd derivative, is required which 
provides the relative percentages of the different secondary structures. The 
technique can also differentiate between subtypes of β-sheets such as parallel 
and anti-parallel β-sheets or native β-sheets and amyloid structures. Therefore, it 
is a complementary technique to CD spectroscopy which is especially sensitive 
for α-helix determination (see above). FT-IR spectroscopy was applied for IgG 
particles both in suspension66 or as a pellet after centrifugation.33,48 
IR microscopy enables visualization and identification of particles in therapeutic 
protein solutions.144 The technique is suitable for particles larger than 20 µm 
using the reflection-absorption spectroscopy mode: the particles are isolated on a 
filter, preferably a metal-coated membrane or a gold filter, which allows light 
that has passed the sample to be reflected by the metal surface and pass 
through the sample again.27 The main benefit of IR microscopy is the possibility 
not only to distinguish between non-proteinaceous and proteinaceous particles, 
but also to identify the source of the non-proteinaceous particles. This was shown 
for a therapeutic protein formulation containing one single particle composed of 
butyl rubber, talc, and silica which was identified by a combination of IR 
microscopy and Raman microscopy.144 In another example, IgG particles were 
shown to contain silicone oil via analysis by IR microscopy and SEM-EDS.27 
3.7.3 Raman spectroscopy 
Raman spectroscopy is based on (inelastic) Raman scattering, which was first 
described in 1928.145,146 When illuminated by a laser, molecules absorb energy 
and emit it as a photon of lower energy/frequency than the absorbed photon. A 
good overview of Raman spectroscopy for therapeutic proteins is given by 
Wen.147 
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Two types of information can be gained from a Raman spectrum: (1) The 
presence and position of bands in the fingerprint region (2000 – 400 cm-1) 
enables the chemical identification of the analyzed material by comparison with a 
database of Raman spectra.148 This principle is also used in Raman microscopy.26 
(2) The exact wavenumber (= 1/λ) of distinct bands in protein samples gives 
information about the environment of the peptide bond, i.e. the secondary 
structure of the protein,147,149 or aromatic side chains and disulfide bonds, 
providing hints about changes in the tertiary structure.150 
Benefits of Raman spectroscopy include easy sample handling as analysis can be 
performed with samples in any physical state149 and even in original closed 
containers.148 As a drawback, fluorescence is often disturbing in Raman 
spectroscopy, as the fluorescence signal is clearly stronger than the Raman 
signal. Raman spectroscopy brings the advantage that the wavelength of the 
incident light can be selected according to the requirements of the sample. Thus, 
using an NIR laser wavelength for excitation can reduce this phenomenon as 
these long wavelengths usually do not contain absorption bands relevant for 
fluorescence and the light intensity is usually too low to induce 
fluorescence.147,149 However, Raman signals are in general low as compared to IR 
signals (see above) and Raman spectroscopy therefore requires sufficient protein 
quantities and very sensitive detectors.149 In the field of therapeutic proteins, 
changes in the secondary structure have been analyzed by Raman spectroscopy 
to monitor the aggregation process.151-153 Analysis of proteinaceous and non-
proteinaceous particles by Raman spectroscopy mostly involves Raman 
microscopy, an emerging technique combining visualization and identification of 
particles. 
In Raman microscopy particles in solution or isolated particles are visualized by 
optical microscopy with the possibility to record Raman spectra of individual 
particles. For particle isolation, gold-coated filters are often used to prevent 
background signals from the filter material. Particles larger than 5 µm (for some 
applications even down to 0.5 µm) can be identified by comparing the recorded 
spectra with a reference database, e.g. by the technique of rap.ID (rap.ID 
Particle Systems GmbH, Berlin, Germany).26  
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As an example, a single particle composed of butyl rubber, talc, and silica was 
analyzed first by Raman spectroscopy in the original container and afterwards by 
IR microscopy of the isolated particle.144 Raman microscopy of isolated particles 
was shown to differentiate between protein particles and protein-silicone oil 
particles.26 The identification of particles by Raman microscopy in a protein 
formulation can be of great benefit as it helps to decide whether the formulation 
needs to be improved or the particles originate from other sources, e.g. from 
silicone oil coating in prefilled syringes or contamination sources. Expensive 
equipment, time-consuming measurements and the risk of “burning” protein 
particles by high laser power are among the shortcomings of this technique. In 
general, this method is still an emerging technique and needs to prove its value 
for the analysis of particles in therapeutic protein formulations. 
3.7.4 Fluorescence methods 
Fluorescence occurs when the energy of a photon absorbed by a molecule is 
partly emitted as a photon of a lower frequency/energy. In contrast to Raman 
scattering (see above), fluorescence is restricted to distinct absorption bands 
triggering a transition of the fluorophore to an excited state. The resulting photon 
emission from the excited state is also restricted to distinct emission bands. A 
good overview of fluorescence spectroscopy for proteins is given in the 
literature.154,155  
Protein fluorescence is analyzed to monitor changes in the tertiary structure and 
the environment of the fluorescent amino acids, mainly tryptophan. 
Measurements are originally performed in cuvettes where incident light beam and 
detector are orientated at right angle.154,155 However, if high amounts of 
aggregates or particles are present in the sample the emitted light does not fully 
reach the detector due to multiple scattering (inner filter effect). For this case, 
front face measurements with cuvettes rotated to a measurement angle of ideally 
34° or 56° are the better option.156 These set-ups have also been used to 
measure protein adsorbed to beads157,158 and are in principle also possible for 
protein particles even though applications for protein particles are still lacking. 
Whereas the protein concentration should be adjusted to show an absorbance at 
the excitation wavelength not higher than 0.1 in normal fluorescence 
measurements because of the inner filter effect, this is less critical for front face 
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measurements. Another possibility to analyze protein particles is the 
measurement in a plate reader where excitation and detection are both vertical 
and higher protein concentrations are possible.159  
Intrinsic protein fluorescence is induced by tryptophan, tyrosine, and 
phenylalanine as fluorophores with fluorescence intensities decreasing in this 
order. The absorption / emission maxima in aqueous solution are located at 
280 nm / 350 nm for tryptophan, 275 nm / 304 nm for tyrosine, and 
258 nm / 282 nm for phenylalanine. Tryptophan is mostly the fluorophore of 
choice as it shows the strongest fluorescence and is selectively excitable at 
wavelengths between 295 and 300 nm. As tryptophan fluorescence depends on 
the polarity of the environment, tryptophan fluorimetry is used to monitor 
changes in protein structure and the formation of aggregates.160,161 However, 
fluorescence is only suitable to detect relative structural changes, not to 
determine the absolute tertiary structure. 
In addition to intrinsic fluorescence, fluorescent dyes can also be used to probe 
the conformation and other properties of protein aggregates. Fluorescent dyes 
can be covalently or non-covalently attached to the protein of interest. For 
detailed information about fluorescent dyes for the analysis of therapeutic 
proteins, the reader is referred to the literature.28,155 Covalently attached 
fluorescent dyes can be used to analyze protein aggregates and particles in 
complex buffers or directly in serum.93,162 Non-covalent fluorescent dyes that 
bind by hydrophobic or electrostatic interactions are typically more interesting for 
the study of therapeutic protein aggregates and particles. The fluorescence 
intensity of non-covalent dyes such as ANS (8-Anilino-1-naphthalenesulfonate), 
Bis-ANS (4,4′-Dianilino-1,1′-binaphthyl-5,5′-disulfonate), SYPRO orange or Nile 
Red depends on the polarity of the environment, e.g. the exposure of 
hydrophobic protein regions by unfolding and aggregation. Fluorescent molecular 
rotors like DCVJ (9-(2,2-dicyanovinyl)-julolidine) and CCVJ (9-(2-carboxy-2-
cyanovinyl)-julolidine) also interact with hydrophobic parts on the protein, 
whereas their fluorescence properties are sensitive to the microviscosity of the 
binding environment.163 Extrinsic dyes can provide information about structural 
changes and/or the formation of aggregates, as well as the properties of the 
formed aggregates.164,165 However, fluorescent dyes are often prepared in 
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organic solvents and one should consider control measurements to exclude 
induction or suppression of aggregation by the organic solvent or by the 
fluorescent dye itself.42-44 As an example ANS was used to detect changes in the 
tertiary structure of a monoclonal antibody,53 Bis-ANS proved to bind strongly to 
heat stressed IgG,166 ANS and SYPRO orange were applied to analyze the surface 
hydrophobicity of monoclonal antibody aggregates31 and ANS fluorescence was 
analyzed to monitor the aggregation process of concanavalin A.164 In case of 
protein particles, fluorescent dyes are mostly used for visualization in 
fluorescence microscopy or for FAPS analysis (see above).  
3.7.5 Energy dispersive X-ray spectroscopy 
Energy dispersive X-ray spectroscopy (EDS or EDX) is used to determine the 
chemical composition of a sample. The irradiation of the sample by an electron 
beam causes the loss of inner shell electrons in the atoms of the sample. The 
replacement of the lost electrons by electrons of lower energy shells enables the 
release of free energy in the form of X-rays. The energy level of these emitted 
X-rays is specific for each atomic element and thereby provides information 
about the chemical identity.167,168 An energy dispersive X-ray spectrometer is 
often coupled with a scanning electron microscope (SEM) to combine optical and 
chemical characterization of protein particles or to identify particulate 
contaminants in pharmaceutical products. For example, IgG particles were shown 
to contain silicone oil by IR microscopy and SEM-EDS.27 In another study, the 
identity of three different materials present in one particle, determined by IR 
microscopy and Raman microscopy, was confirmed by SEM-EDS.144 
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4 Conclusion 
The number of analytical methods for the quantification and characterization of 
protein particles has continuously increased during the last few years. Numerous 
characteristics of particles in therapeutic protein formulations, such as size 
(distribution), shape, chemical composition or structure, can be determined 
based on different measurement principles. However, no single method is 
capable of providing information on all desired parameters for the complete size 
range, which makes a combination of several methods based on different 
measurement principles necessary for a comprehensive characterization.21 For 
data analysis, one needs to consider that in most cases two methods will not 
show exactly the same result for one parameter due to a different underlying 
measurement principle. In this regard, for the comparison of different analytical 
methods, more proteinaceous particle standards rather than the hitherto used 
polystyrene beads would be valuable. As therapeutic proteins can form various 
types of aggregates and particles, the appropriate analytical methods need to be 
selected case by case and general recommendations for the analysis of protein 
particles are difficult to give.  
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          Chapter 2
                         
Evaluation of novel techniques for protein 
particle analysis 
 
Abstract 
The aim of this study was a critical evaluation of novel techniques for protein 
particle analysis. The performance of these techniques (flow imaging microscopy 
(Sysmex FPIA-3000 and Occhio FC200S+), electrical sensing zone (Coulter 
counter Multisizer 4), resonant mass measurement (Archimedes), and image 
directed Raman spectroscopy (rapID)) was compared to the performance of more 
established analytical methods (Micro-Flow Imaging (MFI), light obscuration 
(LO), dynamic light scattering (DLS), and nanoparticle tracking analysis (NTA)). 
The studies demonstrated that flow imaging microscopy results strongly depend 
on the used system, that the non-optical particle counting techniques ESZ and 
RMM provide good sizing and counting performance, and that the identification of 
particles by image directed Raman spectroscopy shows difficulties in the 
detection of protein particles, but appears to be an interesting approach for non-
proteinaceous particles. Taken together, novel techniques need to be evaluated 
carefully case by case before their implementation for routine analysis. 
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1 Introduction 
Aggregates and particles need to be characterized during formulation 
development, production, and release of therapeutic protein formulations not 
only due to regulatory requirements1-4 and the potential risk of immunogenicity,5 
but also to get the best possible insight into product properties.6 The number of 
analytical techniques for protein aggregate and particle analysis available for this 
purpose is constantly increasing.7,8 This includes on the one hand established 
techniques which are used for a different purpose, and on the other hand 
methods which apply completely new measurement principles. As an example for 
the first group, some flow imaging microscopy systems were not originally 
designed for the analysis of protein particles, but for application in the industrial 
production of inks, construction materials or food. For protein particle analysis, 
those techniques are valuable as they combine quantification and 
characterization of particles captured on the images. Two such systems, the 
Sysmex FPIA-3000 and the Occhio FC200S+, were evaluated in this study. The 
principle of electrical sensing zone (ESZ) analysis as applied by the Coulter 
counter was originally intended for cell counting and is still the major technique 
for this purpose.9,10 Only some years ago, the technique was introduced for the 
analysis of protein particles as a non optical particle counting technique11 and 
only few studies about this application are available.12-14  
In contrast to those “recycled” measurement principles, resonant mass 
measurement (RMM) reflects a new approach which is based on the frequency 
change of a resonating cantilever by particles passing a microchannel within the 
cantilever.15 The main strength of this technique is the differentiation of protein 
particles and silicone oil droplets which was evaluated thoroughly in other 
studies.16-18 Further identification of particles in pharmaceutical products by 
chemical or physical approaches may be necessary for root-cause analysis. 
Typically, Fourier-transform infrared (FT-IR) and Raman microscopy or scanning 
electron microscopy coupled with energy-dispersive X-ray spectroscopy (SEM-
EDS) are used for this purpose.19 The recently introduced image directed Raman 
spectroscopy20 combines particle quantification by automated microscopy and 
identification by Raman spectroscopy. 
EVALUATION OF NOVEL TECHNIQUES FOR PARTICLE ANALYSIS                      CHAPTER 2 
51 
 
The aim of this study was a critical evaluation of novel techniques for protein 
particle analysis, either techniques from other fields of application or completely 
new measurement principles. Techniques evaluated were flow imaging 
microscopy (Sysmex FPIA-3000 and Occhio FC200S+), ESZ (Coulter counter 
Multisizer 4), RMM (Archimedes), and image directed Raman spectroscopy 
(rapID). These methods were compared to more established techniques such as 
Micro-Flow Imaging (MFI), light obscuration (LO), dynamic light scattering (DLS), 
and nanoparticle tracking analysis (NTA) with respect to particle detection, 
quantification, sizing or identification. 
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2 Materials and methods  
2.1 Materials 
Infliximab (Remicade®, lots no. 7GD9301402, 7FD8701601, 7RMKA81402, 
pooled) and rituximab (MabThera®, lot no. B6082) were provided by local 
hospitals. Polystyrene particle standards were purchased from Duke Scientific 
(through Thermo Scientific, Fremont, CA) and diluted in water for analysis. 
Infliximab solution at a concentration of 1 mg/mL was prepared by dilution of 
10 mg/mL infliximab commercial product in 100 mM phosphate buffer (pH 7.2). 
Rituximab solution at a concentration of 1 mg/mL was prepared by dilution of 
10 mg/mL rituximab commercial product in 25 mM citrate buffer (pH 6.5) 
containing 154 mM NaCl and 0.07% polysorbate 80. All protein formulations 
were filtered using a 0.2 µm cellulose acetate syringe filter (Minisart®, Sartorius 
Stedim Biotech, Aubagne, France) for further use. 
Freeze-thaw-stressed infliximab was prepared by subjecting 1.5 mL (for FPIA) or 
1 mL (for rapID) of the formulation to 5 (for FPIA) or 7 (for rapID) freeze-
thawing cycles of 30 minutes in a -80 °C freezer and 10 minutes in a 25 °C water 
bath in a 1.5 mL low protein binding reaction tube (Eppendorf, Hamburg, 
Germany). Stir-stressed infliximab was prepared by stirring 8 mL of the 
formulation in a 10R glass vial with a 18 mm Teflon®-coated stir bar at 250 rpm 
at room temperature on a magnetic stirrer (MR Hei-Standard, Heidolph, 
Schwabach, Germany) for 2 hours (for FPIA) or 24 hours (for ESZ and RMM) or 
by stirring 6 mL of the formulation for 1.5 hours (for rapID). Heat-stressed 
rituximab was prepared by incubating 1.5 mL of the formulation for 30 minutes 
at 71 °C in a 1.5 mL reaction tube in a thermomixer (Eppendorf, Hamburg, 
Germany). 
Sodium hydroxide, di-sodium hydrogenphosphate dihydrate and sodium 
dihydrogenphosphate dihydrate were purchased from Merck KGaA (Darmstadt, 
Germany). Sodium chloride, sodium citrate dihydrate and polysorbate 80 were 
from VWR (Darmstadt, Germany). The water used in this study was highly 
purified water (Advantage A10 purification system, Millipore, Newark, NJ). 
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2.2 Light obscuration (LO) 
Subvisible particles in a size range between 1 and 200 µm were analyzed by LO 
using a PAMAS SVSS-C (Partikelmess- und Analysesysteme GmbH, Rutesheim, 
Germany) equipped with an HCB-LD-25/25 sensor. Particle suspensions were 
diluted with the according buffer (filtered by a 0.22 µm cellulose acetate/nitrate 
membrane filter, MF-Millipore®, Millipore, Newark, NJ) or water in order to 
adhere to the concentration limit of the system of 120,000 particles/mL > 1 µm. 
Three measurements of a volume of 0.3 mL of each sample were performed with 
a pre-run volume of 0.5 mL at a fixed fill rate, emptying rate and rinse rate of 
10 mL/min and the mean particle concentration per mL was reported by the 
system. Samples were measured in triplicates and mean and standard deviation 
were calculated.  
2.3 Micro-Flow Imaging (MFI) 
Subvisible particles in a size range between 1 and 70 µm were analyzed by MFI 
using an MFI4100 (ProteinSimple, Santa Clara, CA) equipped with a high-
resolution 100 µm flow cell. Particle suspensions were diluted with the according 
buffer (filtered by a 0.22 µm cellulose acetate/nitrate membrane filter) or water 
in order to adhere to the concentration limit of the system of 1,200,000 
particles/mL > 0.75 µm. Samples were analyzed with a sample volume of 
0.65 mL and a pre-run volume of 0.3 mL at a flow rate of 0.1 mL/min. Prior to 
each sample run the respective diluting buffer was flushed through the system to 
provide a clean flow cell and to perform optimize illumination. Particles stuck to 
the flow cell wall were only counted once and edge particles were ignored for 
analysis. Samples were measured in triplicates and mean and standard deviation 
were calculated. Results were analyzed using the MFI view application software 
version 1.2 (ProteinSimple). 
2.4 Flow particle image analysis (FPIA) 
Subvisible particles in a size range between 1 and 300 µm were analyzed by flow 
particle image analysis (FPIA) using a Sysmex FPIA-3000 system (Malvern, 
Herrenberg, Germany) operated in high power field (HPF) with a 10x 
magnification lens. Particle suspensions were diluted with the according buffer 
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(filtered by a 0.22 µm cellulose acetate/nitrate membrane filter) or water in the 
same dilution as for MFI. Samples were analyzed directly in “particle sheath 
liquid” (containing detergents, exact composition is not disclosed by the 
manufacturer) in which the sample solution is “sandwiched” in order to enable a 
regular liquid flow and the orientation of particles parallel to the flow direction. 
Results were analyzed using the FPIA software version 13 (Malvern). 
2.5 Flow imaging microscopy analysis (Occhio) 
Subvisible particles in a size range between 1 and 100 µm were analyzed by flow 
imaging microscopy using an Occhio FC200S+ system (Occhio, Angleur, Belgium) 
equipped with a 50 µm spacer. Particle suspensions were diluted with the 
according buffer (filtered by a 0.22 µm cellulose acetate/nitrate membrane filter) 
in the same dilution as for MFI. Results were analyzed using the Callisto software 
(Occhio). 
2.6 Flow imaging microscopy analysis (FlowCAM VS1) 
Subvisible particles in a size range between 2 and 50 µm were analyzed by flow 
imaging microscopy using a FlowCAM VS1 Benchtop B3 system (Fluid Imaging, 
Yarmouth, ME) equipped with a 50 µm single-use cell and a 20x magnification 
lens. Samples were analyzed with a sample volume of 0.5 mL with a pre-run 
volume of 0.5 mL (primed manually into the flow cell) with a flow rate of 
0.07 mL/min and a camera rate of 20 frames/s. Prior to each sample run the 
system was flushed with 1 mL purified water at a flow rate of 0.5 mL/min and 
flow cell cleanliness was checked visually. Samples were measured in triplicates 
and mean and standard deviation were calculated. Results were analyzed using 
the VisualSpreadsheet software version 3.1.10 (Fluid Imaging). 
2.7 Electrical sensing zone (ESZ, Coulter counter) 
Subvisible particles in a size range between 1 and 30 µm were analyzed by ESZ 
using a Multisizer 4 system (Beckman Coulter, Fullerton, CA) equipped with a 
50 µm aperture tube. The system was filled with the appropriate buffer for 
analyzing protein particles or Isoton II (solution supplied by Beckman Coulter 
containing 154 mM NaCl as well as detergents, exact composition is not disclosed 
EVALUATION OF NOVEL TECHNIQUES FOR PARTICLE ANALYSIS                      CHAPTER 2 
55 
 
by the manufacturer) for analyzing polystyrene standards. All diluents were 
filtered by a 0.22 µm cellulose acetate/nitrate membrane filter. The system was 
calibrated three times with 5 µm polystyrene standards (supplied by Beckman 
Coulter) in the respective diluent and the mean calibration factor was used for 
further analysis. Each day before the first sample measurement, the calibration 
was verified with the same standards and performed again, if necessary. Particle 
suspensions were diluted with the according buffer or Isoton II in the same 
dilution as for LO. Samples were analyzed with a total sample volume of 10 mL in 
a 20 mL Accuvette® sample container (Beckman Coulter) for polystyrene 
standards or 2.4 mL in a 5 mL sample container (Nalgene®, distributed by VWR) 
for protein particles. Three runs of a volume of 0.1 mL were performed per 
measurement and the mean particle concentration per mL was reported by the 
system. In order to remove air bubbles the aperture tube was flushed with the 
respective diluent before the first run. Samples were measured in triplicates and 
mean and standard deviation were calculated. Results were analyzed using the 
Multisizer 4 software (Beckman Coulter). 
2.8 Resonant mass measurements (RMM, Archimedes) 
RMM was performed using the Archimedes particle metrology system (Affinity 
Biosensors, Santa Barbara, CA) equipped with a Micro sensor (size range 0.3 µm 
to 4 µm) calibrated with 1 µm polystyrene standards. Before each measurement, 
the system was filled with sample and the lower size limit of detection was 
determined three times in automatic mode. The mean value was set as a fixed 
limit of detection for the measurement. The buffer density was determined for 
each sample. The particle density for negatively buoyant particles was set to 
1.05 g/mL for polystyrene standards and 1.32 g/mL for proteinaceous particles 
according to the recommendation of the manufacturer. Particle suspensions were 
diluted with the according buffer (filtered by a 0.22 µm cellulose acetate/nitrate 
membrane filter) or water to achieve a coincidence rate (indicated by the 
system) below 10%. Measurements were performed in triplicates and the sensor 
was filled with fresh sample for each measurement. The measured volume was 
0.15 µL and the overall sample volume for triplicate measurements was 600 µL. 
Between triplicate measurements, the system was rinsed with water. Results 
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were analyzed using the ParticleLab software (v1.8.570, Affinity Biosensors) with 
a size bin step of 10 nm. 
2.9 Dynamic light scattering (DLS) 
Submicron aggregates and particles were analyzed by DLS using a DynaPro plate 
reader (Wyatt Technology Europe, Dernbach, Germany) at 25 °C. If possible 
samples were measured in the original state without sample preparation. 
However, in the presence of large protein particles which impeded the 
measurement due to extensive light scattering, samples were centrifuged for 10 
minutes at 7,000 g to remove those large particles. Three measurements per 
sample of 200 μL each were performed in a Corning 96-well plate using a manual 
mode of 10 runs of 5 or 10 s per measurement. Results were analyzed using the 
Dynamics software (version 6.12.03, Wyatt Technology Europe). 
2.10 Nanoparticle tracking analysis (NTA) 
Submicron aggregates and particles were analyzed by nanoparticle tracking 
analysis (NTA) using a NanoSight LM20 (NanoSight, Amesbury, United Kingdom) 
equipped with a 405 nm blue laser. Particle suspensions were diluted with the 
according buffer (filtered by a 0.22 µm cellulose acetate/nitrate membrane filter) 
or water to achieve particle concentrations between 107 and 109 particles/mL. 
Samples were loaded into the measurement cell using a 1 mL syringe. 
Movements of the particles in the samples were recorded as videos for 60 
seconds at room temperature using the NTA 2.1 software (NanoSight). Shutter 
and gain values were chosen manually to achieve an optimal particle resolution. 
The extended dynamic range mode, which allows different settings for two 
populations in one measurement, was applied for polydisperse samples. The 
recorded videos were analyzed using the NTA 2.1 software (NanoSight). 
2.11 Image directed Raman spectroscopy (rapID) 
Subvisible particles in a size range between 2 and 100 µm were analyzed by 
image directed Raman spectroscopy (rapID) using a liquid particle explorer (LPE, 
rapID Particle Systems, Berlin, Germany) or a single particle explorer (SPE, 
rapID Particle Systems) system.  
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Particle suspensions were filtered onto a gold coated membrane (pore size 
0.8 µm) under laminar air flow conditions and the filter was inserted into the LPE 
or SPE system. Particles larger than 2 µm were counted by automated optical 
microscopy in both systems and then identified by the SPE system by image 
directed Raman spectroscopy by comparison of the obtained Raman spectra for 
individual particles to a database (provided by rapID Particle Systems). Samples 
were analyzed in triplicates and mean and standard deviation were calculated if 
feasible due to long measurement times of several hours per sample. 
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3 Results and discussion 
3.1 Flow imaging techniques 
Flow imaging microscopy techniques are a valuable method to simultaneously 
count and visualize particles in therapeutic protein formulations and several 
different instruments are available which were comparatively evaluated for their 
suitability for protein particle analysis. The most common flow imaging 
microscopy instruments are MFI and FlowCAM which were comparatively 
evaluated in detail in a separate study (see Chapter 4). The systems evaluated in 
this study were originally developed for a different purpose and have entered the 
field of protein particle analysis only recently. 
The first flow imaging microscopy system evaluated in this study is the Sysmex 
FPIA-3000 system. In this instrument the sample is passed through a flow cell 
“sandwiched” between “particle sheath liquid”, particles are illuminated by a 
stroboscopic light source and images are captured by a charge-coupled device 
(CCD) camera. The particle sheath liquid technology is specific for this 
instrument and should ensure a preferential orientation of particles with their 
largest side towards the camera. This is in contrast to other flow imaging 
microscopy systems such as MFI or FlowCAM where the vertical flow presumably 
also ensures an orientation with the longest side, but not necessarily with the 
broadest side of the particle towards the camera. The image resolution is very 
high at the expense of sampling efficiency due to the small focus area connected 
to a very low analyzed volume of less than 1 µL.  
Polystyrene size standards were analyzed to assess size accuracy by FPIA as 
compared to MFI as a standard flow imaging microscopy technique and LO as the 
commonly used compendial technique for subvisible particle analysis (Figure 
2-1). The analysis of 5 µm size standards revealed a very narrow peak for FPIA, 
but at a too large size (around 6 µm), whereas analysis by MFI provided a 
slightly broader peak at the correct size. LO analysis showed a very broad peak 
due to the larger size channels in this instrument. For 10 µm size standards, all 
systems showed good size accuracy with again the FPIA system providing the 
sharpest peak. In contrast, the quantification of polystyrene count standards 
EVALUATION OF NOVEL TECHNIQUES FOR PARTICLE ANALYSIS                      CHAPTER 2 
59 
 
(5 µm count standard, certified concentration 3000+/-300 particles/mL > 3 µm) 
revealed clear differences among the systems: whereas the MFI system slightly 
overestimated the concentration (3488 particles/mL) and LO provided the correct 
concentration (3046 particles/mL), the FPIA system clearly undercounted the 
particles (952 particles/mL). This might be due to the very low analyzed volume 
in FPIA of less than 1 µL which is not representative of a sample of such a 
comparatively low concentration. 
 
Figure 2-1: Size accuracy of FPIA, MFI, and LO for (A) 5 µm and (B) 10 µm polystyrene 
size standards. 
 
The concentration of protein particles detected was clearly lower for FPIA as 
compared with MFI and LO (Figure 2-2). The determined concentration for FPIA 
as compared with MFI was about 10-15x lower for freeze-thaw-stressed (Figure 
2-2A) and about 3-4x lower for stir-stressed infliximab (Figure 2-2B), both for 
particles from 1 to around 8 µm. For freeze-thaw stressed infliximab, the number 
of particles above 8 µm was too low to draw significant conclusions. For stir-
stressed infliximab, the concentration for particles above 8 µm was higher for 
FPIA as compared with MFI. This could be due to the orientation of particles 
induced by the particle sheath liquid which becomes more important for larger 
particles with a clearly detectable shape as compared with small particles which 
appear rather spherical in general due to limitations in image resolution. 
However, the difference was not significant and this is more likely a minor effect. 
Above 10 µm the overall concentration of particles was too low to draw 
significant conclusions for both particle types. As compared with LO, MFI 
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detected about 2-3x higher concentrations as observed also in other          
studies.11,21-23 
 
Figure 2-2: Protein particle concentrations for (A) freeze-thaw-stressed or (B) stir-
stressed infliximab as determined by MFI, LO, and FPIA (cumulative size distribution). 
Error bars represent standard deviations from triplicate measurements. 
 
In addition to the technical differences in image capture between FPIA and MFI, 
the contact of the sample with the particle sheath liquid might also contribute to 
the observed differences in detected particle concentration. This might on the 
one hand lead to a dilution effect of the sample which is not exactly known and 
cannot be quantified, and on the other hand to a direct dissolution or generation 
of particles, e.g. by the contained detergents and other non-disclosed 
ingredients. To assess the second possibility, IgG particles were diluted in 
formulation buffer and in particle sheath liquid with the same dilution factor and 
analyzed by MFI (Figure 2-3). Interestingly, clear differences could be observed 
depending on the type of stress. IgG particles generated by freeze-thawing 
stress were not affected by dilution in particle sheath liquid and showed the same 
concentration in both diluents (Figure 2-3A). In contrast, IgG particles generated 
by stirring stress showed an about 1.5x higher concentration in formulation 
buffer for small particles below 10 µm, but higher concentrations in particle 
sheath liquid for particles above 10 µm (Figure 2-3B). This indicates on the one 
hand that small particles could indeed be partially dissolved by the sheath liquid, 
however only to a small extent as the difference between concentrations in the 
two liquids is not significant. The opposite effect for particles above 10 µm on the 
EVALUATION OF NOVEL TECHNIQUES FOR PARTICLE ANALYSIS                      CHAPTER 2 
61 
 
other hand points towards potentially enhanced aggregation caused by the 
particle sheath liquid, but the difference was again not significant.  
 
Figure 2-3: Protein particle concentrations for (A) freeze-thaw-stressed or (B) stir-
stressed infliximab after dilution in formulation buffer or particle sheath liquid as 
determined by MFI (cumulative size distribution). Error bars represent standard 
deviations from triplicate measurements. 
 
Another flow imaging microscopy system evaluated in this study is the Occhio 
FC200S+ system. This system uses an LED light source for particle illumination 
in a glass flow cell. The official size range starts already at 0.4 µm although 
image analysis in this size range is rather questionable. According to the 
manufacturer, this is possible as every recorded pixel of a particle is 
subsequently divided into 4 parts which can be analyzed separately. Various 
possibilities to change the optical settings allow the user to adjust the 
measurement parameters to the specific sample, but at the same time carry the 
risk of incorrect concentration and size determination due to non-optimal settings 
for threshold, shutter or gain. The evaluated Occhio FC200S+ system detected 
clearly (up to 17x) more protein particles (heat-stressed rituximab) than MFI, 
mainly in the lower size range below 5 µm, whereas lower concentrations were 
detected above 5 µm (Figure 2-4). A clear overestimation of small particles 
together with an underestimation of larger particles in flow imaging microscopy 
points towards image fragmentation - as suspected for the instrument by the 
division of one pixel into four parts after the analysis - which could potentially be 
addressed by the adjustment of the optical measurement settings. However, due 
to limited availability of the system, the sample could only be measured n=1 and 
further experiments to analyze or prevent potential image fragmentation could 
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not be performed. The phenomenon of image fragmentation in flow imaging 
microscopy is further described in Chapter 4. 
 
Figure 2-4: Protein particle concentrations for heat-stressed rituximab as determined by 
MFI and Occhio (cumulative size distribution). 
 
The image quality is an important parameter in flow imaging microscopy for the 
correct size determination and for characterization of particle transparency or 
shape supporting particle identification. Images of protein particles captured by 
the flow imaging microscopy techniques clearly differ (Table 2-1). Images from 
FPIA show the most details and the highest resolution due to the small focus 
area / analyzed volume. This confirms again that this instrument is very suitable 
for detailed particle morphology characterization as needed for example for the 
analysis of raw materials in odontology,24,25 at the expense of a reliable 
quantification. Images from the FlowCAM VS1 system show a similar image 
quality. The FlowCAM VS1 is listed only exemplarily here for a comparison of the 
image quality (see Chapter 4 for a detailed evaluation of this system). Images 
from MFI appear rather blurry as described also in Chapter 4, whereas particle 
images from Occhio are difficult to judge as they are displayed cropped at the 
particle border hampering also the evaluation of potential image fragmentation 
as described above. To our knowledge, neither the FPIA system nor the Occhio 
system has been applied for the characterization of protein particles in published 
studies. 
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Table 2-1: Representative protein particle images in a size range of about 5-20 µm of 
stir-stressed infliximab (MFI, FPIA) or heat-stressed rituximab (Occhio, FlowCAM VS1). 
Instrument MFI FPIA Occhio FlowCAM VS1 
Protein particles 
(5-20 µm) 
  
 
 
 
   
   
 
 
 
  
 
   
 
  
 
  
 
3.2 Non-optical particle analysis 
Non-optical techniques can be a promising alternative to light-based particle 
analysis. ESZ analysis is based on the increase of the electrical resistance caused 
by a particle passing an electrical field between two electrodes which is 
proportional to the non-conductive volume of the particle.12 The determined 
volume is then used to calculate the equivalent spherical diameter (ESD) 
assuming spherical shape. In RMM the change of the resonance frequency of a 
microchannel caused by a particle is proportional to the buoyant mass of the 
particle over the surrounding fluid which is then calculated also into the ESD 
provided that the density of the fluid and the particle is known. This instrument 
was introduced only a few years ago and is taking its first steps in the field of 
particle analysis. A detailed evaluation of RMM for its main application, the 
differentiation of silicone oil droplets and protein particles, is described in a 
separate study26 (see Chapter 3). In this chapter, ESZ and RMM were evaluated 
regarding sizing and counting performance for polystyrene standards and protein 
particles. 
Size accuracy in the µm size range was evaluated using 2 µm polystyrene size 
standards (Figure 2-5A). The standards were detected at exactly the correct size 
with a very narrow distribution by RMM. Also ESZ determined the particle size 
correctly with a marginally broader distribution. In contrast, particles were sized 
clearly below 2 µm by MFI which is probably due to the limited image resolution 
in this low size range. LO showed a very broad size distribution due to the larger 
size channels as discussed above. 
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Concentration linearity was evaluated with different dilutions of 2 µm (for MFI, 
LO, and RMM) or 5 µm standards (for ESZ) over a wide range from about 3x103 
to 1x106 particles/mL, based on LO (Figure 2-5B). The particle concentration 
measured by LO (as the established, compendial technique) was used as the 
theoretical concentration. For concentrations above the coincidence limit of LO 
(120,000 particles/mL), the theoretical concentration was calculated based on 
the concentration measured by LO below the coincidence limit. 
Up to a theoretical concentration of 1x105 particles/mL, all techniques showed 
very good linearity (Figure 2-5B, insert). This is in accordance with the literature 
for MFI, LO, and ESZ.13 Between 1x105 and 3x105 particles/mL, all techniques 
showed still good linearity with ESZ slightly overcounting and RMM slightly 
undercounting the particles (LO is only possible up to 1.2x105 particles/mL due to 
the coincidence limit of the system). Concentrations above 3x105 particles/mL 
could only be analyzed by MFI and RMM. Here, MFI provided good linearity 
whereas RMM clearly underestimated the concentration. This is due to 
coincidence of two particles. Those particles are not identified as coincidence, but 
simply counted as one particle in MFI, LO, and ESZ. In RMM, two particles 
detected too closely together are identified as coincidence, but as a consequence 
excluded completely from the analysis and not counted at all by the system. This 
means that the impact of concentration underestimation due to coincidence is in 
theory two times higher in RMM. However, the advantage of the RMM system is 
that the coincidence level is indicated by the system and it is recommended to 
dilute a sample if a coincidence level of 10% or higher is detected to avoid strong 
concentration underestimation.  
Furthermore, RMM data was affected by higher standard deviations as compared 
with the other techniques as described earlier16 due to the low analyzed volume 
(only 150 nL per measurement in this study). An increase of the analyzed 
volume would come along with very long measurement times (due to the very 
low flow rate of the system) which potentially changes sample properties in case 
of protein particles. Thus, the low sampling efficiency of RMM, which can lead to 
measurement times of several hours for very clean samples in order to count a 
sufficient number of particles, is a clear shortcoming of this technique. 
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Figure 2-5: (A) Size accuracy of 2 µm polystyrene size standards and (B) linearity of 
2 µm polystyrene size standards analyzed by MFI, LO, and RMM and 5 µm polystyrene 
size standards analyzed by ESZ. The insert in (B) shows a zoom into low concentrations. 
Error bars represent standard deviations from triplicate measurements. 
 
Size accuracy and resolution were further evaluated for ESZ as compared with LO 
using 2 µm, 5 µm, and 10 µm polystyrene size standards analyzed separately 
and as a mix (Figure 2-6). ESZ provided very good size accuracy and narrow size 
distributions for all sizes and also very clear resolution between the sizes (Figure 
2-6A). LO showed good size accuracy as well together with broader distributions 
as discussed above, but also acceptable separation between the different 
standards (Figure 2-6B). 
 
Figure 2-6: Size accuracy of polystyrene size standards of different sizes analyzed 
separately and as a mix by (A) ESZ and (B) LO. 
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Size accuracy of RMM, DLS, and NTA in the nm size range was evaluated using 
500 nm polystyrene size standards analyzed separately and as a mix together 
with 200 nm and 800 nm polystyrene size standards (Figure 2-7). RMM showed 
the best size accuracy for 500 nm standards whereas NTA slightly undersized the 
standards and DLS showed a broader distribution (Figure 2-7A). For the mix of 
200, 500, and 800 nm standards, RMM showed two distinct populations at the 
correct sizes of 500 and 800 nm (Figure 2-7B). The 200 nm standards were 
below the size range of the micro sensor used in this study and were therefore 
not detected. This result shows that the smaller 200 nm particles do not disturb 
the analysis of the larger particles. This is an important consideration for the 
analysis of protein samples which often contain large amounts of small particles 
below the measurement range. For NTA, it was not possible to analyze all three 
sizes with one single measurement setting. Thus, two measurements were 
performed with settings either optimized for larger or for smaller particles. 
Settings for larger particles enabled the detection of 500 and 800 nm standards 
at the correct size. Settings for smaller particles led to the detection of 200 and 
500 nm standards, however with diminished size accuracy especially for the 
200 nm standards. With DLS, only one population at about 500 nm was detected. 
These observations are in accordance with earlier studies about DLS and NTA27 
and show the benefit of single particle analysis as applied by NTA and RMM which 
enables excellent size resolution, especially by RMM, as compared with batch 
analysis as by DLS. 
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Figure 2-7: Size accuracy of (A) 500 nm polystyrene size standards and (B) a mix of 200, 
500, and 800 nm polystyrene size standards (number ratio 1:1:1) analyzed by DLS, NTA, 
and RMM. NTA 1* indicates a measurement with settings optimized for larger particles 
and NTA 2* for smaller particles. 
 
Size accuracy was further evaluated for RMM with different concentrations of 
500 nm polystyrene size standards (Figure 2-8). The total particle concentration 
had a clear influence on the size accuracy as a second population was detected 
for higher particle concentrations (Figure 2-8A). A total particle concentration of 
1.5x106 particles/mL led to the best size accuracy with a size mode at 503 nm 
and was therefore used as the basis for the calculation of the theoretical particle 
concentration in the other samples. The second population appeared at around 
600 nm for theoretical total particle numbers of 7.5x106 and 1.5x107 
particles/mL (representing the concentration range recommended by the 
manufacturer). The determined concentrations for those samples were only 
4x106 and 9x106 particles/mL indicating clear undercounting due to the high 
particle concentration as seen also for particles in the µm size range (Figure 
2-5B). For the highest evaluated concentration (theoretical concentration of 
7.5x107 particles/mL), a population at around 700 nm was detected as the only 
population. The total particle concentration in this case was determined as only 
1x107 particles/mL. This is mainly due to the high coincidence level of 16% which 
indicates that 2x16% = 32% of all particles were excluded from the analysis as 
the peaks were located too closely together. This confirms again the coincidence 
level as an important measurement parameter for RMM which should be 
monitored carefully. Coincidence levels above 10% lead not only to clear 
underestimation of the particle load, but also to incorrect particle sizing (Figure 
2-8B) and should therefore be avoided. On the other hand, a minimum particle 
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load of at least around 3x105 particles/mL (with the described measurement 
settings) is necessary to achieve a sufficient number of measured particles 
together with reasonable measurement times. This is due to the very low 
analyzed volume and the very low flow rate. As an example, an analyzed volume 
as small as 150 nL requires a measurement time of 10 minutes. 
 
Figure 2-8: Size accuracy for 500 nm polystyrene size standards (A) depending on the 
theoretical particle concentration (based on a theoretical concentration of 1.5x106 
particles/mL for the sample which showed the best size accuracy) and (B) connected to 
the coincidence level in RMM.  
 
Protein particles were analyzed by ESZ and RMM as novel techniques as 
compared to MFI, LO, DLS, and NTA (Figure 2-9). Samples for the µm-range 
were diluted for ESZ, MFI, and LO with the same dilution factor whereas a lower 
dilution factor could be applied for RMM. The obtained concentrations were 
calculated back to the original concentration in the sample to ensure 
comparability (Figure 2-9A). In the overlapping size range of 1-4 µm, ESZ 
detected a higher number of particles than MFI and LO which is in agreement 
with the literature.11,13 It is unclear whether this is due to an increased sensitivity 
of ESZ for protein particles or the underlying measurement principle. ESZ applies 
a three-dimensional size calculation as a particle “fits” completely into the 
aperture area and thus completely contributes to the electric signal. This is in 
contrast to the two-dimensional particle sizing by MFI and LO which is based on 
the image (MFI) or the shadow (LO) and only considers a cross section of the 
particle. ESZ detects those parts of a protein particle which block the electric 
current and converts this detected volume to the diameter of an equivalent 
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sphere. Buffer parts within the particle but also the protein itself might partially 
carry the electric current in ESZ and might thus be excluded from the calculated 
particle size. A clear disadvantage of ESZ is the requirement for sufficient buffer 
conductivity. In this case, the particles could be analyzed in the original buffer 
solution (100 mM phosphate buffer) as this buffer showed sufficient ionic 
strength for the used aperture tube (50 µm). However, in many cases, the ionic 
strength of the original formulation buffer is not sufficient and needs to be 
increased for the measurement which can then affect the particle properties. 
RMM detected for this specific sample similar particle concentrations as LO, 
clearly less than MFI and ESZ, in all size ranges. The difference to MFI may be 
again connected to the different underlying measurement principle as particle 
analysis by RMM is influenced by the particle density (see also Chapter 5 for 
further results and discussion of this topic). 
Samples for the nm range could be analyzed by DLS and NTA only after a 
centrifugation step to remove intensively scattering large particles (Figure 2-9B). 
In contrast, the sample could be analyzed in its original state by RMM (Figure 
2-9B, insert) enabling RMM to be applied in the “submicron size gap”.6,28 
However, a difficulty with RMM for highly-aggregated samples is potential 
clogging of the sensor which was not observed for this specific sample, but 
occurred for samples in other studies (data not shown). A major drawback of 
RMM is the small analyzed volume leading to a high multiplication factor for the 
calculation of the particle concentration per mL and causing high standard 
deviations. Taken together, RMM is a promising technique due to the light-
independent novel measurement principle, but quantitative data must be 
evaluated carefully and the technique might be more suitable for qualitative 
differentiation between two particle types. RMM was further evaluated in a 
separate study with the focus on the differentiation of silicone oil droplets and 
protein particles as its main area of application (see Chapter 3). 
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Figure 2-9: Protein particles (stir-stressed infliximab) analyzed by (A) MFI, LO, ESZ, and 
RMM for the µm size range and (B) DLS, NTA, and RMM for the nm size range. The insert 
shows results from RMM for the nm size range for the original sample and a sample after 
centrifugation. Error bars represent standard deviations from triplicate measurements. 
 
3.3 Particle identification techniques 
Characterization and identification are required for the root cause analysis about 
the origin of particles detected in therapeutic protein formulations. Also the 
authorities do not only require quantification, but also characterization and 
identification of particles as far as possible starting already at a particle size of 
2 µm.29 Several techniques are available for particle identification such as Raman 
and FT-IR microscopy or SEM-EDS7 (see Chapter 1). Image directed Raman 
spectroscopy, e.g. by rapID Particle Systems, combines automated light 
microscopy after filtration onto a gold-coated filter for quantification and Raman 
spectroscopy for identification by comparison of the obtained spectra of selected 
particles to a database. The difference to conventional Raman spectroscopy is 
that after the digital image analysis by light microscopy, the particle population 
can be filtered in the software e.g. by size, shape, or other parameters. Specific 
populations can then be selected for identification by Raman spectroscopy. 
To evaluate the quantification performance of image directed Raman 
spectroscopy, protein particle samples (freeze-thaw-stressed and stir-stressed 
infliximab) were analyzed by rapID LPE, a system specialized on quantification, 
and rapID SPE, a system specialized on identification. The obtained 
concentrations were compared to MFI and LO as established techniques (Figure 
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2-10). As expected from previous experiments, clearly more particles were 
detected by MFI as compared with LO. Clearly less particles as compared with LO 
were detected for freeze-thaw-stressed infliximab by both rapID LPE and SPE 
whereas similar concentrations as for LO were detected for stir-stressed 
infliximab. The results show that particle quantification by light microscopy after 
filtration may miss particles probably mainly due to the low contrast.30 
Furthermore, especially small, but also large particles may end up after the 
filtration as very thin protein layers on the filter due to their high liquid content 
and low compactness. This might be more critical in the case of freeze-thaw 
stressed samples as this stress induced many small and few large particles 
(Figure 2-2). Concentrations determined by rapID LPE were higher than those 
determined by rapID SPE for both particle types which was expected due to the 
specialization of the instruments. 
  
Figure 2-10: Protein particles (freeze-thaw-stressed or stir-stressed infliximab) analyzed 
by MFI, LO, rapID LPE, and rapID SPE. Error bars represent standard deviations from 
triplicate measurements for all techniques for freeze-thaw-stressed infliximab and MFI 
and LO for stir-stressed infliximab.  
 
Particle identification was performed by automated comparison of the recorded 
Raman spectra of 250 particles > 2 µm per sample to a database (Figure 2-11). 
In the stressed protein samples, only few particles were identified as protein 
particles (Figure 2-11A). The Raman spectra of the particles did not show 
sufficient quality and resolution to draw further conclusions. Very few particles 
were determined as cellulose and glass particles. In total, only 10% of all 
particles could be identified. 
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For samples of protein particles spiked with polystyrene size standards, the 
instrument was able to identify 10 µm polystyrene standards well whereas 5 µm 
polystyrene standards were hardly detected (Figure 2-11B). For 10 µm 
polystyrene standards, the obtained ratio of protein particles to polystyrene 
standards was 1:50 whereas a ratio of 8:1 was expected from the sample 
preparation. This underlines again the difficulty of the system for the detection of 
protein particles as the original purpose of this system is to identify non-
proteinaceous, extrinsic particles. The technique was successfully applied in 
literature to identify particles containing both protein and silicone oil larger than 
10 µm.20  A potential reason for the low performance in this study could be the 
size distribution of the protein particles with many small and few large particles. 
The filtration process for the rapID system should furthermore be improved to 
minimize contaminations, e.g. by single-use filtration units directly attached to 
the instrument. 
 
Figure 2-11: Particle identification by image directed Raman spectroscopy (rapID LPE 
system) for (A) samples prepared to contain only protein particles (freeze-thaw-stressed 
or stir-stressed infliximab) and (B) samples of protein particles (stir-stressed infliximab) 
spiked with polystyrene size standards. Error bars represent standard deviations from 
triplicate measurements for freeze-thaw-stressed infliximab. 
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4 Conclusion 
This study showed that a critical evaluation of novel analytical techniques for the 
specific purpose of application is crucial to judge the suitability for protein 
particle analysis. Table 2-2 provides an overview of the systems evaluated in this 
study including the most important benefits and shortcomings which were 
observed. Flow imaging microscopy provided varying results depending on the 
used instrument: The FPIA system showed its strength in capturing images of 
high resolution enabling a profound particle characterization, but its weakness in 
particle quantification. The Occhio system determined a clearly different particle 
size distribution as compared to MFI pointing towards strong dependency on the 
optical measurement settings for this instrument. Thus, the more established 
flow imaging microscopy techniques for the analysis of protein particles are to be 
preferred. The non-optical particle counting techniques ESZ and RMM displayed 
both good sizing and counting performance. Analysis by RMM demonstrated clear 
benefits for highly polydisperse samples, especially in the high nm size range, 
which enables this technique to be applied in the “submicron size gap”. However, 
the main application of this technique is the differentiation of silicone oil droplets 
and protein particles. The identification of particles in therapeutic protein 
formulations by image directed Raman spectroscopy appeared as an interesting 
approach with the need for further technical improvements. Taken together, 
techniques and systems which were originally developed for other purposes and 
also novel measurement principles might be beneficial for protein particle 
analysis, but need to be evaluated carefully case by case. 
 
 
 
 
Table 2-2: Overview of the properties as well as benefits and shortcomings of the systems evaluated in this study. 
Technique Principle Purpose Instrument Size range Benefits Shortcomings 
Flow imaging 
microscopy 
Image analysis of 
digital particle images 
captured in a flow cell 
Size and count 
information, 
characterization 
of particle 
transparency, 
shape, identity 
(limited) 
Sysmex 
FPIA-3000 
1-300 µm 
High image 
resolution 
Very low analyzed 
volume  limited 
quantification 
performance 
Occhio 
FC200 S+ 
1-100 µm - 
Large difference to 
concentration in MFI 
(reason unclear, 
potentially image 
fragmentation) 
FlowCAM 
VS1 
2-50 µm 
High image 
resolution 
n.a. a 
Electrical 
sensing zone 
Increase of the 
electrical resistance in 
an electrical field  
proportional to particle 
size 
Size and count 
information 
Coulter 
counter 
Multisizer 4 
1-30 µm 
Non-optical 
measurement 
principle 
Sufficient buffer 
conductivity required 
Resonant 
mass 
measurement 
Frequency shift of a 
resonating cantilever 
proportional to 
buoyant mass of 
particles in the 
cantilever 
Size and count 
information, 
differentiation 
between 
particles of 
different 
density b 
Archimedes 0.3-4 µm 
Non-optical 
measurement 
principle, suitable 
for the analysis in 
the submicron 
size gap 
Very low analyzed 
volume  low 
sampling efficiency, 
potential clogging of 
the sensor by large 
particles 
Image 
directed 
Raman 
spectroscopy 
Image analysis after 
filtration followed by 
Raman spectroscopy 
on selected particles 
Identification of 
extrinsic 
particles 
rapID LPE 
rapID SPE 
2-100 µm 
Additional 
information about 
particle identity 
Difficulties for the 
detection of protein 
particles probably due 
to shrinkage during 
filtration 
a see Chapter 4 for a detailed evaluation of this instrument; b see Chapter 3 for a detailed evaluation of this application 
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                Chapter 3
                                
Micro-Flow Imaging and resonant mass 
measurement (Archimedes) – Complementary 
methods to quantitatively differentiate 
protein particles and silicone oil droplets 
Abstract 
Our study aimed to comparatively evaluate Micro-Flow Imaging (MFI) and the 
recently introduced technique of resonant mass measurement (Archimedes, 
RMM) as orthogonal methods for the quantitative differentiation of silicone oil 
droplets and protein particles. This distinction in the submicron and micron size 
range is highly relevant for the development of biopharmaceuticals, in particular 
for products in prefilled syringes. Samples of artificially generated silicone oil 
droplets and protein particles were quantified individually and in defined mixtures 
to assess the performance of the two techniques. The built-in MFI software 
solution proved to be suitable to discriminate between droplets and particles for 
sizes above 2 µm at moderate droplet/particle ratios (70:30 – 30:70). A 
customized filter developed specifically for this study greatly improved the results 
and enabled reliable discrimination also for more extreme mixing ratios (95:5 – 
15:85). RMM showed highly accurate discrimination in the size range of about 
0.5 to 2 µm independent of the ratio, provided that a sufficient number of 
particles (> 50 counted particles) were analyzed. We recommend applying both 
techniques for a comprehensive analysis of biotherapeutics potentially containing 
silicone oil droplets and protein particles in the submicron and micron size range. 
 
The following chapter was published as a research article in the Journal of Pharmaceutical Sciences 
and appears in this thesis with the journal’s permission: 
D. Weinbuch*, S. Zölls*, M. Wiggenhorn, W. Friess, G. Winter, W. Jiskoot, A. Hawe: “Micro-Flow 
Imaging and resonant mass measurement (Archimedes) – complementary methods to 
quantitatively differentiate protein particles and silicone oil droplets”; J Pharm Sci 102(7):2152-
2165 (2013); *joint first authors  
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1 Introduction 
Protein aggregates can be classified according to their size as visible (>100 µm), 
micron (1-100 µm), submicron (100 nm-1000 nm) and nanometer particles 
(<100 nm).1 Especially aggregates in the micron and submicron size range raise 
concerns as they are potentially immunogenic,2,3 could coalesce to form larger 
particles over time or function as nuclei for further aggregation.4 Even though the 
United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) 
currently define concentration limits in parenteral solutions only for particles 
larger than 10 µm, regulatory authorities increasingly expect quantitative 
characterization of micron particles from 1 to 10 µm and qualitative 
characterization of submicron particles from 100 nm to 1000 nm already in early 
stages of the development phase.5-7 In many cases substantial amounts of 
particles below 10 µm are often present in formulations that meet the limits of 
the pharmacopoeias for larger particles.8-10 
In general, particles of all sizes can be proteinaceous or non-proteinaceous. 
Among the group of non-proteinaceous particles, silicone oil droplets, which are 
also quantified as particles by routine methods like light obscuration, play a 
major role. This is especially important for products in prefilled syringes or 
cartridges, where silicone oil droplets are introduced into the product deriving 
from the lubrication of the glass barrel and the plunger. In a case study, silicone 
oil droplets were identified inside the eyes of patients after intravitreal injection, 
likely originating from the siliconized glass syringes.11 In earlier studies, silicone 
oil droplets were detected in insulin syringes and associated with loss of insulin 
efficacy.12,13 Furthermore, silicone oil droplets were present in Interferon 
products in prefilled syringes.14 Even though silicone oil itself is not necessarily 
harmful to the patient,15 it has been described to induce aggregation of 
monoclonal antibodies16 and various other proteins17,18 and the formation of 
protein-silicone oil complexes18,19 which might potentially be immunogenic.20 
From a manufacturing perspective, elevated concentrations of (silicone) oil 
droplets can indicate problems during the production process, e.g. improper 
siliconization of syringes or contamination from leaking components during 
lyophilization. These factors make an analytical differentiation of the total particle 
load into protein particles and silicone oil droplets necessary. 
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Among the various techniques for particle analysis,21 scanning electron 
microscopy coupled with energy dispersive X-ray spectroscopy (SEM-EDS),22 
Fourier-transformed infrared (FT-IR)22 and Raman microscopy,23 asymmetrical 
flow field flow fractionation,24 electrical sensing zone as well as flow cytometry25 
are in principle able to differentiate silicone oil droplets and protein particles. 
However, mainly flow imaging microscopy techniques and the recently introduced 
resonant mass measurement (RMM) technique are designed for the 
differentiation of these particles in a higher throughput and without cumbersome 
sample preparation (e.g. staining or fixation). Micro-Flow Imaging (MFI) has 
received major attention for the analysis of protein particles22,26-28 but has also 
been applied for the identification of silicone oil droplets.29 Silicone oil droplets 
were successfully differentiated from protein particles on MFI images on the basis 
of their spherical shape30 and, more efficiently, by employing a multi-parametric 
filter.31 
The recently introduced Archimedes system employs the novel principle of RMM 
for the analysis of submicron and micron particles.32 The sample solution is 
flushed through a microchannel inside a resonating cantilever (also designated as 
suspended microchannel resonator (SMR)) which changes its frequency 
depending on the mass of the particles passing the channel. Importantly, 
positively buoyant particles (e.g. silicone oil droplets) and negatively buoyant 
particles (e.g. protein particles) can be clearly discriminated as they increase and 
decrease the frequency of the cantilever, respectively.33 With a theoretical size 
range from about 50 nm up to about 6 µm (depending on the sensor and the 
particle type), RMM aims to bridge the “submicron size gap”15,34 between on the 
one hand flow imaging microscopy and light obscuration, which cover the 
micrometer size range, and on the other hand nanoparticle tracking analysis and 
dynamic light scattering, which allow analysis in the nanometer size range. 
Literature on RMM is still very limited. Patel et al.35 presented a first study on the 
principle of RMM using various microspheres as well as silicone oil droplets and 
protein particles for a technical evaluation of the system. Barnard et al.14 applied 
RMM to analyze protein particles and silicone oil droplets in marketed Interferon-
beta products. However, the accuracy of the differentiation between these two 
particle types was not investigated in those studies and remains to be elucidated. 
CHAPTER 3                     MFI AND RMM FOR QUANTITATIVE PARTICLE DIFFERENTIATION 
80 
 
The aim of our study was to evaluate MFI and RMM as orthogonal tools for the 
quantitative discrimination between silicone oil droplets and proteinaceous 
particles in the micron and submicron range. For this purpose, defined mixtures 
of silicone oil droplets and protein particles were prepared at various ratios on 
the basis of the distributions expected in marketed biopharmaceutical products in 
prefilled syringes. The optical discrimination of silicone oil droplets from protein 
particles in MFI by (i) the built-in software solution “find similar” and (ii) a new 
customized data filter developed in this study was compared to the physical 
discrimination principle of RMM. 
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2 Materials and methods 
2.1 Materials 
Etanercept (Enbrel®, prefilled syringe, lot no. 31576, exp. 12/2008; lot no. 
32411, exp. 09/2009), adalimumab (Humira®, prefilled syringe, lot no. 
292209A05, exp. 10/2006; lot no. 430989A04, exp. 02/2008), rituximab 
(MabThera®, vial, lot no. B6073, exp. 12/2013) and infliximab (Remicade®, vial, 
lot no. 7GD9301402, 7FD8701601, 7RMKA81402, pooled) were donated by local 
hospitals. Sucrose, mannitol, sodium chloride, trisodium citrate dihydrate and 
polysorbate 80 were purchased from VWR (Darmstadt, Germany), disodium 
hydrogenphosphate dihydrate and sodium dihydrogenphosphate dihydrate were 
purchased from Merck KGaA (Darmstadt, Germany). Silicone oil with a viscosity 
of 1000 cSt (same viscosity as used in other studies15,16,25 and as listed in the 
Ph.Eur. monography for silicone oil as a lubricant36), citric acid and arginine 
hydrochloride were purchased from Sigma Aldrich (Steinheim, Germany). 
2.2 Preparation of protein samples 
Etanercept solution at a concentration of 5 mg/mL was prepared by dilution of 
50 mg/mL etanercept (removed from the prefilled syringe through the needle) in 
25 mM phosphate buffer (pH 6.3) containing 100 mM NaCl, 25 mM arginine 
hydrochloride and 1% sucrose. Adalimumab solution at a concentration of 
5 mg/mL was prepared by dilution of 50 mg/mL adalimumab in 15 mM 
phosphate/citrate buffer (pH 5.2) containing 105 mM NaCl, 1.2% mannitol and 
0.1% polysorbate 80.  
Rituximab solution at a concentration of 1 mg/mL was prepared by dilution of 
10 mg/mL rituximab commercial product in 25 mM citrate buffer (pH 6.5) 
containing 154 mM NaCl and 0.07% polysorbate 80 (formulation buffer). The 
formulation was filtered using a 0.2 µm polyethersulfone syringe filter (Sartorius, 
Göttingen, Germany) and kept at 2-8 °C for a maximum of one week. Heat-
stressed rituximab was prepared by incubating 1.5 mL of the 1 mg/mL rituximab 
solution for 30 minutes at 71 °C in a thermomixer (Eppendorf, Hamburg, 
Germany). Stir-stressed rituximab was prepared by incubating 3 mL of the 
1 mg/mL rituximab solution in a 5R glass vial using a 12 mm Teflon®-coated stir 
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bar at 1000 rpm for 24 hours at room temperature on a magnetic stirrer 
(Heidolph MR 3001K, Heidolph, Schwabach, Germany). Stressed rituximab at 
1 mg/mL (protein particle stock suspension) was stored at 2-8 °C until the 
measurement. 
Infliximab solution at a concentration of 1 mg/mL was prepared by dilution of 
10 mg/mL infliximab commercial product in 100 mM phosphate buffer (pH 7.2). 
The formulation was filtered using a 0.2 µm polyethersulfone syringe filter. Heat-
stressed infliximab was prepared by incubating 0.5 mL of the 1 mg/mL infliximab 
solution for 30 minutes at 60 °C in a thermomixer. Stir-stressed infliximab was 
prepared by incubating 8 mL of the 1 mg/mL infliximab solution in a 10R glass 
vial using a 18 mm Teflon®-coated stir bar at 250 rpm for 24 hours at room 
temperature on a magnetic stirrer (Heidolph MR Hei-Standard).  
2.3 Preparation of silicone oil emulsion 
Pure silicone oil was added to filtered formulation buffer (0.2 µm 
polyethersulfone syringe filter) in a particle-free 15 mL conical tube (VWR) to a 
final concentration of 2% (w/v) to generate a pure emulsion without additives. 
After vortexing briefly, silicone oil droplet formation was induced by sonication in 
a water bath (Sonorex, Brandelin, Berlin, Germany) for 10 minutes. Fresh 
silicone oil emulsion (silicone oil droplet stock emulsion) was prepared on the day 
of the measurement and kept at room temperature. 
2.4 Preparation of individual and mixed samples of 
silicone oil droplets and protein particles 
Silicone oil droplet stock emulsion and/or protein particle stock suspension (heat-
stressed rituximab) was diluted in unstressed protein solution or filtered 
formulation buffer for the preparation of mixed and individual samples. Unless 
stated otherwise, samples were prepared to a final protein concentration of 
0.5 mg/mL. Mixed samples were prepared to cover ratios of silicone oil droplets 
to protein particles of 95:5 to 15:85 based on particle counts > 1 µm determined 
by MFI. Individual samples were prepared to contain the same amount of silicone 
oil droplets and protein particles, respectively, as in the mixed samples and were 
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referred to as the theoretical concentration. The samples were gently mixed with 
a pipette, kept at room temperature and measured on the day of preparation. 
2.5 Micro-Flow Imaging (MFI) 
An MFI DPA4100 series A system (ProteinSimple, Santa Clara, CA) equipped with 
a 100 µm flow cell, operated at high magnification (14x) and controlled by the 
MFI View software version 6.9 was used. The system was flushed with 5 mL 
purified water at maximum flow rate and flow cell cleanliness was checked 
between measurements. Unstressed and filtered rituximab or the appropriate 
formulation buffer was used to perform “optimize illumination” prior to each 
measurement. Samples of 0.65 mL with a pre-run volume of 0.3 mL were 
analyzed at a flow rate of 0.1 mL/min (n=3). MVAS version 1.2 was used for data 
analysis. 
2.6 Development of a customized filter for MFI 
The MVAS software of the MFI system enables the discrimination of particles 
based on optical parameters of the generated images through the “find similar” 
operation. For our study, a minimum of 20 particles above 5 µm clearly 
recognizable as silicone oil droplets was selected for the discrimination. In 
addition to this, a customized filter was developed specifically for the heat-
stressed rituximab samples of this study. In detail, the new filter was based on 
four customized size-specific cut-offs for particle parameters of silicone oil 
droplets provided by MFI (Figure 3-1), which proved to be suitable to 
discriminate silicone oil droplets and protein particles. This approach is a 
modification of previous work by Strehl et al.31 The four parameters used for our 
filter were intensity mean (Figure 3-1A), intensity minimum (Figure 3-1B), 
intensity standard deviation (Figure 3-1C) and aspect ratio (Figure 3-1D). The 
first three parameters are based on the intensity of the particle image, which is 
directly proportional to the transparency of the particle.27 The intensity mean 
describes the mean intensity value over all pixels within one particle; the 
intensity minimum describes the intensity of the darkest pixel of a particle; and 
the intensity standard deviation describes differences between higher and lower 
intensity values within the same particle. The aspect ratio defines the shape of a 
particle with “1” for an absolutely spherical particle and “0” for a needle with an 
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infinite length. For each of the four particle parameters, the individual 
distributions for silicone oil droplets and protein particles from heat-stressed 
rituximab were compared as a function of size. 
Cut-offs were defined at the mean value of the 95% confidence intervals 
between the two populations (Figure 3-2). A polynomial function was 
automatically fitted to these points from 1 to 11 µm and applied for particles 
from 1 to 9 µm. Above 11 µm, the number of counts acquired was not sufficient 
for this statistical approach; therefore, the fit was adjusted manually in this 
larger size range. The automated and the manual fit were overlapped in the size 
range from 9 to 11 µm to ensure a smooth transition. Since the silicone oil 
droplet population was more homogeneous than the protein particle population, 
the customized filter was set to identify objects as silicone oil droplets only when 
they fulfilled all four cut-off fit criteria. Particles showing values below the cutoff 
for intensity mean and minimum (Figure 3-1A and B) and at the same time 
above the cutoff for intensity standard deviation and aspect ratio (Figure 3-1C 
and D) were marked as silicone oil droplets by the algorithm. Particles fulfilling 
less than four of these criteria were assigned as non-silicone oil particles, which 
means in our case protein particles. 
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Figure 3-1: Scatter plots of particle parameters (A) intensity mean, (B) intensity 
minimum, (C) intensity standard deviation, and (D) aspect ratio for individual samples 
containing only protein particles (heat-stressed rituximab) or only silicone oil droplets 
analyzed separately by MFI and merged into one graph per particle parameter. The solid 
red lines illustrate cutoffs as a function of size, generated by our customized fit for the 
discrimination between silicone oil droplets and protein particles. The dash-dotted green 
lines illustrate linear cutoffs used by the MVAS software for the “find similar” operation. 
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Figure 3-2: Distribution of the MFI particle parameters (A) intensity mean, (B) intensity 
minimum, (C) intensity standard deviation and (D) aspect ratio for individual samples of 
silicone oil droplets and protein particles (heat-stressed rituximab). Box plots show 
25/75% (box) and 5/95% percentiles (whisker) as well as minimum and maximum 
values (X). The mean values of the 95% confidence intervals (CI) were used as a basis 
to fit the function for the customized filter. 
 
2.7 Resonant mass measurement (RMM) 
An Archimedes system (Affinity Biosensors, Santa Barbara, CA) was equipped 
with a Hi-Q Micro Sensor and controlled by the ParticleLab software version 1.8. 
The sensor was flushed for 60 seconds with purified water prior to analysis. 
Subsequently, possible impurities in the system were removed by two “sneeze” 
operations (liquid in the sensor is pushed into both directions) and the system 
was flushed again for 60 seconds with purified water. The sample solution was 
then loaded for 45 seconds. Prior to analysis, the limit of detection (LOD) was 
determined three times in automatic LOD mode. The mean value was then set 
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fixed for each measurement. Samples of 150 nL were analyzed (n=3) and fresh 
sample solution was loaded for each of the triplicate measurements. 
Size determination of particles by RMM is based on the frequency shift f which is 
proportional to the buoyant mass MB and depending on the sensitivity S of the 
resonator (Equation 3-1). 
SfM
B
  
Equation 3-1 
 
The conversion of buoyant mass MB into dry mass M (Equation 3-2) and diameter 
D (Equation 3-3) is then based on the density of the particle, ρparticle (1.32 g/mL 
for protein particles, based on the density estimation of pure protein37 and the 
recommendation of the manufacturer; 0.97 g/mL for silicone oil, according to the 
supplier) and the density of the fluid, ρfluid (calculated based on the sensor 
frequency relative to the frequency and the density of water as a reference).  
particlefluid
B
M
M
 /1 
  
Equation 3-2 
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3 Results and discussion 
3.1 Silicone oil droplets in prefilled syringes 
Expired prefilled syringes of etanercept and adalimumab were available for the 
study and analyzed in order to gain insight into relevant levels and size 
distributions of silicone oil droplets in marketed products as a worst case 
scenario. Four and six years after expiration, respectively, MFI determined for 
both products about 4x105 particles/mL above 1 µm. Based on the images 
generated by MFI, about 80% of the particles above 5 µm in both products could 
be identified as silicone oil droplets using the “find similar” operation provided by 
the MVAS software. RMM determined 3.2x106 particles/mL larger than 0.5 µm for 
etanercept and 2.0x106 particles/mL for adalimumab, of which 51% and 97%, 
respectively, could be attributed to silicone oil. Three and four years after 
expiration, RMM determined for both analyzed products lower concentrations of 
protein particles and of silicone oil droplets when compared to products four and 
six years after expiration, respectively (Table 3-1). This implies that total particle 
concentrations as well as the ratio between silicone oil droplets and protein 
particles can vary substantially between products, lots, and age of the product. 
Table 3-1: Total particle and silicone oil droplet concentrations of expired marketed 
products in prefilled syringes determined by RMM. 
Product 
Total particle 
concentration per mL 
(> 0.5 µm) 
Identified as silicone oil 
droplets per mL 
(> 0.5 µm) 
Etanercept   
lot 32411, exp. 09/2009 1.50 x 106 1.46 x 106 
lot 31576, exp. 12/2008 3.25 x 106 1.68 x 106 
Adalimumab   
lot 430989A04, exp. 02/2008 1.74 x 106 1.61 x 106 
lot 292209A05, exp. 10/2006 2.01 x 106 1.94 x 106 
 
3.2 Determination of total particle concentrations 
(without discrimination) 
For the evaluation of MFI and RMM, silicone oil droplets were artificially 
generated, which appeared similar to those found in etanercept and adalimumab 
prefilled syringes with respect to their shape, optical properties (Figure 3-3) and 
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size distribution (Figure 3-4). The concentrations used in our study (0.003% to 
0.025% (w/v) silicone oil) provided droplet concentrations similar to those 
identified in the expired etanercept and adalimumab prefilled syringes and are in 
agreement with other studies suggesting the presence of up to 0.03% of silicone 
oil in prefilled syringes.38,39 
 
Figure 3-3: Examples of MFI images of protein particles and silicone oil droplets detected 
in marketed products and artificially generated samples. 
 
CHAPTER 3                     MFI AND RMM FOR QUANTITATIVE PARTICLE DIFFERENTIATION 
90 
 
 
Figure 3-4: Cumulative size distributions of silicone oil droplets determined by MFI and 
identified by the “find similar” operation in (A) etanercept prefilled syringes, (B) 
adalimumab prefilled syringes, (C) a sample containing only artificially generated 
silicone oil droplets. Error bars represent standard deviations from triplicate 
measurements. 
 
A heat-stress method was developed using rituximab as a model for the 
generation of particles with a similar appearance to protein particles in 
etanercept prefilled syringes. A stir-stress method was developed for the 
generation of particles similar to those in adalimumab prefilled syringes (Figure 
3-3). All protein samples showed comparable particle size distributions with the 
smaller particles representing the largest fraction (Figure 3-5). Protein particles 
in concentrations from 1x105 to 5x105 particles/mL above 1 µm (according to 
MFI) were combined with silicone oil droplets in concentrations from 1x105 to 
3x105 particles/mL above 1 µm (according to MFI). Using MFI and RMM, several 
samples with varying concentrations of protein particles and silicone oil droplets 
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were analyzed, both individually and as mixtures at various defined 
droplet/particle ratios. 
 
Figure 3-5: Cumulative size distributions of protein particles determined by MFI and 
identified by the “find similar” operation for silicone oil droplets (protein particles are 
identified as the inverse population) in (A) etanercept prefilled syringes, (B) adalimumab 
prefilled syringes, (C) heat-stressed rituximab, (D) stir-stressed rituximab, (E) 
unstressed rituximab. Error bars represent standard deviations from triplicate 
measurements. 
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First, the particle concentrations for individual samples containing either only 
silicone oil droplets or only protein particles were determined by MFI and RMM. 
One combination is shown as a representative example in Figure 3-6 for the 
overlapping measurement size range of both techniques (1-4 µm). Overall, the 
results indicate that particle counts and size distributions by MFI and RMM are in 
general agreement. However, certain differences were observed depending on 
the type of sample and the ratio of protein particles and silicone oil droplets: For 
samples containing only silicone oil, RMM detected slightly more droplets of 1 to 
4 µm as compared to MFI, while MFI detected more droplets in the size range 
from 2 to 4 µm (Figure 3-6A). This trend was reproducible for all silicone oil 
droplet samples, with an up to twofold higher silicone oil droplet count in the size 
range of 1 to 4 µm detected by RMM as compared to MFI. 
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Figure 3-6: Cumulative size distributions in the size range of 1-4 µm of (A) a sample 
containing only silicone oil droplets, (B) a sample containing only protein particles (heat-
stressed rituximab), and (C) the corresponding mixture (droplet/particle ratio 40:60 for 
particles > 1 µm based on MFI) as determined by MFI and RMM. Error bars represent 
standard deviations from triplicate measurements. 
 
This difference might be due to two major reasons: 
(i) Silicone oil droplets of sizes up to 50 µm were identified by MFI, which are 
much larger than the microchannel diameter of RMM (8 µm). Those particles 
larger than 8 µm represent only 4% of all silicone oil droplets in the sample 
detected by MFI by number; however, they contain 72% of the total mass of all 
silicone oil droplets in the sample detected by MFI (mass was calculated based on 
droplet counts at the respective diameter and the density of silicone oil of 
0.97 g/mL). These observations led us to the hypothesis that larger silicone oil 
droplets might be fragmented into smaller ones by shear forces inside the 
microchannels and capillaries of the RMM system. This would result in an 
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increased number of smaller silicone oil droplets in RMM. Our hypothesis was 
supported by MFI data from a sample containing only silicone oil, which was 
analyzed before RMM and collected after an RMM measurement. In this case, an 
increase in silicone oil droplet concentration between 1 and 2 µm with a 
concomitant decrease above 2 µm was observed when comparing particle 
concentrations before and after the RMM measurement (Figure 3-7A). It could be 
shown that this was clearly an effect of the RMM measurement itself and not of 
the dilution of the sample during the RMM measurement (Figure 3-7B). A 
decreased flow rate during sample analysis might reduce this fragmentation 
effect but would further increase the already long measurement time of RMM. 
(ii) Additionally, small particles near the detection limit of MFI could be 
“overlooked” by the software, as suggested also by others,40 further enhancing 
the differences between MFI and RMM for small (1 µm) silicone oil droplet counts. 
 
Figure 3-7: Differential size distribution of a sample containing only silicone oil droplets 
(0.04% (w/v)) analyzed by MFI (A) before RMM and collected after RMM analysis and 
(B) before and after dilution according to the dilution factor of 218 of the sample during 
RMM analysis. Counts were normalized to the total particle count. 
 
In contrast to the results from silicone oil samples, RMM detected consistently 
less protein particles than MFI in individual samples over the entire 1 to 4 µm 
size range (Figure 3-6B). This was also observed in another study by our group.41 
This difference is suggested to occur for two reasons:  
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(i) MFI and RMM apply fundamentally different measurement principles (Figure 
3-8): MFI captures 2D microscopic particle images (Figure 3-8A) and size 
determination of particles by MFI is performed according to their spatial 
dimension on the images defined by the outer boundary of the particle. The 
differentiation of protein particles and silicone oil droplets is based on 
morphological parameters such as particle shape and transparency. In contrast, 
RMM detects particles as distinct positive or negative peaks in the frequency 
trace caused by the physical parameter of particle buoyancy (Figure 3-8B). 
However, protein particles may vary in density and contain substantial amounts 
of liquid.42 This is not included into the size calculation by RMM, causing a 
potential underestimation of particle sizes in RMM as compared to MFI, which 
includes liquid inside the particle in the size calculation. This in turn would lead to 
an apparent shift of the complete particle size distribution in RMM towards 
smaller particle sizes resulting in lower concentrations detected for the respective 
size bins in RMM as compared to MFI. 
 
Figure 3-8: Raw data of an exemplary mixed sample containing protein particles (heat-
stressed rituximab) and silicone oil droplets from (A) MFI (image-based discrimination) 
and (B) RMM (frequency-based discrimination). 
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(ii) As a second reason, the micron-sized capillaries and channels of the RMM 
sensor are vulnerable to clogging by particles at or above the upper size limit of 
the system. Even though RMM offers several tools to remove stuck particles, 
clogging cannot always be avoided. Thus, large stuck particles could hinder other 
particles from reaching the sensor. This could explain why the concentration 
discrepancy between RMM and MFI is more pronounced at larger particle sizes, 
because smaller particles will pass a clogged site more easily, whereas larger 
particles, although still in the measurement range, are more likely to be excluded 
from the analysis. Altogether, this will result in lower apparent protein particle 
concentrations in RMM. A possible solution would be sample preparation for 
highly aggregated samples, e.g. filtration or centrifugation, which can however 
potentially change sample properties. 
Total particle concentrations for mixed samples containing both silicone oil 
droplets and protein particles also revealed slight differences between MFI and 
RMM for the overlapping size range of 1 to 4 µm (Figure 3-6C). For moderate 
ratios (silicone oil droplets/protein particles 40:60 based on MFI shown as a 
representative sample), RMM detected less particles than MFI, likely due to the 
underestimation of protein particles as described before. However, in mixed 
samples of higher silicone oil content (silicone oil droplets/protein particles 80:20 
or 95:5 based on MFI) similar concentrations were determined by the two 
techniques. In those samples, the overestimation of silicone oil droplets by RMM 
was balanced out by the underestimation of protein particles by RMM leading to 
similar total particle counts in MFI and RMM. For all samples, RMM showed higher 
standard deviations than MFI. This is probably mainly due to the small analyzed 
volume in RMM (about 0.15 µL) as compared to MFI (about 35 µL). 
It was further investigated whether the presence of both silicone oil droplets and 
protein particles within the same sample influenced the accuracy of MFI or RMM 
to determine total particle concentrations. For MFI, the concentration determined 
for mixed samples of silicone oil droplets and protein particles from heat-stressed 
rituximab matched very closely the sum of the concentrations determined for the 
corresponding individual samples (Figure 3-9A). For RMM, the concentration for 
the mixed sample reasonably matched the sum of the individual samples for the 
main size classes (Figure 3-9B). These observations were consistent for different 
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ratios and also for protein particles from stir-stressed rituximab mixed with 
silicone oil droplets. This justified the use of particle counts of individual samples 
as the theoretical concentrations for mixed samples. 
 
Figure 3-9: Cumulative size distributions  in individual samples of silicone oil droplets 
and protein particles (heat-stressed rituximab) and the corresponding mixture analyzed 
by (A) MFI and (B) RMM. Error bars represent standard deviations from triplicate 
measurements. 
 
3.3 Discrimination between silicone oil droplets and 
protein particles 
The discrimination between silicone oil droplets and protein particles by MFI and 
RMM is based on clearly different mechanisms (see above and Figure 3-8). The 
optical discrimination by MFI bears the potential risk of false classification due to 
optically similar silicone oil droplets and protein particles in the lower size range, 
especially near the detection limit. In contrast, the discrimination by RMM based 
on the physical parameter of particle buoyancy enables a clear discrimination 
with minimal risk of false classification. In this case, the difference in density 
between silicone oil droplets and protein particles is beneficial. 
3.3.1 Discrimination between droplets and particles by MFI 
In the present paper, the performance of MFI was assessed using the built-in 
software solution “find similar” and a customized data filter developed specifically 
for this study. To evaluate the reliability of our customized filter, the following 
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control experiments were performed: the filter was applied on samples 
containing only silicone oil droplets and the number of objects falsely marked as 
protein particles was determined and vice versa. Our customized filter marked 
less than 3% of the counts in the samples containing only silicone oil droplets 
(3x105 particles/mL > 1 µm based on MFI) falsely as protein particles (> 2 µm) 
and less than 8% of the counts in the samples containing only protein particles 
(4x105 particles/mL > 1 µm based on MFI) falsely as silicone oil droplets 
(> 2 µm). These controls illustrate the capability of our filter to properly 
discriminate protein particles and silicone oil droplets. The requirement that all 
four criteria of particle parameters need to be fulfilled at the same time is the 
main difference of our filter compared to the filter previously developed by Strehl 
et al.31, which used the product of four particle parameters as criterion for 
particle classification. In this case, extreme values in one parameter could shift 
the product to the side of one particle type although the other three parameters 
would classify it clearly as the other particle type. Thus, their filter led to errors 
of 10% to 12% (> 2 µm) for silicone oil droplets classified falsely as protein 
particles; the error for protein particles classified falsely as silicone oil droplets 
depended strongly on the type of protein particles and varied between 2% and 
42% in their study.31 In contrast, our filter applies more strict criteria for silicone 
oil droplet identification as particles fulfilling only three out of four criteria are not 
marked as silicone oil droplets leading to lower errors as discussed above. 
However, for protein particles generated from a different monoclonal IgG 
(infliximab) by heat stress or stir stress the customized filter marked up to 40% 
(> 2 µm) falsely as silicone oil droplets. This was most likely due to the lower 
intensity (lower transparency) of particle images of this IgG, which makes a 
misclassification as silicone oil droplets of similarly low transparency more likely. 
This is in agreement with the literature, where large variations were also 
observed by Strehl et al.31 when their filter was applied to different types of 
protein particles. The MVAS software filter could not be tested on these protein 
samples as it was based on manual selection of silicone oil droplet images which 
were not present in these pure protein samples. 
The “find similar” operation of the MVAS software as well as the customized filter 
were both used to categorize particles from mixed samples into silicone oil 
droplets and non-silicone oil particles. Non-silicone oil particles were defined as 
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protein particles in our case. The obtained concentrations were compared to the 
theoretical concentrations based on the analysis of the individual samples, which 
were used to assess the accuracy of both methods (Figure 3-10A,C, Figure 3-11). 
For moderate droplet/particle number ratios from 30:70 to 70:30 based on MFI, 
both the selection by “find similar” and the customized filter were able to 
determine the correct concentrations within acceptable deviations for particles 
> 2 µm. This was observed for samples containing silicone oil droplets and 
protein particles from heat-stressed rituximab (Figure 3-10A exemplarily shows 
the results for a sample with a droplet/particle ratio of 40:60 based on MFI). For 
stir-stressed rituximab (Figure 3-10C) the customized filter for MFI showed 
superior discrimination compared to the “find similar” method for particles 
> 2 µm, even though the customized filter was designed based on heat-stressed 
rituximab particles. The even higher intensity of MFI particle images of stir-
stressed rituximab compared to those of heat-stressed rituximab (Figure 3-3) 
likely contributes to this: since three out of four parameters of the customized 
filter are based on the particle intensity, it facilitates discrimination from the 
lower intensity silicone oil droplets. Furthermore, the customized filter was 
superior for samples with more extreme droplet/particle number ratios (see 
Figure 3-11A, B for representative examples) and for samples based on original, 
undiluted rituximab solution (Figure 3-11C). 
CHAPTER 3                     MFI AND RMM FOR QUANTITATIVE PARTICLE DIFFERENTIATION 
100 
 
 
Figure 3-10: Results from MFI (A and C) or RMM (B and D) for the discrimination 
between silicone oil droplets and protein particles. Histograms comparing the theoretical 
concentrations (based on individual samples) and determined concentrations of silicone 
oil droplets and protein particles (A and B, heat-stressed rituximab; C and D, stir-
stressed rituximab) in mixed samples with moderate ratios (droplet–particle ratio 40:60 
based on MFI). Error bars represent standard deviations from triplicate measurements. 
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Figure 3-11: MFI cumulative counts comparing theoretical concentrations (based on 
individual samples) and determined concentrations of silicone oil droplets and protein 
particles (heat-stressed rituximab) in droplet/particle ratios of (A) 95:5 and (B) 15:85 in 
samples containing 0.5 mg/mL rituximab as well as (C) 60:40 in a sample containing 
undiluted rituximab (10 mg/mL). Error bars (A and B) represent standard deviations 
from triplicate measurements. 
 
Thus, for particles between 2 µm and 25 µm, the development of a customized 
filter is useful for an accurate discrimination by MFI. For particles with a size 
below 2 µm, discrimination by an alternative method is recommended (e.g. RMM, 
as discussed later) as both “find similar” and the customized filter were not 
reliably capable of determining the correct concentration. For particles larger 
than 25 µm, due to usually low particle numbers in this size range, manual 
classification of the MFI images might be preferred over the built-in software 
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solution or a customized filter. Those particles can usually be identified easily by 
visual evaluation of the images. 
3.3.2 Discrimination between droplets and particles by RMM 
As described for MFI, RMM was evaluated with respect to an accurate 
discrimination between silicone oil droplets and protein particles in mixed 
samples (Figure 3-10B,D, Figure 3-12). For moderate particle/droplet ratios, 
RMM was consistently able to discriminate particles correctly with small 
deviations from the theoretical concentrations for heat-stressed (Figure 3-10B) 
and stir-stressed rituximab (Figure 3-10D). Large deviations of 20% or more 
from the theoretical concentration were only observed if the discrimination was 
based on less than 50 counted particles (corresponding in this case to total 
concentrations (droplets + particles) < 3x105 particles/mL) and thus statistical 
representation of the sample population was limited. This was for example the 
case for particles larger than 2 µm (Figure 3-10B,D). Increasing the analyzed 
sample volume would compensate for the limited reliability of RMM to quantify 
low particle concentrations, as also reported by others.35 However, it needs to be 
considered that very long measurement times associated with large analyzed 
volumes could also provoke changes in sample properties. In contrast, fairly high 
concentrations of protein particles > 2x106 particles/mL caused high standard 
deviations potentially due to the increased probability of coinciding particles and 
also blockage of the channel by particles (Figure 3-12A). However, extreme 
droplet/particle ratios with high amounts of silicone oil droplets provided 
moderate standard deviations and also fairly accurate determination of the 
theoretical concentration (Figure 3-12B exemplarily displays results for a 
droplet/particle ratio of 95:5 based on RMM). Those results provide evidence that 
RMM discrimination is reliable for particles below 2 µm. 
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Figure 3-12: RMM cumulative counts comparing theoretical concentrations (based on 
individual samples) and determined concentrations of silicone oil droplets and protein 
particles (heat-stressed rituximab) in droplet/particle ratios of (A) 40:60 and (B) 95:5. 
Error bars represent standard deviations from triplicate measurements. 
 
3.4 Comparison of results for MFI and RMM 
For a final evaluation of MFI and RMM regarding the discrimination of silicone oil 
droplets and protein particles, results for the same sample were compared 
between the two techniques. For silicone oil droplets and heat-stressed rituximab 
(Figure 3-10A,B, droplet/particle ratio 40:60) as well as stir-stressed rituximab 
(Figure 3-10C,D, droplet/particle ratio 40:60), RMM detected a higher fraction of 
silicone oil droplets as compared to MFI for the sizes above 1 µm already in the 
individual samples. This originated foremost from the differences in total 
concentration determination as discussed earlier: RMM detected in general more 
silicone oil droplets than MFI, whereas MFI detected in general more protein 
particles than RMM (see also Figure 3-6). However, in this size range, RMM 
results for the mixed samples are considered more reliable as RMM differentiation 
was shown to be highly accurate (Figure 3-10B,D). MFI differentiation suffered 
from low image resolution in the lower size range leading to large deviations for 
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both the “find similar” operation and the customized filter (Figure 3-10A,C). With 
increasing particle size, the ratios between MFI and RMM in the individual 
samples converged and similar ratios for individual samples were obtained for 
particles > 2 µm (Figure 3-10A,B shows a droplet/particle ratio of 30:70 for 
particles > 2 µm in individual samples for both MFI and RMM). For mixed 
samples, the concentration obtained by MFI is suggested to be more reliable for 
sizes above 2 µm as the discrimination between droplets and particles was highly 
accurate, especially when the customized filter was applied (Figure 3-10A,C). 
RMM analysis of objects with a size above 2 µm was based on small numbers of 
counts, questioning the reliability of the determined concentrations (Figure 
3-10B,D) in our study. 
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4 Recommendations and conclusions 
Table 3-2 summarizes properties as well as pros and cons during the application 
of MFI and RMM which were identified in our study. For MFI, the customized filter 
was shown to provide correct results for moderate and extreme ratios between 
silicone oil droplets and protein particles. The filter was developed using heat-
stressed rituximab particles, but was also found applicable for rituximab particles 
generated by stir stress and for samples containing rituximab solution in high 
concentrations (10 mg/mL). In contrast, the application for infliximab particles 
generated by either heat or stir stress resulted in large errors. These results 
emphasize the necessity of customizing the filter to each specific protein, the 
formulation, and the particle type / stress method of interest. Thus, the 
development of a customized filter for quality control of protein therapeutics in 
prefilled syringes with comparable manufacturing conditions can be considered 
reasonable. In contrast, the implementation during formulation development with 
varying conditions should be critically evaluated case by case. The separation by 
the MVAS software was acceptably accurate especially for moderate ratios of 
silicone oil droplets and protein particles. It could still be applied in those cases, 
when costs and time for the development of a customized filter would exceed the 
benefit of a more accurate discrimination. However, the differentiation by “find 
similar” showed clearly higher standard deviations as compared to the 
customized filter. This higher variation of the “find similar” operation originated 
most likely from the underlying sample and operator dependent manual selection 
of the particle images. For both MFI-based solutions it is important to consider 
that the separation is based on the identification of silicone oil droplets, whereas 
the remaining particles, identified only as “non-silicone oil particles”, are simply 
equated with protein particles by the operator. 
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Table 3-2: Summarizing comparison of MFI and RMM for the analysis of silicone oil 
droplets and protein particles. 
 
MFI  
(MFI4100, HighMag settings) 
RMM  
(Archimedes, Micro sensor) 
                              Properties of the techniques 
Principle 
Flow imaging microscopy with 
digital image analysis 
Sizing based on optical particle 
boundary 
Mass determination by 
quantification of frequency shift 
Sizing based on particle density 
Size range 1-70 µm 0.3-4 µm 
Differentiation of 
protein particles and 
silicone oil droplets 
Based on morphological 
parameters (shape, 
transparency…) of particle 
images 
Differentiation may be time-
consuming (esp. development 
of customized filter) 
Based on particle buoyancy 
(density) 
Differentiation during the 
measurement without 
additional time consumption 
Concentration range 
Up to 1x106 particles/mL 
(coincidence not indicated by 
the system) 
3x105 to 1x107 particles/mL 
(coincidence indicated by the 
system) 
Reproducibility Higher reproducibility 
Lower reproducibility 
(due to lower analyzed volume) 
Status of the 
technique 
Established R&D and cGMP 
technique 
Novel R&D technique 
                           Pros and Cons during application 
Protein particles 
Clear visualization of larger 
particles 
Clogging by larger particles 
possible 
Silicone oil droplets 
Detection of larger droplets 
without fragmentation 
Fragmentation of larger 
droplets possible 
Samples containing 
protein particles and 
silicone oil droplets 
2-10 µm: good differentiation 
by built-in software filter or 
(preferably) customized filter 
>10 µm: easy identification by 
visual evaluation of particle 
images 
0.5-2 µm: unambiguous 
differentiation due to physical 
detection principle 
 
Complexes of 
protein particles and 
silicone oil droplets 
Potential identification of larger 
complexes (> about 5-10 µm) 
Potential misclassification, 
miscalculation of particle size 
or no detection 
More than one 
particle type of 
higher density (e.g. 
protein and rubber, 
steel, glass) 
Potential differentiation 
according to optical appearance 
(refractive index or shape) 
No differentiation possible 
 
For RMM, the discrimination was very accurate for different types of protein 
particles and different ratios as long as sufficiently high numbers of particles 
were detected. The high accuracy of RMM is due to the straightforward 
categorization of particles and droplets according to buoyant mass. This makes 
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RMM a very robust technique for exactly this task. It needs to be considered that 
RMM can only discriminate one type of positively buoyant from one type of 
negatively buoyant particles. Thus, if a sample contains protein particles as well 
as other particles of higher density than the buffer, e.g. particles shed from filling 
pumps or rubber stoppers, RMM is not able to discriminate them. Here, methods 
such as SEM-EDS, FT-IR or Raman microscopy43 could be used as orthogonal 
methods to further identify these “non-silicone oil” particles. Furthermore, 
complexes consisting of both protein and silicone oil can pose a challenge for the 
technique of RMM: The reported size of those complexes may be incorrect due to 
the simultaneous influence of both material densities on the density of the 
complex. As a worst case the complexes might be missed entirely as the higher 
density of protein is compensated by the lower density of silicone oil, eliminating 
a clear density difference between particle and formulation. Those complexes 
might be detectable by MFI (given that they are large enough) as shown for an 
IgG particle containing silicone oil.22 In our study, only very few of those 
complexes were observed in MFI, because protein particles and silicone oil 
droplets were prepared separately to avoid interactions of protein and silicone oil 
during the particle formation process.  
Taken together, the robust detection principle of RMM has brought significant 
benefit to the field of protein product characterization, especially for the 
discrimination of silicone oil droplets and protein particles. RMM differentiation is 
recommended for particles below 2 µm, provided that sufficient particle 
quantities are detected. MFI differentiation is recommended above 2 µm, 
preferably using a customized filter. In order to cover a size range as broad as 
possible, both techniques should be applied in parallel for a comprehensive 
analysis of samples potentially containing silicone oil droplets and protein 
particles in the size range from 500 nm to 70 µm.  
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                                                                   Chapter 4
               
Flow imaging microscopy for protein particle 
analysis – a comparative evaluation of four 
different analytical instruments 
Abstract 
Flow imaging microscopy was introduced as a technique for protein particle 
analysis a few years ago and has strongly gained in importance ever since. The 
aim of the present study was a comparative evaluation of four of the most 
relevant flow imaging microscopy systems for biopharmaceuticals on the market: 
MFI4100, MFI5200, FlowCAM VS1, and FlowCAM PV. The performance was 
critically assessed regarding particle quantification, characterization, image 
quality, differentiation of protein particles and silicone oil droplets, and handling 
of the systems. The FlowCAM systems, especially the FlowCAM VS1, showed high 
resolution images. The FlowCAM PV system provided the most precise 
quantification of particles of therapeutic monoclonal antibodies, also under 
impaired optical conditions by an increased refractive index of the formulation, 
and furthermore, the most accurate differentiation of protein particles and 
silicone oil droplets could be achieved with this instrument. The MFI systems 
provided excellent size and count accuracy (evaluated with polystyrene 
standards), especially the MFI5200 system. This instrument also showed very 
good performance for protein particles, also in case of an increased refractive 
index of the formulation. Both MFI systems were easier to use and appeared 
more standardized regarding measurement and data analysis as compared to the 
FlowCAM systems. Our study shows that the selection of the appropriate flow 
imaging microscopy system depends strongly on the main output parameters of 
interest and it is recommended to decide based on the intended application. 
The following chapter was accepted for publication as a research article in The AAPS Journal: 
S. Zölls*, D. Weinbuch*, M. Wiggenhorn, G. Winter, W. Friess, W. Jiskoot, A. Hawe: “Flow imaging 
microscopy for protein particle analysis – a comparative evaluation of four different analytical 
instruments”; The AAPS Journal (accepted); *joint first authors 
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1 Introduction 
Protein aggregates and particles are important quality attributes of therapeutic 
protein formulations.1-3 Especially micron sized aggregates (subvisible protein 
particles)4 are considered as critical due to their potential risk of enhancing an 
immunogenic response.5 Quantification of (not necessarily proteinaceous) 
subvisible particles larger than 10 µm and 25 µm in parenterals is required by 
the pharmacopoeias, and is commonly performed using light obscuration (LO) 
techniques.6,7 For therapeutic protein products regulatory agencies increasingly 
ask for quantification and characterization of particles with a size below 10 µm by 
an orthogonal approach.8,9 Furthermore, the availability of an increasing number 
of emerging techniques10,11 extends the spectrum of particle analysis tools and 
enables a more detailed characterization of the particles counted. These factors 
inspired the development of a new educational chapter USP<1787> entitled 
“Measurement of Subvisible Particulate Matter in Therapeutic Protein 
Injections”.12 It is currently being discussed whether this chapter should include 
particle analysis starting already from 2 µm as well as the use of additional 
techniques, such as flow imaging microscopy. Flow imaging microscopy has 
already been used extensively in research and development13-19 and more 
recently also for quality control/routine testing (own experiences). 
Flow imaging microscopy uses a CCD camera with high magnification to capture 
images of the sample solution passing a thin flow cell. The flow cell is illuminated 
and particles with a different refractive index (RI) than the solution decrease the 
light intensity compared to the background and can be detected on the captured 
images.20,21 Particle size and count information is then generated based on image 
analysis. Besides quantification, the digital particle images allow for subsequent 
morphological characterization including size, shape and optical parameters. 
This, however, requires sufficiently high image quality to draw reliable 
conclusions.21 A prominent application example is the differentiation of silicone oil 
droplets and protein particles in prefilled syringes and cartridges. For this 
approach, flow imaging microscopy has been successfully applied in several 
studies.22-24 In general, flow imaging microscopy tends to be more sensitive than 
LO for small transparent protein particles and therefore usually detects higher 
particle numbers.13,15,25 An increased RI of the formulation, leading to a 
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decreased RI difference between particles and formulation, can impede a correct 
detection of protein particles by light-based techniques. Compared to LO, MFI 
was shown to be slightly more robust against such a decreased RI difference.13,26 
There are several flow imaging microscopy instruments available on the market 
provided by different suppliers. Those are, for example, Sysmex Flow Particle 
Image Analyzer (FPIA) 3000 by Malvern Instruments (Worcestershire, UK), 
various Occhio Flowcell systems by Occhio (Angleur, Belgium), the MicroFlow 
Particle Sizing System by JM Canty (Buffalo, NY), several Micro-Flow Imaging 
(MFI) systems by Protein Simple (Santa Clara, CA), and various Flow Cytometer 
And Microscope (FlowCAM) systems by Fluid Imaging (Yarmouth, ME). In this 
study, MFI and FlowCAM systems with different settings were evaluated (Table 
4-1). Both systems are often used for the analysis of subvisible particles in 
research and development and partly also for routine testing in a QC 
environment. A short general article about the handling of MFI and FlowCAM is 
available,27 but no comprehensive report about a direct comparison of the four 
systems has been published until now.  
Here we present the first study thoroughly challenging four of the most relevant 
flow imaging microscopy systems for biopharmaceuticals on the market: 
MFI4100 and MFI5200 as well as FlowCAM VS1 and FlowCAM PV. By that we 
want to provide a basis for the increasing use of such systems in QC and support 
industry and authorities in their efforts towards new standards in the field of 
subvisible particle characterization.  
 Table 4-1: Overview of technical parameters and settings of the systems evaluated in this study. 
Parameter Effect on MFI4100 MFI5200 FlowCAM VS1 FlowCAM PV 
Magnification 
(combination of 
camera and lens 
magnification) 
Image resolution 14x 5x 200x 100x 
Flow cell depth 
(depth of field) 
Sample volume, 
flow rate, 
measurement time 
100 µm 100 µm 50 µm 80 µm 
Focus 
adjustment 
Size accuracy 
By screw driver 
(supported by software) 
By turning knob 
(evaluated optically) a 
By manufacturer 
(not adjustable by user) 
Size range - 0.75 – 70 µm 1 – 70 µm 2 – 50 µm b 2 – 80 µm b 
Flow rate 
Sampling 
efficiency, 
measurement time 
Fixed 
(0.1 mL/min) 
Fixed 
(0.17 mL/min) 
Adjustable 
(0.005-200 mL/min) c 
(0.07 mL/min in this study) 
Adjustable 
(0.005-20 mL/min) c 
(0.04 mL/min in this study) 
Image capture 
rate 
Fixed to maximize efficiency 
and to minimize image overlaps 
Adjustable 
(1-22 frames/sec) 
(20 frames/s in this study) 
Adjustable 
(1-22 frames/sec) 
(21 frames/s in this study) 
Sampling 
efficiency 
Statistical 
relevance of the 
data 
Fixed 
(5-8%) 
Fixed 
(80-85%) 
Adjustable 
(5-8% in this study) 
Adjustable 
(80-85% in this study) 
CFR21 part 11 
compatibility 
GMP suitability No Yes No Yes 
a support by software available in the newest generation of the FlowCAM VS1 according to the manufacturer; b official size range as indicated by the 
manufacturer, lower size limit could be extended to 1 µm in this study; c depending on the syringe size 
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2 Materials and methods 
2.1 Materials 
Infliximab (Remicade®, lots no. 7GD9301402, 7FD8701601, 7RMKA81402, 
pooled) and rituximab (MabThera®, lot no. B6082) were provided by local 
hospitals. Polystyrene particle standards were purchased from Duke Scientific 
(through Thermo Scientific, Fremont, CA) and diluted in water for analysis. 
Sucrose, sodium hydroxide, di-sodium hydrogenphosphate dihydrate and sodium 
dihydrogenphosphate dihydrate were purchased from Merck KGaA (Darmstadt, 
Germany). Sodium chloride, sodium citrate dihydrate and polysorbate 80 were 
from VWR (Darmstadt, Germany). Silicone oil with a viscosity of 1000 cSt was 
purchased from Sigma Aldrich (Steinheim, Germany). The water used in this 
study was highly purified water (Advantage A10 purification system, Millipore, 
Newark, NJ). 
Sucrose solutions were prepared by dilution (w/w) of a 70% (w/w) solution, 
filtered using a 0.2 µm cellulose acetate syringe filter (Minisart®, Sartorius 
Stedim Biotech, Aubagne, France) and air bubbles were removed by 
centrifugation for 5 minutes at 7,000 g (Centrifuge 5810R, Eppendorf, Hamburg, 
Germany) prior to use. 
2.2 Preparation of protein samples 
Rituximab solution at a concentration of 1 mg/mL was prepared by dilution of 
10 mg/mL rituximab commercial product in 25 mM citrate buffer (pH 6.5) 
containing 154 mM NaCl and 0.07% polysorbate 80 (formulation buffer). The 
formulation was filtered using a 0.2 µm polyethersulfone syringe filter (Sartorius, 
Göttingen, Germany) and kept at 2-8 °C for a maximum of one week. Heat-
stressed rituximab was prepared by incubating 1.5 mL of the 1 mg/mL rituximab 
solution for 30 minutes at 71 °C in a thermomixer (Eppendorf, Hamburg, 
Germany). Stressed rituximab at 1 mg/mL (protein particles stock suspension) 
was stored at 2-8 °C until the measurement. 
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Infliximab solution at a concentration of 1 mg/mL was prepared by dilution of 
10 mg/mL infliximab commercial product in 100 mM phosphate buffer (pH 7.2). 
The formulation was filtered through a 0.2 µm polyethersulfone syringe filter. 
Stir-stressed infliximab was prepared by incubating 8 mL of the 1 mg/mL 
infliximab solution in a 10R glass vial using a 18 mm Teflon®-coated stir bar at 
250 rpm for 24 hours at room temperature on a magnetic stirrer (MR Hei-
Standard, Heidolph, Schwabach, Germany). 
For analysis of protein samples, stressed protein solution was diluted in the 
appropriate buffer (filtered through a 0.22 µm cellulose acetate/nitrate 
membrane filter, MF-Millipore®, Millipore), sucrose solution or water. 
2.3 Preparation of silicone oil emulsion 
Silicone oil was added to filtered formulation buffer in a particle-free 15 mL 
conical tube to a final concentration of 2% (w/v) to generate an emulsion without 
additives. After vortexing briefly, silicone oil droplet formation was induced by 
sonication in a water bath (Sonorex, Brandelin, Berlin, Germany) for 10 min. 
Fresh silicone oil emulsion (silicone oil droplet stock emulsion) was prepared on 
the day of the measurement and kept at room temperature. 
2.4 Preparation of individual and mixed samples of 
silicone oil droplets and protein particles 
Silicone oil droplet stock emulsion and/or protein particles stock suspension was 
diluted in unstressed protein solution or filtered formulation buffer for the 
preparation of mixed and individual samples. Mixed samples were prepared in a 
number ratio of 10:90 based on particle counts > 2 µm determined by MFI4100. 
Individual samples were prepared to contain the same number of silicone oil 
droplets and protein particles, respectively, as in the mixed samples and are 
referred to as the theoretical concentration. All samples were prepared to a final 
protein concentration of 0.5 mg/mL rituximab. The samples were gently mixed 
with a pipette, kept at room temperature and measured on the day of 
preparation. 
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2.5 Refractive index determination 
Refractive indices of sucrose solutions were determined using an Abbé 
refractometer (Carl Zeiss, Oberkochen, Germany). Measurements were 
performed in triplicate at a wavelength of 589 nm at room temperature and the 
mean value was calculated. 
2.6 Light obscuration (LO) 
Polystyrene standards were analyzed by LO using a PAMAS SVSS-C 
(Partikelmess- und Analysesysteme, Rutesheim, Germany) equipped with an 
HCB-LD-25/25 sensor in order to obtain a reference value for linearity evaluation 
with polystyrene standards of MFI4100, MFI5200, FlowCAM VS1, and FlowCAM 
PV. Samples were diluted to a concentration of approx. 103 particles/mL as a 
reference point for the flow imaging microscopy instruments. Three 
measurements of a volume of 0.3 mL for each sample were performed with a 
pre-run volume of 0.5 mL at a fixed fill rate, emptying rate and rinse rate of 
10 mL/min and the mean particle concentration per mL was reported by the 
system. Samples were measured in triplicate and mean and standard deviation 
were calculated. 
2.7 Micro-Flow Imaging (MFI) 
2.7.1 MFI4100 
An MFI4100 system (ProteinSimple) equipped with a 100 µm flow cell, operated 
at high magnification (14x) and controlled by the MFI View software version 6.9 
was used. The system was flushed with 5 mL purified water at maximum flow 
rate and flow cell cleanliness was checked visually between measurements. 
Water, the appropriate sucrose solution, filtered unstressed rituximab 
formulation (0.5 mg/mL) or the appropriate formulation buffer was used to 
perform “optimize illumination” prior to each measurement to ensure correct 
thresholding of the MFI system. Samples of 0.65 mL with a pre-run volume of 
0.3 mL were analyzed at a flow rate of 0.1 mL/min and a fixed camera rate (not 
adjustable by the user) leading to a sampling efficiency of about 5-8%. Samples 
were measured in triplicate and mean and standard deviation were calculated. 
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2.7.2 MFI5200 
An MFI5200 system (ProteinSimple) equipped with a 100 µm flow cell and 
controlled by the MFI View System Software (MVSS) version 2-R2.6.1.20.1915 
was used. The system was flushed with 10 mL purified water at maximum flow 
rate and flow cell cleanliness was checked visually between measurements. 
“Optimize illumination” prior to each measurement was done comparably to 
MFI4100. Samples of 0.5 mL with a pre-run volume of 0.2 mL were analyzed at a 
flow rate of 0.17 mL/min and a fixed camera rate (not adjustable by the user) 
leading to a sampling efficiency of about 80-85%. Samples were measured in 
triplicate and mean and standard deviation were calculated. 
2.7.3 Particle data analysis MFI 
For both systems, MFI View Analysis Suite (MVAS) version 1.2 was used for data 
analysis. Particles stuck to the flow cell wall were only counted once and edge 
particles were excluded from analysis. Particle size was evaluated as the 
diameter of a circle with the same projected area as the particle (designated as 
ECD, equivalent circular diameter, in the MFI software). For the discrimination of 
silicone oil droplets and protein particles, a minimum of 20 particles (MFI4100) or 
50 particles (MFI5200) above 5 µm clearly recognizable as silicone oil droplets 
was selected for the “find similar” operation in the MVAS software. 
2.8 FlowCAM analysis 
2.8.1 FlowCAM VS1 
A FlowCAM VS1 Benchtop B3 system (Fluid Imaging Technologies) was equipped 
with a 50 µm single-use cell, a 20x magnification lens and controlled by the 
VisualSpreadsheet software version 3.1.10. The system was flushed with 1 mL 
purified water at a flow rate of 0.5 mL/min and flow cell cleanliness was checked 
visually. 0.5 mL sample solution with a pre-run volume of 0.5 mL (primed 
manually into the flow cell) was analyzed with a flow rate of 0.07 mL/min and a 
camera rate of 20 frames/s leading to a sampling efficiency of about 5-8%. Only 
dark pixels were selected for particle size determination at the preset default 
threshold value of 20. Particle size was evaluated as the diameter of a circle with 
the same projected area as the particle (designated as ABD, area based 
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diameter, in the FlowCAM software). For the discrimination of silicone oil droplets 
and protein particles, a filter can be developed and the parameters can be saved 
in the software. However, to ensure comparability with the MFI systems and to 
represent the analysis of a single sample as good as possible, the selection of 
silicone oil droplets in this study was performed on a sample-by-sample basis. A 
minimum of 20 particles above 5 µm clearly recognizable as silicone oil droplets 
was selected for the “find similar as selected” function. Samples were measured 
in triplicate and mean and standard deviation were calculated. 
2.8.2 FlowCAM PV 
A FlowCAM PV-100 Benchtop system (Fluid Imaging Technologies) was equipped 
with a 80 µm multi-use cell, a 10x magnification lens and controlled by the 
VisualSpreadsheet software version 3.4.2. The system was flushed with 5x1 mL 
purified water by the flushing function in the software and flow cell cleanliness 
was accepted if less 10 particles were counted in 0.02 mL water in the 
“autoimage mode (no save)”. 0.5 mL sample solution with a pre-run volume of 
0.2 mL (primed manually into the flow cell) was analyzed with a flow rate of 
0.04 mL/min and a camera rate of 21 frames/s leading to a sampling efficiency 
of about 80-85%. Dark and bright pixels were selected for particle size 
determination at the preset default threshold value of 30. Particle size was 
evaluated as the diameter of a circle with the same projected area as the particle 
(designated as ABD, area based diameter, in the FlowCAM software). For the 
discrimination of silicone oil droplets and protein particles through the “find 
similar” operation, a minimum of 100 particles above 5 µm clearly recognizable 
as silicone oil droplets was selected to generate a library. The complete particle 
population was filtered by the “find similar as library” function. The resulting 
particle population was sorted by filter score and particles with filter scores of 0 
to 5 (with 0 describing images which the highest match to the images in the 
library) were defined as silicone oil droplets. This procedure was necessary as the 
software was not able to perform the same “find similar as selected function” as 
applied for the FlowCAM VS1 which was probably due to the clearly higher 
number of particles images captured by the FlowCAM PV. Samples were 
measured in triplicate and mean and standard deviation were calculated. 
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2.9 Performance evaluation 
Critical performance parameters (e.g. image quality, size accuracy, and several 
other factors as described below) were ranked relatively within the evaluated 
systems. The system with the strongest performance for one specific parameter 
was scored as “4” (++++), the system with the weakest performance in this 
parameter was scored as “1” (+). In detail, the performance was quantified as 
follows: The image quality parameters were evaluated by eye. Polystyrene sizing 
and counting performance was judged with respect to the specifications by the 
manufacturer (NIST-traceable), linearity was evaluated based on the deviation 
from the theoretical concentration expected from the dilution factor and the 
linearity of the obtained concentrations (assessed by the R2 value). For the 
robustness towards RI influences, the relative decrease in the measured protein 
particle concentration in formulations with a higher RI was used for the ranking. 
The differentiation of silicone oil droplets and protein particles was evaluated 
based on the match with the theoretical concentration within the system (based 
on individual samples) and the standard deviation, defined as precision. 
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3 Results and discussion 
3.1 Count and size performance with polystyrene 
standards 
The four systems MFI4100, MFI5200, FlowCAM VS1, and FlowCAM PV were first 
evaluated regarding their size and count performance with monodisperse 
certified polystyrene standards. All systems determined the correct concentration 
of a 5 µm polystyrene count standard with 3000 ± 300 particles/mL > 3 µm 
(Table 4-2). 
Table 4-2: Results of polystyrene standard measurements with MFI4100, MFI5200, 
FlowCAM VS1, and FlowCAM PV. 
Standard 
type 
Specification MFI4100 MFI5200 
FlowCAM 
VS1 
FlowCAM 
PV 
5 µm count 
standard 
3000 ± 300  
part./mL a 
2906 ± 324 
part./mL c 
3203 ± 116 
part./mL c 
2779 ± 162 
part./mL c 
2974 ± 184 
part./mL c 
2 µm size 
standard 
1.999 ±  
0.020 µm b 
1.74 ±  
0.28 µm d 
1.95 ±  
0.35 µm d 
3.20 ±  
1.39 µm d 
2.38 ±  
0.90 µm d 
5 µm size 
standard 
4.993 ±  
0.040 µm b 
5.10 ±  
0.80 µm d 
5.12 ±  
0.57 µm d 
5.94 ±  
1.61 µm d 
4.66 ±  
1.52 µm d 
10 µm size 
standard 
10.00 ±  
0.08 µm b 
10.56 ± 
1.22 µm d 
10.16 ± 
1.16 µm d 
10.71 ± 
2.41 µm d 
9.66 ±  
1.43 µm d 
a based on light obscuration for particles > 3 µm; b based on microscopy; c standard deviation from 
three measurements; d full peak width at half of the maximum height 
 
Concentration linearity was evaluated with different dilutions of 5 µm polystyrene 
size standards over a wide range from about 4x102 to 8x106 particles/mL. The 
obtained concentrations for particles > 3 µm (as specified for the 5 µm count 
standard) were compared to the theoretical concentration as determined by LO in 
the low concentration range (4056 particles/mL for the second highest dilution) 
and calculated for the higher concentrations (Figure 4-1). All systems showed 
good overall linearity, but underestimated the particle number at high 
concentrations (Figure 4-1A) probably due to coincidence of particles, meaning 
that two particles which are located very closely next to or behind each other are 
detected as one particle. For the highest concentration of theoretically 8x106 
particles/mL, a measurement was only possible with the MFI4100 and FlowCAM 
VS1. MFI5200 and FlowCAM PV were not able to handle such high particle 
CHAPTER 4                                 FLOW IMAGING MICROSCOPY FOR PARTICLE ANALYSIS 
122 
 
concentrations as the measurements were automatically aborted at 1x106 and 
5x105 captured particles, respectively. This is due to a software setting limiting 
the number of captured particles to 500,000 per analysis to ensure proper data 
handling. The limit can be increased, but this would slow down data processing 
by the software. For the sample with a theoretical concentration of 4x106 
particles/mL, MFI4100, MFI5200, and FlowCAM VS1 underestimated the particle 
concentration by less than 10%, whereas the FlowCAM PV system detected 25% 
less particles than actually expected. In the medium concentration range of 
theoretically 4x103 to 1x106 particles/mL, all systems showed good results 
(Figure 4-1B,C). Whereas the FlowCAM systems slightly underestimated the 
concentration, the MFI4100 system overestimated the concentration in the case 
of theoretically 4x105 particles/mL. The MFI5200 system constantly showed 
deviations from the theoretical concentration of less than 2%. For the lowest 
concentration of theoretically 406 particles/mL, MFI4100, MFI5200 and FlowCAM 
PV showed large deviations of 11-28% and only the FlowCAM VS1 system 
detected the theoretical concentration within 1% (Figure 4-1C). All systems 
showed large relative standard deviations in the low concentration range below 
4x103 particles/mL (8% for MFI5200, 18% and more for the other systems). 
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Figure 4-1: Linearity of particle concentration measurements by MFI4100, MFI5200, 
FlowCAM VS1, and FlowCAM PV. 5 µm PS standards measured at various dilutions. The 
theoretical concentrations are based on the counts of the second highest dilution 
obtained by LO (result: 4056 particles/mL). (A) Full concentration range, (B) zoom into 
medium concentrations, (C) zoom into low concentrations. Error bars represent standard 
deviations from triplicate measurements. 
CHAPTER 4                                 FLOW IMAGING MICROSCOPY FOR PARTICLE ANALYSIS 
124 
 
Size accuracy was evaluated with monodisperse polystyrene size standards of 2, 
5, and 10 µm. Overall, the MFI systems rendered images of poorer resolution, 
but better size accuracy as compared with the FlowCAM systems evaluated in 
this study (Table 4-2 and Figure 4-2). The MFI4100 system underestimated the 
size of the 2 µm polystyrene standards due to resolution limitations for those 
small particles, but showed satisfying size accuracy for 5 µm and 10 µm as well 
as a narrow distribution for all sizes (Figure 4-2A). MFI5200 was the only system 
that determined all sizes accurately and with a high precision (Figure 4-2B). The 
images of size standards obtained by the MFI systems appeared rather blurry, 
but comparable in size and optical appearance, leading to the observed good size 
accuracy and precision. In contrast, the images obtained by the FlowCAM 
systems showed high resolution and sharpness, but also a large variability in size 
and optical appearance. Especially the FlowCAM VS1 system showed clear 
deviations from the correct size (Table 4-2) and also a broad size distribution 
with apparently more than one population per analyzed size standard (Figure 
4-2C). This is particularly striking for the 10 µm polystyrene standard, for which 
two apparent populations around 10 µm and 12 µm were detected. The 10 µm 
peak particles appear to be captured in focus, whereas the 12 µm peak particles 
appear out of focus as indicated by the concentrical rings. Although the FlowCAM 
software VisualSpreadsheet is theoretically able to exclude out-of-focus particles, 
this was not performed as it would compromise the accuracy of the particle 
concentration and does therefore not represent a suitable option for real protein 
sample analysis. The FlowCAM PV rendered images of slightly lower resolution, 
but in return better size homogeneity leading to better size accuracy and 
precision (Figure 4-2D). For a mixed sample of 2, 5, and 10 µm polystyrene size 
standards, the described differences in image quality and homogeneity led to a 
better separation between the sizes in the MFI systems as compared with the 
FlowCAM systems (Figure 4-2A-D, lower panels). The underlying reasons for the 
differing image quality and homogeneity are assumed to be (i) the magnification 
and (ii) the depth of focus (Table 4-1). Furthermore, the threshold value in the 
FlowCAM systems influences the size accuracy as there is always a trade-off 
between size accuracy and image fragmentation. 
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Figure 4-2: Size accuracy and precision of 2 µm, 5 µm and 10 µm PS size standards 
measured separately (upper panels) and as a mix (lower panels) by (A) MFI4100, (B) 
MFI5200, (C) FlowCAM VS1, and (D) FlowCAM PV. Representative images are shown 
above the corresponding peak of the size distribution. 
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3.2 Image properties 
As discussed above, differences in the image properties and especially in the 
image homogeneity lead to divergences in size determination. Furthermore, the 
image quality is a crucial parameter for morphological analysis and for a reliable 
discrimination of different particle types, e.g. proteinaceous vs. non-
proteinaceous particles. Therefore, we compared images of polystyrene 
standards, artificially generated silicone oil droplets, and protein particles (heat-
stressed rituximab) (Figure 4-3). In general, images provided by the FlowCAM 
systems appeared sharper and of higher resolution than images captured by the 
MFI systems. This is mainly due to the smaller focus area and higher 
magnification of the FlowCAM optics. Thus, many morphological details were 
already visible on particles as small as 5 µm in size, especially for the FlowCAM 
VS1 system. However, the small focus area caused particles of the same type to 
appear optically different, which could be well observed on images for 
polystyrene standards and silicone oil droplets. Dark particles with a bright halo 
as well as bright particles with a dark edge and several nuances in between were 
detected within one sample. For protein particles, images captured by the 
FlowCAM systems appeared more uniform regarding the optical contrast than for 
polystyrene standards and silicone oil droplets. The MFI4100 system provided 
comparable images of protein particles. In contrast the images captured by the 
MFI5200 system appeared more variable, presumably due to its larger view 
window which results in different illumination of particles depending on their 
location within the view window. For protein particles, this can lead to a high 
diversity in the optical appearance due to diffraction patterns within those 
heterogeneous particles.21 However, it is difficult to judge which instrument 
displays the real heterogeneity of protein particles as this is not known. The 
difference in sharpness and resolution between MFI systems and FlowCAM 
systems was particularly obvious for protein particles with sizes of about 5 µm 
and 10 µm. Here, FlowCAM images provide more morphological details, whereas 
MFI images appear rather blurry. Furthermore, the MFI systems capture only 
pixels of the particle which are darker than the background. In contrast, the 
FlowCAM systems use a different background calibration procedure allowing the 
additional depiction of pixels brighter than the background which probably result 
from specific diffraction patterns.21 This contributes to the enhanced visibility of 
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morphological details but also leads to the heterogeneity in FlowCAM images. 
Within the brands, the MFI4100 and FlowCAM VS1 captured better images than 
the MFI5200 and FlowCAM PV. 
 
Figure 4-3: Representative images of polystyrene standards, silicone oil droplets, and 
protein particles (heat-stressed rituximab) of different particle sizes scaled to the same 
image size. 
 
An additional cause of image variability in the FlowCAM systems for polystyrene 
standards and silicone oil droplets might be the illumination of the flow cell. 
While the background of an MFI flow cell appears uniformly grey (Figure 4-4A,B), 
the background of a FlowCAM flow cell seems to be less evenly illuminated, 
especially for the FlowCAM VS1 system (Figure 4-4C,D). This can affect the 
overall brightness of an image depending on where within the flow cell it was 
captured. According to the manufacturer, this feature is currently under 
development for the FlowCAM systems. 
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Figure 4-4: Images of a clean flow cell (purged with water) in (A) MFI4100, (B) 
MFI5200, (C) FlowCAM VS1, and (D) FlowCAM PV. 
 
3.3 Quantification of protein particles 
Because the captured particle images form the basis for particle analysis, a 
potential correlation between image quality and detected particle numbers was 
investigated. To this end, protein particles were generated by heating a rituximab 
formulation and analyzed by the four systems. Due to the time-shifted 
availability of the FlowCAM systems, the exact same sample could not be 
analyzed in parallel by all four systems. Instead, one sample was analyzed in 
parallel by the MFI4100 and FlowCAM VS1 (Figure 4-5A). Another sample, 
prepared later under the same conditions, was analyzed in parallel by the 
MFI5200 and FlowCAM PV as well as by MFI4100 for comparison (Figure 4-5B). 
Thus, the difference in the cumulative size distribution between Figure 4-5A and 
Figure 4-5B can be attributed to the variability in the sample preparation. 
System-dependent differences can only be evaluated within Figure 4-5A or within 
Figure 4-5B. Although the image resolution for particles below 2 µm was poor 
and the official lower size limit of the FlowCAM systems is 2 µm, counting of 
particles could be performed for particles > 1 µm with satisfying data quality for 
all systems. For the same sample, the FlowCAM VS1 system detected more 
particles below 3 µm but fewer particles above 3 µm, particularly above 10 µm, 
as compared with the MFI4100 system (Figure 4-5A). 
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Figure 4-5: Cumulative particle counts for protein particles of heat-stressed rituximab 
analyzed by (A) MFI4100 and FlowCAM VS1 and (B) MFI4100, MFI5200, and FlowCAM 
PV. Error bars represent standard deviations from triplicate measurements. 
 
A possible reason for this might be image fragmentation which was observed for 
the FlowCAM VS1 when using the setting “only dark particles” (Figure 4-6). It 
seems that bright parts of particles were detected as the particle boundary by 
the software. This effect was observed for particles larger than 10 µm. Although 
image fragmentation might also have occurred for smaller particles it could not 
be confirmed by optical evaluation of the images due to resolution limitations. 
Changing the settings to “dark & bright” might have decreased this effect but, as 
discussed earlier, failed to provide the correct size for polystyrene size standards 
and was therefore not chosen. This shows again that the user has to accept a 
certain trade-off between good size accuracy and robustness against image 
fragmentation for the FlowCAM systems which on the one hand brings along 
certain user-dependency and data variability. On the other hand, those many 
adjustable settings in the FlowCAM systems enable the handling of a specific 
problem. In contrast, the MFI systems require the trust of the user in the 
predefined settings which cannot be changed. For the other systems evaluated in 
this study image fragmentation was not observed for the same samples. 
However, for an IgG-containing sample from a different study image 
fragmentation was observed for the MFI4100 system (data not shown due to 
confidentiality). 
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Figure 4-6: Images of protein particles around 10 µm (heat-stressed rituximab) captured 
by the FlowCAM VS1 system. Red boxes indicate overlapping or doubly imaged regions in 
two separate images due to image fragmentation. 
 
For the second sample analyzed, MFI5200 and FlowCAM PV detected similar size 
distributions with slightly less particles detected by the FlowCAM PV system 
(Figure 4-5B). Clearly more small particles larger than 1 µm were detected by 
the MFI5200 system, pointing on the one hand towards a better sensitivity for 
small transparent particles, on the other hand potentially also towards 
undetected image fragmentation. For the FlowCAM PV system it needs to be 
considered that the official size range of this system starts only at 2 µm and was 
extended consciously in this study. For total particle concentrations larger than 
2 µm, similar concentrations were detected by all three systems. The difference 
for particles larger than 10 µm is probably due to the low total number in this 
size range causing higher standard deviations. In general, the MFI5200 and 
FlowCAM PV showed lower standard deviations for total particle counts larger 
than 1 µm as compared with the MFI4100 and FlowCAM VS1, as could be 
expected from the differences in the analyzed volume. 
It was shown earlier that light-based quantification of protein particles is 
influenced by the RI of both, particles and surrounding formulation and that this 
effect is partly system dependent.26 Therefore, the robustness of MFI4100, 
MFI5200, and FlowCAM PV towards RI influences was determined by quantifying 
protein particles larger than 1 µm (stir-stressed infliximab) in the same 
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concentration in formulations of increasing RI, adjusted by addition of sucrose 
(Figure 4-7). The FlowCAM VS1 system was not available at the time of these 
experiments. Particle concentrations obtained by MFI4100 were rather sensitive 
to an increase in RI of the formulation. In 20% sucrose (RI 1.36), 80% of the 
original particle concentration was still detected whereas in 50% sucrose 
(RI 1.42), only 25% could be detected. MFI5200 and FlowCAM PV were both 
more robust towards RI influences: in 20% sucrose, 93% and 89% of the original 
particle concentration, respectively, were still detected and in 50% sucrose the 
apparent concentration decreased only to 54% and 69% with MFI5200 and 
FlowCAM PV, respectively. The reason for the superior performance of MFI5200 
and FlowCAM PV is potentially connected to optimized optical settings of these 
newer systems. Two different control experiments in a previous study have 
shown that the particle concentration was not affected directly by the high 
sucrose concentration, e.g. by dissolution or generation of particles.26 Instead, 
the decreased RI difference between particles and surrounding formulation 
reduced the apparent particle concentration. The RI of a 20% sucrose solution 
(1.36) represents pharmaceutically relevant conditions, e.g. at high protein 
concentration or a combination of excipients such as sucrose and high protein 
concentration.26 
 
Figure 4-7: Total particle counts for protein particles of stir-stressed infliximab for fixed 
particle concentrations in sucrose solutions of varying concentration and thus RI. Error 
bars represent standard deviations from triplicate measurements. 
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3.4 Differentiation of silicone oil droplets and protein 
particles 
A major advantage of flow imaging microscopy as compared with other analytical 
techniques for subvisible particles, e.g. LO or electrical sensing zone analysis, is 
the possibility to characterize particles based on images.10 Parameters such as 
shape and transparency can be used to differentiate between different particle 
types.22,23 In this context, the discrimination of silicone oil droplets and protein 
particles is especially relevant due to the increasing application of prefilled 
syringes. Similar to a previous study,22 protein particles (heat-stressed 
rituximab) and silicone oil droplets were analyzed by MFI4100, MFI5200, 
FlowCAM VS1, and FlowCAM PV as individual samples (to obtain the theoretical 
concentration within the same system) and in controlled mixtures. The “find 
similar” algorithm in the respective software was used to differentiate between 
silicone oil droplets and protein particles. Due to the time-shifted availability of 
the FlowCAM systems, the exact same sample could not be analyzed in parallel 
by all four systems. Instead, one group of samples was analyzed in parallel by 
the MFI4100 and FlowCAM VS1 (Figure 4-8A,C). Another group of samples which 
was prepared later under the same conditions was analyzed in parallel by the 
MFI5200 and FlowCAM PV (Figure 4-8B,D). The concentration was adjusted in 
such a way that similar total particle counts larger than 1 µm were obtained for 
both groups of samples with the MFI4100 as the bridging instrument. However, 
the relative size distribution for protein particles differed clearly between the two 
sample groups. Thus, the differentiation performance was evaluated within the 
systems, but not between the systems. The evaluation was based on the match 
of the detected concentration (in mixed samples) and the theoretical 
concentration (in individual samples) within each system. The theoretical 
concentration may differ from system to system and is only valid for the mixed 
samples analyzed by the same system. Although an optical discrimination of 
silicone oil droplets and protein particles based on the particle images, which is 
the basis for the “find similar” operation, was only reasonable for particles 
of 5 µm and larger, the “find similar” function of the software was able to 
differentiate particles down to 2 µm. 
FLOW IMAGING MICROSCOPY FOR PROTEIN PARTICLE ANALYSIS                   CHAPTER 4 
133 
 
The FlowCAM PV system showed the best match with the theoretical 
concentration, thus the best differentiation of silicone oil droplets and protein 
particles (Figure 4-8D). The MFI5200 and FlowCAM PV (Figure 4-8B,D) showed a 
higher precision than the MFI4100 and FlowCAM VS1 (Figure 4-8A,C). However, 
the differences were rather small and results might depend on the specific 
sample properties. In conclusion, all systems proved to be suitable for the 
differentiation of silicone oil droplets and protein particles from 2 to 10 µm. For 
particles below 2 µm, alternative techniques such as resonant mass 
measurement (RMM) can be beneficial.22 For particles larger 10 µm, it is 
recommended independently of the system to differentiate particles by optical 
evaluation of the images rather than by applying the “find similar” function. This 
approach is feasible due to the clear images and usually low particle counts in 
this size range. 
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Figure 4-8: Cumulative particle counts comparing theoretical concentrations (based on 
individual samples measured with the corresponding instrument) and determined 
concentrations (mixed samples) of artificially generated silicone oil droplets and protein 
particles (heat-stressed rituximab) in a droplet/particle ratio of 10:90 (based on particle 
counts > 2 µm with MFI4100). (A) MFI4100, (B) MFI5200, (C) FlowCAM VS1, (D) 
FlowCAM PV. Error bars represent standard deviations from triplicate measurements. 
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3.5 Handling of the systems 
Concerning the hardware, MFI systems only allow the adjustment of the sample 
volume. This ensures standardized, user-independent measurements and 
repeatable results, but requires full trust in the settings predefined by the 
manufacturer, which cannot be customized to specific needs or samples. In 
contrast, the FlowCAM systems allow changes in optical settings (e.g. threshold, 
shutter, and gain) or technical settings (flow rate, image capture rate) offering 
customization of the analysis to specific needs for experienced users, but impede 
comparability between samples analyzed by different operators, at different 
times or even by different instruments of the same type. 
The exchange of a flow cell, which requires the adjustment of the focus as a 
critical parameter for image-based particle analysis, is straightforward and 
unambiguous for the MFI systems. For the FlowCAM systems, especially the 
FlowCAM VS1, this process was found to be cumbersome but this is currently 
being improved by the manufacturer. Furthermore, the MFI systems use a 
peristaltic pump enabling high flow rates and large volumes which is useful for an 
efficient cleaning step, but the flow rate needs to be calibrated regularly. The 
FlowCAM systems for small volumes (as applicable for protein samples) are 
typically equipped with a syringe pump, which does not require calibration by the 
user, but is restricted in volume and speed limited by the flow cell diameter. 
Thus, cleaning cycles with FlowCAM need to be performed several times with low 
volume and flow rate, especially in case of small syringe sizes. 
Concerning the software, the MFI systems use different software types for the 
measurement (MFI View software for MFI4100, MVSS for MFI5200) and the data 
analysis (MVAS), whereas the FlowCAM systems apply the same software for 
both steps (VisualSpreadsheet). While the latter allows the analysis of the 
particle population, regarding size distribution and cropped images, already 
during the measurement as a real time analysis, this data becomes available only 
after the measurement for the MFI systems. However, the MVAS software 
includes an essential function to “remove stuck particles” (particles stuck to the 
flow cell wall which would otherwise be counted on every image they were 
captured on). This option is not yet available for VisualSpreadsheet but is 
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currently under development. In both software solutions, particle data can be 
exported in many different ways and the raw data of every single particle (e.g. 
shape or transparency values) is available. MVAS enables export of single particle 
images, whereas VisualSpreadsheet offers collages of particle images. Regarding 
the differentiation of silicone oil droplets and protein particles, the analysis of a 
single sample is simpler in MVAS, while VisualSpreadsheet enables the 
generation of libraries from selected particles, which can be used to build a filter 
for future samples. In addition, VisualSpreadsheet offers the possibility to sort 
the resulting population of similar particles by “filter score”, i.e. by similarity to 
the selected particles. Taken together, MFI systems are more standardized, 
whereas FlowCAM systems are designed for more flexibility for the user, 
concerning both hardware and software. 
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4 Conclusion 
Our study showed that the selection of the appropriate flow imaging microscopy 
system depends strongly on the main output parameters of interest and the 
intended application. Each system shows its strengths and weaknesses in 
different aspects (Table 4-3). The four systems evaluated in this study can be 
categorized based on the technical data and the results obtained in this study 
into high-resolution systems (MFI4100 and FlowCAM VS1) and high-efficiency 
systems (MFI5200 and FlowCAM PV). The best images were obtained by the 
FlowCAM VS1 system, which was seen as the best system among the high-
resolution instruments. The best performance regarding particle counting 
accuracy and precision was achieved by the MFI5200 system, which appeared to 
be the preferred system among the high-efficiency instruments. The MFI4100 
and the FlowCAM PV system were observed as all-round systems which might be 
a good compromise between the other two systems that are more biased 
towards particle counting (MFI5200) or particle imaging (FlowCAM VS1). 
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Table 4-3: Summarizing assessment of important analysis factors for MFI4100, MFI5200, 
FlowCAM VS1, and FlowCAM PV. 
Parameter MFI4100 MFI5200 FlowCAM VS1 FlowCAM PV 
Image 
properties 
Resolution ++ + ++++ +++ 
Contrast 
within the 
particle 
+ ++ ++++ +++ 
Image 
consistency 
(standards) 
++++ ++++ + + 
Polystyrene 
size 
Accuracy +++ ++++ + ++ 
Precision +++ ++++ + ++ 
Polystyrene 
count 
Accuracy +++ ++ + ++++ 
Precision + ++++ +++ ++ 
Linearity ++ ++++ ++++ + 
Protein 
particle 
quantification 
Precision + +++ + ++++ 
Robustness 
against RI 
influences 
++ +++ n.a. ++++ 
Differenti-
ation of 
silicone oil 
droplets and 
protein 
particles 
Match with 
the 
theoretical 
concentration 
+ ++ +++ ++++ 
Precision  + +++ ++ ++++ 
Handling 
Hardware +++ ++++ + ++ 
Software 
for 
measurement 
++++ +++ + ++ 
Software 
for data 
analysis 
++++ +++ 
++++ = strongest performance; +++ = second strongest performance; ++ = third strongest 
performance; + = weakest performance; all criteria were judged only relatively among the 
evaluated systems. 
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                 Chapter 5
                                 
Material screening and investigation of 
particle density for the development of 
standardized protein-like particles 
Abstract 
The aim of this study was the identification of suitable materials and preparation 
methods for the development of standardized protein-like particles. In the first 
part, a material screening based on optical particle properties was performed. 
Proteinaceous (human serum albumin (HSA)-starch particles, spray-dried HSA, 
gelatin particles, and zein) and non-proteinaceous materials (chitosan and 
polytetrafluoroethylene (PTFE)) were compared to HSA particles generated by 
heat stress as a representative model for protein particles in therapeutic 
formulations. The particle properties size, size distribution, shape, transparency, 
and stability were assessed by light obscuration (LO) and Micro-Flow Imaging 
(MFI). As a result, gelatin and PTFE particles reflected the most relevant optical 
properties (shape and transparency) of protein particles and were regarded as 
promising candidates for the development of standardized protein-like particles 
for light-based techniques. In the second part, the density of protein particles in 
aqueous formulations as a further crucial property was investigated. Two 
different methods based on resonant mass measurement (RMM) were developed 
to determine (i) the density of pure protein and (ii) the apparent density of 
protein particles including entrapped liquid. The first method provided a density 
around 1.4 g/mL for pure protein, which complied with theoretically calculated 
values. The second method was only applicable for particles showing a clear 
maximum in the size distribution and yielded an apparent density of around 
1.1 g/mL for protein particles including entrapped liquid. Based on these 
parameters, PTFE particles were regarded as suitable standard material 
especially for light-based techniques, whereas gelatin particles could be used for 
both light-based and weight-based methods.  
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1 Introduction 
The analysis of particles in therapeutic protein formulations requires calibration 
of the instruments with certified particle standards. Mostly polystyrene particle 
standards are used for this purpose, although these standards do not represent 
optical and morphological properties of protein particles.1 Thus, novel standards 
are more and more claimed by academia and industry2-4 which should be applied 
mainly for comparison and evaluation of results acquired by different techniques 
or instruments and if possible also for instrument calibration. These novel 
standards should reflect protein particle properties (size, size distribution, optical 
and morphological parameters), should be stable as an aqueous suspension, and 
should behave similar to protein particles in the commonly applied analytical 
techniques regarding measurement performance and data evaluation. This could 
involve the direct use of raw material powder or preparation of particles from raw 
materials. Proteinaceous and non-proteinaceous materials are theoretically 
suitable for both alternatives. Proteinaceous materials bring the benefit of high 
similarity, but might bear the risk of low stability, especially at ambient 
conditions in solution. Non-proteinaceous materials have the advantages of 
easier handling and potentially increased stability, but might face the problem of 
low conformity with protein particles as known for polystyrene standards. 
Proteinaceous materials evaluated in this study include human serum albumin 
(HSA)-starch particles, which were originally developed as particles with an 
irregular and rough surface structure for mucosal delivery of vaccines,5 spray-
dried HSA and gelatin particles prepared by desolvation, both stabilized by a 
cross-linker, and the hydrophobic water insoluble protein zein as the raw 
material powder. Non-proteinaceous raw material powders screened for their 
suitability as standardized protein-like particles were the polysaccharide chitosan 
and the synthetic fluoropolymer polytetrafluoroethylene (PTFE). The application 
purpose of the novel standards are light obscuration (LO) and Micro-Flow 
Imaging (MFI) as the workhorses of protein particle analysis. Therefore, the 
focus was set on the similarity of particle properties relevant for those 
techniques: Size, size distribution, shape, and transparency for the novel 
materials were compared to those of HSA particles generated by heat stress as a 
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representative for particles of therapeutic proteins. Furthermore, the stability in 
an aqueous suspension was assessed. 
The density of protein particles is a crucial parameter for protein particle analysis 
which has not been characterized well up to now.6 Light-based techniques like LO 
and MFI determine the particle size based on the optical signal which is caused 
by the combination of protein parts and entrapped liquid within a particle. The 
novel technique of resonant mass measurement (RMM) detects the buoyant 
mass which is only influenced by protein parts within the particle and the size 
calculation depends on the particle density as an input parameter. Thus, the 
techniques consider the particle density in different ways and a deeper 
understanding of protein particle density is valuable for data evaluation and 
therefore also the development of protein-like standards. RMM was applied in 
this study to investigate (i) the density of pure protein and (ii) the density of 
protein particles including entrapped liquid and the results were compared to the 
density of the screened materials. 
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2 Materials and methods  
2.1 Materials 
5 µm polystyrene particle size standards were purchased from Duke Scientific 
(through Thermo Scientific, Fremont, CA) and diluted in water for analysis. Dry 
borosilicate glass particle standards (5 µm) were purchased from Duke Scientific, 
suspended in water containing a minimum amount of isopropanol (according to 
the instructions by the manufacturer), sonicated for 1.5 h and vortexed directly 
before analysis. 5 µm silica particle size standards were purchased from 
microparticles GmbH (Berlin, Germany) and diluted in water for analysis. 
Rituximab (MabThera®, lot no. B6082) was provided by local hospitals, diluted to 
1 mg/mL in 25 mM citrate buffer (pH 6.5) containing 154 mM NaCl and 0.07% 
polysorbate 80 and filtered (0.2 µm polyethersulfone syringe filter, Sartorius, 
Göttingen, Germany) for further use. HSA was purchased from Sigma-Aldrich 
(Steinheim, Germany), formulated at 1 mg/mL in 50 mM citrate buffer (pH 4.8) 
or at 5% (m/v) in water and filtered (0.2 µm cellulose acetate syringe filter, 
Minisart®, Sartorius Stedim Biotech, Aubagne, France) for further use. Gelatin 
from porcine skin (type A, medium gel strength, 170-190 g Bloom, for 
microbiology) was purchased from Sigma-Aldrich. Chitosan (poly-(D-
glucosamine) deacetylated chitin, >75% deacetylated, coarse ground flakes and 
powder) was obtained from Sigma-Aldrich and suspended in water for analysis. 
Zein F 4000 was obtained as a gift from capol GmbH (Elmshorn, Germany), 
sieved through a 100 µm mesh and suspended in 10% polysorbate 80 in water. 
PTFE (Microdispers 8000 from Polysciences Inc., Warrington, PA) was suspended 
at a concentration of 50 mg/mL in 0.5% polysorbate 80 using an Ultra Turrax 
dispersing system (T10 basic, IKA® Werke, Staufen, Germany) for 3 minutes. 
Larger agglomerates were removed by filtration through a coarse tea filter (dm, 
Karlsruhe, Germany). 
Dimethylsulfoxide (DMSO, for synthesis) was purchased from Merck Schuchardt 
(Hohenbrunn, Germany). Rape oil was obtained from A&P (Kaiser’s Tengelmann, 
Mühlheim an der Ruhr, Germany). Glutaraldehyde (technical, 50% in water, 
5.6 M) and hydrochloric acid were purchased from Sigma-Aldrich. White soluble 
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potato starch (GR for analysis), sucrose, acetone for analysis, citric acid 
monohydrate, and sodium hydroxide were purchased from Merck KGaA 
(Darmstadt, Germany). Polysorbate 80 and tri-sodium citrate dehydrate were 
from VWR (Darmstadt, Germany). The water used in this study was highly 
purified water (Advantage A10 purification system, Millipore, Newark, NJ). 
2.2 Particle preparation 
Rituximab particles were prepared by incubating 1.5 mL of the 1 mg/mL 
rituximab solution for 30 minutes at 71 °C in a thermomixer (Eppendorf, 
Hamburg, Germany). HSA particles were generated by heating 50 mL of the 
1 mg/mL formulation in a 50 mL tube (Greiner bio-one, Frickenhausen, 
Germany) for 30 minutes at 70 °C in a water bath (HSA (heating)) or by spray-
drying 50 mL of the 5% formulation using a Büchi Mini Spray-Dryer B-290 (HSA 
spray-dried (Mini)) or Büchi Nano Spray-Dryer B-90 (HSA spray-dried (Nano)) 
(Büchi Labortechnik, Flawil, Switzerland) with subsequent cross-linking. For the 
Mini Spray-Dryer, process parameters were chosen based on previous studies by 
Schüle7 and Fuhrherr8: inlet temperature (Tin) 130 °C, outlet temperature (Tout) 
60-70 °C, liquid feed flow rate 3 mL/min (9%), atomizing air volumetric flow rate 
670 L/min (40 mmHg), aspirator flow rate 35 m3/h (100%), cooled two-fluid 
nozzle (0.7 mm). For the Nano Spray-Dryer, the following process parameters 
were applied: Tin 55 °C, Tout 25 °C, gas flow 115 L/min, pressure 37 hPa, pump 
mode 1, spray cap diameter 5.5 µm, spray head temperature 33 °C, spray rate 
100%, spray angle 45°. After the spray-drying process, 150 mg of the particles 
generated by the two different approaches were suspended in 30 mL acetone and 
cross-linked by the addition of 500 µL glutaraldehyde (8%) under stirring at 
400 rpm (Heidolph MR 3001K, Schwabach, Germany). After stirring for additional 
30 minutes at 400 rpm, the suspensions were centrifuged for 10 minutes at 
7,000 g (centrifuge 5810 R, Eppendorf AG, Hamburg, Germany) and the 
supernatants were discarded. Subsequently, the sediments were resuspended in 
4 mL water and filtered through a coarse tea filter to remove large agglomerates. 
Gelatin microparticles were prepared by a two-step desolvation method, which 
was originally developed for preparing nanoparticles.9 The first precipitation was 
triggered by the addition of 25 mL acetone at 500-600 rpm to 25 mL of a 5% 
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gelatin solution at room temperature with a precipitation time of 2 minutes. The 
supernatant was discarded and the deposit was redissolved in 25 mL water at 
50 °C. The pH was adjusted to 3.9 with 1 M HCl. The second precipitation was 
initiated by adding 50 mL acetone at about 9-10 mL/min using a burette. After 
10 minutes of stirring at 500-600 rpm, 500 µL glutaraldehyde (8%) were added 
as a cross-linker and the suspension was stirred for another 30 minutes. The 
particles were harvested by centrifugation at 10,000 g for 10 minutes at room 
temperature. The supernatant was discarded and the pellet was resuspended in 
5 mL water and filtered through a coarse tea filter to remove large agglomerates. 
For the evaluation of particle density, the preparation process was optimized to 
maximize the number of particles in the target size range of 2-8 µm. The cross-
linking time with glutaraldehyde was extended to 40 minutes and the 
centrifugation speed for particle harvesting was decreased to 5,000 g. After 
filtration through a coarse tea filter to remove large agglomerates an additional 
purification step was introduced to minimize the number of particles below 2 µm: 
The pH of the filtrate was adjusted to pH 3 to provoke electrostatic repulsion 
between the particles prior to an additional centrifugation step (200 g, 
20 minutes). The pellet was discarded and the supernatant was used. 
HSA starch particles were produced by an emulsion-based process according to 
previous studies by Heritage et al.5 1 g starch was dissolved in 2 mL DMSO under 
stirring at 85 °C, cooled down to room temperature and subsequently 1 mL 
10% (w/v) aqueous HSA solution was added drop-wise. This solution was 
emulsified drop-wise in 20 mL rape oil under stirring at 1250 rpm (Heidolph MR 
3001K) and sonication. Afterwards this emulsion was added drop-wise to 400 mL 
acetone containing 0.5 mL polysorbate 80, again under stirring at 1250 rpm. The 
generated microparticles were then collected by filtration (0.22 µm Durapore® 
(PVDF) membrane filter, Millipore) under vacuum, washed with 1 L acetone, and 
dried on the filter by vacuum. The powder was sieved through a 100 µm mesh to 
exclude large agglomerates and the particles were stored under desiccation at 
5±3 °C. 30 mg of the particles were suspended in 4 mL water for analysis. 
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2.3 Light obscuration (LO) 
Subvisible particles in a size range between 1 and 200 µm were analyzed by LO 
using a PAMAS SVSS-C (Partikelmess- und Analysesysteme GmbH, Rutesheim, 
Germany) equipped with an HCB-LD-25/25 sensor. Particle suspensions were 
diluted with the according buffer (filtered by a 0.22 µm cellulose acetate/nitrate 
membrane filter, MF-Millipore®) or water in order to adhere to the concentration 
limit of the system of 120,000 particles/mL > 1 µm. Three measurements of a 
volume of 0.3 mL of each sample were performed with a pre-run volume of 
0.5 mL at a fixed fill rate, emptying rate and rinse rate of 10 mL/min and the 
mean particle concentration per mL was reported by the system. Samples were 
measured in triplicates and mean and standard deviation were calculated.  
2.4 Micro-Flow Imaging (MFI) 
Subvisible particles in a size range between 1 and 70 µm were analyzed by MFI 
using an MFI4100 (ProteinSimple, Santa Clara, CA) equipped with a high-
resolution 100 µm flow cell. Particle suspensions were diluted with the according 
buffer (filtered by a 0.22 µm cellulose acetate/nitrate membrane filter) or water 
in order to adhere to the concentration limit of the system of 1,200,000 
particles/mL > 0.75 µm. Samples were analyzed with a sample volume of 
0.65 mL and a pre-run volume of 0.3 mL at a flow rate of 0.1 mL/min. Prior to 
each sample run the appropriate diluting buffer was flushed through the system 
to provide a clean flow cell and to perform “optimize illumination”. Particles stuck 
to the flow cell wall were only counted once and edge particles were ignored for 
analysis. Samples were measured in triplicates and mean and standard deviation 
were calculated. Results were analyzed using the MFI view application software 
(version 1.2, ProteinSimple). 
2.5 Resonant mass measurements (RMM) 
RMM was performed using the Archimedes particle metrology system (Affinity 
Biosensors, Santa Barbara, CA) equipped with a Micro sensor (size range 0.3 µm 
to 4 µm) calibrated with 1 µm polystyrene standards. Before each measurement, 
the system was filled with sample and the lower size limit of detection was 
determined three times in automatic mode. The mean value was set as a fixed 
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limit of detection for the measurement. The buffer density was determined for 
each sample based on the sensor frequency relative to the frequency and the 
density of water as a reference. The density of the solid part of a particle (pure 
protein in case of protein particles) was determined by quantifying the buoyant 
mass (sum of all particles in the sample) in aqueous buffer and two liquids of 
higher density (20% and 40% sucrose). The buoyant mass decreases with the 
decreasing density difference between particles and liquid and was extrapolated 
to a buoyant mass of zero which indicates a density match between particles and 
surrounding liquid. The density of the solution was then set as the density of the 
solid part of the particle (liquid parts within the particle do not contribute to the 
buoyant mass as they possess the same density as the surrounding liquid). The 
apparent density of protein particles including entrapped liquid was determined 
by adjusting the particle density input in the software from 1.37 g/mL (as used in 
another RMM study10) to smaller values until the size distributions determined by 
RMM and MFI for the same sample overlapped (defined by the same location of 
the maximum). Measurements were performed in triplicates and the sensor was 
filled with fresh sample for each measurement. The measured volume was 
0.15 µL and the overall sample volume for triplicate measurements was 600 µL. 
Between triplicate measurements, the system was rinsed with water. Results 
were analyzed using the ParticleLab software (v1.8.570, Affinity Biosensors) with 
a size bin step of 250 nm. 
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3 Results and discussion 
3.1 Comparison of current standards to protein 
particles by LO and MFI 
HSA particles generated by heat stress were analyzed as a representative for 
protein particles in general to determine typical properties of protein particles 
regarding size, size distribution, shape, and transparency in order to derive 
target specifications for novel standardized protein-like particles. The size 
distribution of HSA particles generated by heat stress appeared polydisperse with 
small particles representing the largest fraction (Figure 5-1). Furthermore, it 
revealed 3 to 10x higher particle concentration detected by MFI compared to LO 
which is in agreement with the literature.4,11,12 
 
Figure 5-1: Cumulative size distribution for HSA particles generated by heat stress as 
determined by MFI and LO. Error bars represent standard deviations from triplicate 
measurements. 
 
In contrast, 5 µm size standards made of polystyrene, glass, and silica showed a 
monodisperse size distribution (Figure 5-2) and identical concentrations in LO 
and MFI (data not shown). 
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Figure 5-2: Differential size distribution of 5 µm polystyrene, glass, and silica particle 
size standards and HSA particles generated by heat stress determined by (A) LO and (B) 
MFI. 
 
The optical particle properties shape and transparency are especially important 
for standards for the light-based techniques LO and MFI. The aspect ratio 
(between 1 for an absolutely spherical particle and 0 for a needle with an infinite 
length) of HSA (heating) particles was broadly distributed between 0.3 and 1.0 
whereas the particle standards showed higher aspect ratios mainly above 0.8 
(Figure 5-3A). The transparency was evaluated by the directly proportional 
intensity minimum which describes the darkest pixel on a particle image.13 As the 
intensity depends on the particle size14 the 2-6 µm range was used for the 
evaluation of the different materials (see Chapter 6 for further details). Particle 
standards displayed low intensity values (polystyrene standards approx. 300) 
corresponding to low transparency. In contrast, HSA (heating) particles are 
highly transparent with intensity values of about 700, which is close to the 
maximum intensity values of the instrument of about 850 typically (Figure 5-3B). 
These clear differences in shape and transparency between the current standards 
and protein particles are also reflected in the MFI images (Table 5-1). The results 
demonstrate that current standards do not represent protein particles adequately 
and justify a material screening in order to identify better materials for novel 
standardized protein-like particles. 
MATERIAL SCREENING AND INVESTIGATION OF PARTICLE DENSITY CHAPTER 5 
151 
 
 
Figure 5-3: Histogram of (A) aspect ratio of all particles and (B) intensity minimum of 
particles in the size range of 2-6 µm for 5 µm particle size standards and HSA particles 
generated by heat stress determined by MFI. 
 
Table 5-1: Representative MFI images of 5 µm particle size standards and protein 
particles. 
Material Polystyrene Glass Silica 
HSA 
(heating) 
Representative 
MFI images 
     
 
     
     
 
     
     
 
     
     
 
     
 
3.2 Evaluation of novel materials  
HSA starch particles, spray-dried HSA, gelatin particles and raw powder of zein, 
chitosan, and PTFE were evaluated as candidates for standardized protein-like 
particles. In LO, only HSA-starch, gelatin, and PTFE particles displayed a similar 
size distribution as HSA (heating) particles, whereas spray-dried HSA and in 
particular chitosan and zein particles contained substantial fractions of larger 
particles (Figure 5-4A). These larger particles were hardly detected by MFI, 
presumably as they were stuck at the flow cell inlet. Overall, in MFI the size 
distributions of the different materials appeared rather similar (Figure 5-4B). 
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Figure 5-4: Differential size distribution (normalized) of 5 µm particle size standards and 
evaluated materials determined by (A) LO and (B) MFI. 
 
With aspect ratios between 0.4 and 0.9 all evaluated particles appeared more 
spherical than HSA (heating) particles, but less spherical than the current particle 
standards (Figure 5-5A). Gelatin and PTFE particles showed higher similarity to 
HSA (heating) particles as compared to the other materials. The transparency as 
a crucial parameter was only matched by gelatin and PTFE particles whereas all 
other materials were clearly less transparent (Figure 5-5B). Spray-dried HSA 
particles were even more similar to the particle standards than to HSA (heating) 
particles. HSA-starch, chitosan, and zein particles showed a broad distribution in 
transparency with most particles in medium transparency region around 500. 
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Figure 5-5: Histogram of (A) aspect ratio of all particles and (B) intensity minimum of 
particles in the size range of 2-6 µm for 5 µm particle size standards and evaluated 
materials determined by MFI. 
 
The comparison of all evaluated parameters renders HSA starch, gelatin, and 
PTFE particles as most similar to HSA (heating) particles (Table 5-2). Of those 
three, only gelatin and PTFE particles displayed an aspect ratio mean over all 
particles below 0.8. 
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Table 5-2: Overview of results for all screened materials regarding size evaluated by MFI 
and LO as well as shape and transparency evaluated by MFI and representative MFI 
images in a size range of about 5-20 µm, scaled to the same image size. Particles most 
similar to HSA (heating) particles are in bold face. 
Material 
Size mean 
MFI (µm) 
Size mean 
LO (µm) 
Aspect 
ratio 
mean 
Intensity 
minimum 
mean 
Representative 
MFI images  
(5-20 µm) 
Polystyrene 5.07 5.05 0.89 315 
     
Glass 4.76 5.10 0.89 356 
     
Silica 5.09 5.36 0.89 430 
     
HSA 
(heating) 
3.09 1.67 0.68 714 
     
HSA-starch 1.78 1.85 0.86 651 
     
HSA spray-
dried (Mini) 
3.26 3.61 0.86 531 
     
HSA spray-
dried (Nano) 
3.65 3.55 0.86 515 
     
Gelatin 2.71 1.94 0.77 731 
     
Zein 1.87 15.5 0.86 630 
     
Chitosan 3.56 10.49 0.81 570 
     
PTFE 3.19 3.01 0.76 649 
     
 
As storage stability is an important criterion for the potential use of a material for 
standardized protein-like particles, HSA (heating) particles and the most 
promising candidates were subjected to a short stability test. Particles were 
stored as aqueous suspensions over 8 weeks, HSA (heating), gelatin, and HSA 
starch particles at 5±3 °C, PTFE particles at 25±2 °C. All particles showed 
variations in the concentration over 8 weeks (Figure 5-6). For HSA-starch 
particles the concentration increased significantly already after 2 days and had 
doubled after 8 weeks (Figure 5-6B). The concentration of PTFE particles 
increased clearly, but not significantly, over time (Figure 5-6D). HSA (heating) 
particles (Figure 5-6A) and gelatin particles (Figure 5-6C) displayed less than 
40% deviation from the initial concentration. 
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Figure 5-6: Particle concentration over time as determined by MFI for (A) HSA particles 
generated by heat stress, (B) HSA-starch particles, (C) gelatin particles, and (D) PTFE 
particles. Error bars represent standard deviations from triplicate samples. 
 
The limited stability of HSA (heating) particles became obvious in the strong 
decrease in mean particle size in contrast to consistent values for HSA-starch, 
gelatin, and PTFE particles over storage time (Figure 5-7A). The aspect ratio 
varied only slightly for all materials (Figure 5-7B) and the intensity minimum 
mean increased slightly for all materials except gelatin particles (Figure 5-7C). 
Taken together, gelatin particles possessed the most constant particle properties 
in this stability study followed by PTFE particles. HSA-starch particles were not 
considered suitable due to the clear increase in concentration pointing towards 
particle instability. 
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Figure 5-7: Particle properties (A) size mean, (B) aspect ratio mean, and (C) intensity 
minimum mean over time. Error bars represent standard deviations from triplicate 
samples. 
 
3.3 Investigation of protein particle density 
In addition to particle size and optical properties evaluated above, the particle 
density is an important criterion for particle analysis which is not yet well 
understood:6 On the one hand, a high density difference between medium and 
particles could influence the result by particle sedimentation or floating during 
the measurement. On the other hand, the non-optical technique of RMM requires 
knowledge of the particle density for correct size calculation. Thus, the density of 
protein particles is a critical property for the development of standardized 
protein-like particles, especially for RMM. In general, protein particles are 
irregularly structured and may contain substantial amounts of liquid between the 
solid protein parts.6 Therefore, two different types of density can be defined: (i) 
the density of only the protein part and (ii) the apparent mean density of the 
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complete particle including protein parts and entrapped liquid. Accordingly, 
methods to determine both types of density were developed in this study. 
The density of only the protein part was determined based on the RMM 
principle.10,15 The buoyant mass measured by the system is converted to the 
particle size based on the density difference between particle and surrounding 
liquid. This means that if the system is not able to detect particles, the two 
densities must be identical making the particles “weightless”. However, an exact 
density match is difficult to achieve due to density variation of the particles and a 
viscosity limit of the system which constraints the addition of excipients for 
density adjustment. Alternatively, the particles can be analyzed in solutions of 
increasing density thereby decreasing the buoyant mass. From this data, the 
density at which the particles would theoretically become “weightless” can be 
extrapolated. As only the solid part of a particle contributes to its buoyant mass 
(the liquid within the particle has the same density as the surrounding liquid), 
only the density of the solid part is the decisive factor. This principle was used to 
determine the pure protein density of rituximab particles generated by heat 
stress and gelatin particles prepared by a two-step desolvation method. 
Rituximab particles and gelatin particles were analyzed in aqueous buffer without 
or with 20% and 40% sucrose. Due to the broad size distribution of the particles, 
the sum of the buoyant mass of all particles was used for the calculation rather 
than the mean buoyant mass. The sum of the buoyant mass in the respective 
solutions was extrapolated to a buoyant mass of zero indicating a density match 
of particles and surrounding liquid (Figure 5-8). This method provided a density 
of about 1.36 g/mL and 1.42 g/mL for the solid part of rituximab (Figure 5-8A) 
and gelatin particles (Figure 5-8B), respectively. The results are in the range of 
calculated values of 1.38-1.39 g/mL for a 150 kDa antibody16 and 1.39-
1.42 g/mL16 or 1.41-1.44 g/mL17 for a 40-50 kDa protein like gelatin, based on 
van der Waals radii and hydrodynamic volume of atomic groups (based on crystal 
structures of small molecules with the same atomic groups). 
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Figure 5-8: Sum of the buoyant mass over all particles determined in sucrose solutions of 
different density and extrapolated to the density match of particles and solution for (A) 
rituximab particles generated by heat stress and (B) gelatin particles. Error bars 
represent standard deviations from triplicate measurements. 
 
The second type of particle density, the density of protein particles including 
entrapped liquid, is important for correct size determination by RMM and cross-
correlation of data obtained from RMM and optical techniques. MFI and LO as 
light-based techniques do not consider the particle density in the size calculation. 
Instead, the border of the particle’s image (MFI) or shadow (LO) including both 
solid parts and liquid parts is defined as the border of the particle. The particle 
size is then calculated as the equivalent circular diameter, i.e. the diameter of a 
circle with the same area as the particle. Thus the same particle size can only be 
detected by MFI/LO and RMM if the density of protein particles including liquid 
parts is used for the calculation in RMM. When adjusting the density value in the 
RMM software until the same particle size is detected in MFI/LO and RMM, i.e. the 
size distributions overlap, this very density reflects the density of the protein 
particles including liquid parts. This method requires a clear maximum in the size 
distribution as a reference point. 
Rituximab particles generated by heat stress showed an interesting size 
distribution in MFI and RMM with a clear maximum (Figure 5-9) which is not 
typical for protein.4,14,18,19 Usually small particles represent the largest fraction in 
a protein particle size distribution as seen for example for HSA particles 
generated by heat stress (Figure 5-1) or other therapeutic proteins (see also 
Chapter 2, Chapter 3, Chapter 4, and Chapter 6). In RMM, the maximum for 
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rituximab particles was located at about 2.5 µm with an input density of 
1.37 g/mL as used in another study for RMM10 (Figure 5-9A). In this case, the 
particle size represents the size of a protein particle without liquid parts. In MFI, 
the maximum was located at about 4.5 µm which displays the particle size 
including liquid parts (Figure 5-9A). The input density for size calculation in RMM 
was then adjusted until the size distributions from both techniques overlapped 
(assessed by the location of the maximum, Figure 5-9B). This suggested a 
particle density including liquid parts of 1.07 g/mL ± 0.05 g/mL and indicated 
that a protein particle could consist of approx. 70-95% of aqueous liquid and only 
5-30% of protein (calculated with 1.02 g/mL as the lowest possible and 
1.12 g/mL as the highest possible density including liquid parts, 1.0 g/mL for 
aqueous liquid and 1.36 g/mL for pure protein as determined above). 
 
Figure 5-9: Differential size distribution of rituximab particles generated by heat stress 
determined by MFI and RMM using an input density of (A) 1.37 g/mL and (B) 1.07 g/mL 
for RMM. Error bars represent standard deviations from triplicate measurements. 
 
For gelatin particles, density determination by this method was not possible due 
to a size distribution without a clear maximum of the size distribution in the µm 
range (Figure 5-10). 
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Figure 5-10: Differential size distribution of gelatin particles determined by MFI and RMM 
using an input density of 1.37 g/mL. Error bars represent standard deviations from 
triplicate measurements. 
 
Thus, particle density is important for the development of standardized protein-
like particles to be used not only in light-based methods. The density of 
polystyrene standards (1.05 g/mL) is very close to the density of protein 
particles including entrapped liquid whereas glass and silica standards show 
clearly higher density values (2.5 g/mL and 1.8-2.0 g/mL). Thus, polystyrene 
standards can be considered suitable for RMM if an input density of 1.07 g/mL is 
used. If the density of pure protein of around 1.4 g/mL (calculated or 
determined) is used, gelatin particles might be better as they showed a similar 
density of pure protein (calculated and determined). 
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4 Conclusion 
This study identified gelatin particles, prepared by a two-step desolvation method 
with subsequent cross-linking by glutaraldehyde, and PTFE particles (raw 
material powder), as optically similar to particles of therapeutic proteins. 
Especially the particle properties shape and transparency were represented well 
– in contrast to polystyrene standards. This justifies the further investigation of 
gelatin and PTFE particles as promising candidates for the development of 
standardized protein-like particles especially for light-based techniques (see 
Chapter 6 for an application of PTFE particles). Two methods for determination of 
protein particle density based on RMM were developed in this study. They 
revealed a density of pure protein of around 1.4 g/mL, which was congruent with 
theoretical values, and furthermore a density of protein particles with entrapped 
liquid of 1.07 g/mL. Taken together, both optical properties and density are 
crucial for the development of novel standardized protein-like particles. PTFE 
particles showed useful properties especially for light-based techniques whereas 
gelatin particles might be suitable for both light-based and weight-based 
methods. 
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                 Chapter 6
                                 
How subvisible particles become invisible – 
relevance of the refractive index for protein 
particle analysis 
Abstract 
The aim of the present study was to quantitatively assess the relevance of 
transparency and refractive index on protein particle analysis by the light-based 
techniques light obscuration (LO) and Micro-Flow Imaging (MFI). A novel method 
for determining the refractive index of protein particles was developed and 
provided a refractive index of 1.41 for protein particles from two different 
proteins. An increased refractive index of the formulation by high protein 
concentration and/or sugars at pharmaceutically relevant levels was shown to 
lead to a significant underestimation of the subvisible particle concentration 
determined by LO and MFI. A refractive index match even caused particles to 
become “invisible” for the system, i.e. not detectable anymore by LO and MFI. To 
determine the influence of formulation refractive index on particle 
measurements, we suggest the use of polytetrafluoroethylene (PTFE) particles to 
test a specific formulation for refractive index effects. In case of refractive index 
influences, we recommend also using a light-independent technique such as 
resonant mass measurement (Archimedes) for subvisible particle analysis in 
protein formulations. 
 
The following chapter was published as a research article in the Journal of Pharmaceutical Sciences 
and appears in this thesis with the journal’s permission: 
S. Zölls, M. Gregoritza, R. Tantipolphan, M. Wiggenhorn, G. Winter, W. Friess, A. Hawe: “How 
subvisible particles become invisible – relevance of the refractive index for protein particle 
analysis”; J Pharm Sci 102(5):1434-1446 (2013) 
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1 Introduction 
Protein aggregates and particles are an important instability product in 
therapeutic protein formulations, which need to be quantified and characterized 
due to quality requirements, potential loss of activity and the potential risk of 
immunogenicity.1-4 For many years pharmacopeias have required the analysis of 
subvisible particles, i.e. particles below 100 µm, also designated as micron 
aggregates,5 in size classes larger than 10 µm and 25 µm.6,7 However, in the last 
few years, there has been a trend to monitor particles in the size range below 
10 µm. This trend is due to regulatory interest in particle data for sizes below 
10 µm as part of the analytical characterization of a new product and post 
marketing commitment.8 This resulted amongst others in the compilation of the 
new educational chapter USP<1787> which deals with the analysis of subvisible 
particles, specifically in protein formulations, also below 10 µm and will be 
available soon.9 
Light-based techniques like light obscuration (LO) and flow imaging techniques, 
e.g. Micro-Flow Imaging (MFI), are commonly used for subvisible particle 
analysis.10-15 Light obscuration is the current compendial method but both LO and 
MFI will be included in the new educational chapter USP<1787>.9 Alternative 
techniques which do not rely on the interaction of particles with light are 
electrical sensing zone (ESZ, Coulter counter)16 or resonant mass measurements 
(RMM, Archimedes).17 However, ESZ requires large sample volumes and 
sufficient buffer conductivity which is often not feasible for protein formulations14 
and experience using RMM is limited.18,19 Particle techniques are generally 
calibrated with polystyrene particle standards which have optical and 
morphological properties clearly different from those of protein particles.12 Thus, 
researchers in the field of particle analysis from industry, regulatory agencies, 
and academia have emphasized the need of “proteinaceous subvisible particle 
standards”,20 “alternative particle standards with more protein-like 
morphology",10 or “relevant protein particulate standards”.1  
One of the major differences between polystyrene particle standards and protein 
particles is the transparency12,21-23 which is in turn connected to the refractive 
index (RI) of the particles.24 The RI is a dimensionless unit which describes the 
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refraction of light by a specific material.25 However, the RI of protein particles 
has not been determined so far and is only estimated to be in the range from 
1.33 to 1.412 or 1.4 to 1.6.11 The influence of the RI on light-based techniques for 
particle analysis has been qualitatively studied by analyzing glass particle 
standards in ethylene glycol12 and protein particles in highly-concentrated protein 
solutions.11 Consequently, there is a need for methods for RI determination of 
protein particles24,26 as well as for the quantitative evaluation of RI effects on 
protein particle analysis. 
Our aim was to quantitatively assess the relevance of the optical properties 
transparency and RI for protein particle analysis. Therefore, we set out to 
develop a method for RI determination of protein particles based on the 
immersion principle (minimized light scattering and maximized light transmission 
at the RI match).27 The influence of the RI difference of particles and surrounding 
formulation on the measured particle concentration and size by LO and MFI was 
investigated at pharmaceutically relevant test conditions and in marketed 
pharmaceutical products. 
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2 Materials and methods 
2.1 Materials 
Infliximab (Remicade®, lots no. 7GD9301402, 7FD8701601, 7RMKA81402, 
pooled), rituximab (MabThera®, lot no. B6073, exp. 12/2013), adalimumab 
(Humira®, lot no. 292209A05, exp. 10/2006) and etanercept (Enbrel®, lot no. 
31576, exp. 12/2008) were provided by local hospitals. Infliximab solution 
(IgG A) at a concentration of 1 mg/mL was prepared by dilution of 10 mg/mL 
infliximab in 100 mM phosphate buffer (pH 7.2). Rituximab solution (IgG B) at a 
concentration of 1 mg/mL was prepared by dilution of 10 mg/mL rituximab in 
25 mM citrate buffer (pH 6.5) containing 154 mM NaCl and 0.07% polysorbate 
80. Adalimumab solution at a concentration of 5 mg/mL was prepared by dilution 
of 50 mg/mL adalimumab in 15 mM phosphate/citrate buffer (pH 5.2) containing 
105 mM NaCl, 1.2% mannitol and 0.1% polysorbate 80. Etanercept solutions at 
concentrations of 1, 2, and 5 mg/mL were prepared by dilution of 50 mg/mL 
etanercept in 25 mM phosphate buffer (pH 6.3) containing 100 mM NaCl, 25 mM 
arginine hydrochloride and 1% sucrose. Human serum albumin (HSA) was 
purchased from Sigma-Aldrich (Steinheim, Germany) and formulated at 1 mg/mL 
in a 50 mM citrate buffer (pH 4.8). All protein formulations were filtered using a 
0.2 µm cellulose acetate syringe filter (Minisart®, Sartorius Stedim Biotech, 
Aubagne, France) for further use. 
Particles were generated by (i) stir stress, (ii) freeze-thaw stress or (iii) heat 
stress. For (i), 8 mL of the formulation was stirred in a 10R glass vial with a 
18 mm Teflon®-coated stir bar at 250 rpm at room temperature on a magnetic 
stirrer (Heidolph MR Hei-Standard, Schwabach, Germany) for 24 hours (IgG A 
(stirring)). For (ii), 1 mL of the formulation in a 1.5 mL low protein binding 
reaction tube (Eppendorf, Hamburg, Germany) was subjected to 7 freeze-
thawing cycles of 30 minutes in a -80 °C freezer and 10 minutes in a 25 °C water 
bath (IgG A (freeze-thawing)). For (iii), 0.5 mL of the formulation was heated for 
30 minutes at 60 °C (IgG A (heating)) or 1.5 mL of the formulation was heated 
for 30 minutes at 71 °C (IgG B (heating)) in a 1.5 mL low protein binding 
reaction tube in a thermomixer (Eppendorf, Hamburg, Germany) or 50 mL of the 
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formulation was heated in a 50 mL tube (Greiner bio-one, Frickenhausen, 
Germany) for 30 minutes at 70 °C in a water bath (HSA (heating)). 
Polystyrene and glass particle standards were purchased from Duke Scientific 
(through Thermo Scientific, Fremont, CA), silica particle standards from 
Microparticles GmbH (Berlin, Germany) and PTFE microparticles (Microdispers 
8000) from Polysciences Inc. (Warrington, PA). Polystyrene, glass, and silica 
particle standards were suspended in water. PTFE particles were suspended at a 
concentration of 50 mg/mL in 0.5% polysorbate 80 using an Ultra Turrax 
dispersing system (T10 basic, IKA® Werke, Staufen, Germany) for 3 minutes. 
Larger agglomerates were removed by filtration through a coarse tea filter (dm, 
Karlsruhe, Germany). 
Sucrose solutions were prepared by dilution (w/w) of a 70% (w/w) solution 
(prepared by dissolving sucrose in water under stirring and heating to 60 °C in a 
closed container). All solutions were filtered using a 0.2 µm cellulose acetate 
syringe filter and air bubbles were removed by centrifugation for 5 minutes at 
10,400 rpm (Centrifuge 5810R, Eppendorf, Hamburg, Germany) prior to use. 
Sucrose, citric acid monohydrate, sodium hydroxide, di-sodium 
hydrogenphosphate dihydrate and sodium dihydrogenphosphate dihydrate were 
purchased from Merck KGaA (Darmstadt, Germany). Sodium chloride, sodium 
citrate dihydrate and polysorbate 80 were from VWR (Darmstadt, Germany). The 
water used in this study was highly purified water (Advantage A10 purification 
system, Millipore, Newark, NJ). 
2.2 Refractive index determination 
Refractive indices of sucrose and HSA solutions as well as Humira® and Enbrel® 
formulations were determined using an Abbé refractometer (Carl Zeiss AG, 
Oberkochen, Germany). Measurements were performed in triplicates at a 
wavelength of 589 nm at room temperature. 
For particle RI determination, the protein particle suspensions were concentrated 
by centrifugation and resuspension of the pellet for 5 minutes at 10,400 rpm to a 
final concentration between 1x108 particles/mL and 5x108 particles/mL > 1 µm as 
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controlled by LO (corresponding to a minimal protein concentration of about 
70 µg/mL within the particles based on a minimum particle size of 1 µm and a 
density of protein particles of 1.32 g/mL). An overview of the procedure for 
particle RI determination, based on immersion, is given in Figure 6-1. Twelve 
different sucrose solutions, in a concentration range depending on the expected 
RI of the particles, e.g. from 5% to 60% in 5% steps, were pipetted into a 96 
well plate (Corning Inc., Corning, NY) by an automated liquid handling station 
(Microlab Star®, Hamilton Robotics, Reno, NV) in surface dispense mode (n=6, 
190 µL per well with parameters optimized for highly viscous solutions). A 
background measurement of the sucrose solutions was performed using a Safire2 
plate reader (Tecan Group AG, Männedorf, Switzerland) with optimized 
measurement parameters. Light scattered by the sample was determined in 
“absorbance mode” (= scattering) and light transmitted through the sample was 
determined in “fluorescence mode” (= transmission), both at a wavelength of 
589 nm. A pathlength correction was performed for the absorbance mode to 
account for the varying pathlength due to the different viscosity of the sucrose 
solutions according to the manufacturer’s recommendation.28  
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Figure 6-1: Schematic overview of the developed method for RI determination of 
(protein) particles based on the immersion principle. 
 
 
For particle measurements, 10 µL concentrated particle suspension were added 
manually to each well (total volume 200 µL) and scattering and transmission 
were determined as described before. Mean and standard deviation for each 
sixtuplicate were calculated, outliers were excluded from further calculation 
(Grubbs test, α = 0.05) and means of scattering and transmission were plotted 
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against the RI of the sucrose solutions (determined by Abbé refractometry). 
Scattering minimum and transmission maximum (= RI match points between 
sucrose solution and particles) were determined by a polynomial fit (OriginPro 
software, version 8.5) and the particle RI was calculated as the mean from three 
independent experiments. 
2.3 Light obscuration (LO) 
Subvisible particles in a size range between 1 and 200 µm were analyzed by LO 
using a PAMAS SVSS-C (Partikelmess- und Analysesysteme GmbH, Rutesheim, 
Germany) equipped with an HCB-LD-25/25 sensor. Particle suspensions were 
diluted with the appropriate buffer (filtered by a 0.22 µm cellulose acetate/nitrate 
membrane filter, MF-Millipore®, Millipore) or water in order to adhere to the 
concentration limit of the system of 120,000 particles/mL > 1 µm. Three 
measurements of a volume of 0.3 mL of each sample were performed with a pre-
run volume of 0.5 mL at a fixed fill rate, emptying rate and rinse rate of 
10 mL/min and the mean particle concentration per mL was reported by the 
system. Samples were measured in triplicates and mean and standard deviation 
were calculated.  
2.4 Micro-Flow Imaging (MFI) 
Subvisible particles in a size range between 1 and 70 µm were analyzed by MFI 
using a MFI4100 (ProteinSimple, Santa Clara, CA) equipped with a high-
resolution 100 µm flow cell. Particle suspensions were diluted with the 
appropriate buffer (filtered by a 0.22 µm cellulose acetate/nitrate membrane 
filter) or water with the same dilution factor as for LO. Samples were analyzed 
with a sample volume of 0.65 mL and a pre-run volume of 0.3 mL at a flow rate 
of 0.1 mL/min. Prior to each sample run the respective diluting agent was flushed 
through the system to provide a clean flow cell. The “optimize illumination” 
procedure was performed with an appropriate diluent of the respective sample, 
e.g. formulation buffer, to ensure correct thresholding of the MFI system. 
Particles stuck to the flow cell wall were only counted once and edge particles 
were excluded for analysis. Samples were measured in triplicates and mean and 
standard deviation were calculated. Results were analyzed using the MFI view 
application software version (MVAS) 1.2. For samples in prefilled syringes, 
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protein particles and silicone oil droplets were differentiated by the “find similar” 
algorithm in the MVAS software (at least 20 images clearly identified as silicone 
oil droplets were selected manually as a basis for the automatic search function 
by the software). 
2.5 Resonant mass measurements (RMM) 
Resonant mass measurements were performed using the Archimedes particle 
metrology system (Affinity Biosensors, Santa Barbara, CA) equipped with a Micro 
sensor (size range 0.3 to 4 µm) calibrated with 1 µm polystyrene standards. 
Before each measurement, the system was filled with sample and the lower size 
limit of detection was determined three times in automatic mode. The mean 
value was set as a fixed limit of detection for the measurement. The buffer 
density was determined for each sample. The particle density was set to 
1.32 g/mL for negatively buoyant particles (proteinaceous particles) according to 
the recommendation of the manufacturer. Measurements were performed in 
triplicates and the sensor was filled with fresh sample for each measurement. 
The measured volume was 0.15 µL and the overall sample volume for triplicate 
measurements was 600 µL. Between triplicate measurements, the system was 
rinsed with water. Results were analyzed using the ParticleLab software 
(v1.8.570) with a size bin step of 10 nm. 
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3 Results and discussion 
3.1 Transparency evaluation of protein particles 
Protein particles generated by freeze-thawing, stirring or heating an IgG 
formulation at 1 mg/mL were analyzed by MFI. Besides the particle size 
distribution (Figure 6-2), the optical properties of the particles, in particular the 
transparency, were evaluated. The transparency can be judged by means of the 
intensity value obtained from MFI images, which is proportional to particle 
transparency.23 The intensity can vary in a unit-less theoretical range from 0 
(= low transparency, “dark particles”) to 1,023 (= high transparency, “bright 
particles”). Due to the calibration settings of the MFI system, maximum intensity 
values of around 850 are typically reached. The MFI system applies bright-field 
microscopy and thereby excludes pixels in the particle from the analysis which 
are brighter than the background, which are probably present due to specific 
diffraction patterns.29 Thus, intensity parameters such as intensity mean or 
intensity maximum might not be representative for the real particle 
transparency. In contrast, the intensity minimum, which describes the 
transparency of the “darkest pixel” of a particle, is not influenced by pixels 
brighter than the background and can also be used to differentiate particles of 
various origins by MFI.12 Therefore, we chose the intensity minimum for the 
evaluation of particle transparency in this study. 
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Figure 6-2: Cumulative size distributions of the different types of protein particles 
obtained by MFI analysis for IgG A particles generated by (A) freeze-thaw stress, (B) stir 
stress, (C) heat stress. (D) IgG B particles generated by heat stress, (E) HSA particles 
generated by heat stress. 
 
For the protein particles generated by the three different types of stress, the 
intensity minimum was distributed over a broad range that was clearly influenced 
by the particle size (Figure 6-3A). Small particles showed high transparency, e.g. 
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intensity minimum values of about 700-800 for the smallest sizes of 1-2 µm, 
whereas larger particles appeared at lower transparency, e.g. intensity minimum 
values of about 300-500 for particles > 10 µm. Size-dependent differences were 
material-independent, as can be seen in the comparison of the particle images of 
protein particles and polystyrene particle standards (Figure 6-3B). The lower 
reported transparency values of larger particles can mainly be attributed to the 
longer optical path length (Z-dimension) of a larger particle which decreases the 
light transmission more strongly as compared to a smaller particle with a shorter 
optical path length. Due to the size dependence and the varying size distribution 
between different samples, it is reasonable to evaluate the transparency of 
particles in a specific size range. In this study the size range of 2-6 µm was 
selected for quantitative intensity evaluation, as particles in the low µm range 
represented the largest fraction in all samples evaluated (Figure 6-2). Below 
2 µm, the image quality was insufficient to draw conclusions from intensity 
values. Particles larger 6 µm showed similar trends but were less representative 
due to lower total particle counts. 
In the resulting size-specific histogram (Figure 6-3C), the intensity minimum 
peaks were located in very similar regions of about 600-800 for all types of 
protein particles. In contrast, polystyrene, glass and silica particle standards 
showed clearly lower intensity minimum values of about 300-400 reflecting the 
lower transparency of the commonly used standards. Larger particles displayed 
similar differences in the intensity minimum values: 300-500 for protein particles 
vs. about 200 for polystyrene particles of 10 µm and 200-300 for protein 
particles vs. about 100 for polystyrene particles of 20 µm. Differences in the 
transparency are also directly visible in the MFI images, as exemplarily shown for 
IgG A particles and polystyrene particle standards (Figure 6-3B). This confirms 
that transparency is an important parameter which is not represented well by 
current particle standards as stated by several experts in the field12,21-23 and 
explains the need for more proteinaceous particle standards.1,10,20 Therefore, we 
screened several materials in order to identify one with an intensity minimum 
that was more representative of protein particles. Among various proteinaceous 
and non-proteinaceous materials (see Chapter 5) PTFE displayed similar 
transparency as compared to protein particles (Figure 6-3C). Interestingly, the 
observed low transparency of polystyrene correlated with its high RI of 1.59 
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whereas the high transparency of PTFE corresponded with its lower RI of 
1.35-1.38.30,31 This indicated a connection between RI and transparency and 
made the knowledge of the RI of protein particles, which has only been 
estimated so far,11,12 even more important. Consequently, we set out to develop 
a method for RI determination of protein particles to support the identification of 
a suitable reference material and to better understand the impact of the RI of 
both the formulation and the protein particles on the results of LO and MFI 
analyses. 
 
Figure 6-3: (A) Scatter plot of the intensity minimum from MFI against the particle size; 
the red lines indicate the size range of 2-6 µm used for further evaluation of the intensity 
minimum. (B) Representative particle images from MFI, scaled to the same size, 
indicating differences in particle transparency depending on particle size and material. 
(C) Histogram of the intensity minimum of particles in the size range of 2-6 µm for 
different materials. The RI of the respective material is indicated above the data if 
known. tbd = to be determined. 
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3.2 Refractive index determination of protein particles 
A prerequisite for light scattering by an object is an RI difference between the 
object and the surrounding medium (usually air or liquid). In case of an RI 
match, light directed towards the object can pass directly through the object 
leading to minimized light scattering and maximized light transmission 
(immersion effect).27 Close to the RI match, light is still scattered and 
transmission is still interrupted by the object. However, decreased light 
interaction at the edges of the object leads to decreased light scattering and 
increased light transmission around the absolute turning point at the RI match. 
Because light scattering and transmission are critical parameters in light-based 
particle analysis, RI determination of protein particles based on those principles 
is reasonable. In order to identify the RI of the protein particles, sucrose 
solutions of different concentrations/RIs were prepared to identify the point at 
which the RI of the particles and the carrier solution matched. 
Light scattering and transmission of silica particle standards of known RI was first 
quantified for the proof of concept of the method. The obtained RI of 1.42 
corresponded with the value provided by the manufacturer32 for 2 µm silica 
particles (Figure 6-4A) and also for 5 µm and 8 µm silica particles (Figure 6-4A, 
insert, only scattering mode). This shows that our method provides correct 
results in the lower µm size range. 
For both HSA particles (heating) and IgG A particles (stirring) an RI of about 
1.41 was measured. The RI of HSA particles was very uniform for scattering and 
transmission mode (Figure 6-4B) whereas the RI of IgG A particles was slightly 
higher for scattering mode as compared to transmission mode (Figure 6-4C). 
This value of 1.41 falls into the center of the RI estimates for protein particles in 
literature of 1.33 to 1.412 and 1.4 to 1.6.11 Furthermore, a time course study 
revealed that the RI of HSA particles did not change significantly upon incubation 
in the sucrose solutions for three hours at room temperature showing that the 
stability of the protein particles was not compromised by the sucrose solutions.  
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Figure 6-4: Particle RI determined by scattering or transmission for (A) silica particle 
standards (2 µm, the insert shows 5 µm and 8 µm) (B) HSA particles (heating), (C) IgG A 
particles (stirring). A polynomial fit around the extreme values is shown as a line. The RI 
obtained at the calculated extreme values is indicated as the mean from three 
independent experiments. Each graph represents one out of three independent 
experiments with error bars representing the standard deviation of sixtuplicates within 
one experiment. A.U. = arbitrary units. 
 
Alternative methods for RI determination of particles are turbidity 
measurements, which apply the same measurement principle as our method,30 
and digital holographic microscopy33 and quantitative phase microscopy.34 These 
methods were applied to spherical particles30 or cells,33,34 but have not yet proved 
to be suitable for protein particles, to the best of our knowledge. Furthermore, 
the microscopic methods have rather low throughput as the RI of individual cells 
or particles is determined. In contrast, the method developed during our studies 
is fast, suitable to be automated and determines the mean RI of the complete 
particle population. One important prerequisite for the application of our method 
is a particle concentration of at least 1x108 particles/mL larger than 1 µm. Such 
large quantities of protein particles need to be generated either by concentration 
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of particles (e.g. by centrifugation) or by applying stress. Our method is probably 
not suitable to determine the RI of particles in a final therapeutic protein 
formulation with low particle numbers without further sample preparation steps. 
Even though the determined RI of protein particles (1.41) was close to the RI of 
silica particles (1.42), the transparency of protein particles (around 700) was 
higher than the transparency of silica particles (around 400). Thus, as a next 
step we aimed to elucidate the relationship between transparency, RI, and the 
number of particles detected by light-based techniques. 
3.3 Relevance of RI for protein particle analysis 
The influence of RI on protein particle analysis was investigated by suspending 
protein particles or standard particles at one fixed concentration in solutions of 
varying RI and quantifying total particle counts larger 1 µm by LO and MFI 
(Figure 6-5). Because products meeting the specifications for the compendial size 
classes > 10 µm and > 25 µm can nonetheless contain substantial amounts of 
smaller particles,13,35,36 and the quantification of particles below 10 µm is gaining 
more and more importance,8,9 we decided to extend the evaluation of RI effects 
for particles to smaller size classes > 1 µm. Although the image resolution for 
particles below 2 µm was not sufficient to characterize particles using optical 
parameters such as transparency, counting of particles could be performed for 
particles > 1 µm with satisfying data quality. The RI of the solutions was 
adjusted by the addition of sucrose and/or increasing the protein concentration 
by adding HSA, both of which resulted in an increase in RI of the formulation. 
Both approaches represent pharmaceutically relevant conditions found in many 
therapeutic protein products. Sucrose is a common excipient with a roughly 
linear correlation of concentration to RI. High protein concentrations are often 
used for subcutaneous administration, in particular for monoclonal antibody 
preparations.37  
 REFRACTIVE INDEX RELEVANCE FOR PROTEIN PARTICLE ANALYSIS               CHAPTER 6 
179 
 
 
Figure 6-5: Particle counts determined by LO and MFI for fixed particle concentrations in 
sucrose solutions of varying RI of (A) silica particle standards (5 µm), (B) polystyrene 
particle standards (2 µm), (C) HSA particles (heating), (D) IgG A particles (stirring). The 
additional x-axis shows the RI of the respective solutions. Stars (*) indicate data points 
differing significantly from the initial concentration (ANOVA, p < 0.05). Error bars 
represent standard deviations from triplicate samples (dilutions were prepared in 
triplicates). 
 
5 µm silica particle standards of known RI (1.42) were analyzed by LO and MFI 
at one fixed particle concentration in sucrose solutions of increasing 
concentration / RI (Figure 6-5A). The measured particle concentration (“apparent 
concentration”) in LO declined at higher sucrose concentrations (>40%) / RI 
values (>1.40) whereas particle counts in MFI stayed rather constant up to 45% 
sucrose / RI 1.41. Nevertheless, the particles appeared more transparent, as 
reflected in increasing intensity minimum values (mean of all particles) from 427 
in water to 722 in 45% sucrose. Strikingly, in both techniques, silica particle 
standards became completely “invisible” and not detectable anymore at 50% 
sucrose when the RI of particles and solution matched exactly (RI 1.42).  
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The quantification of polystyrene particle standards by LO and MFI was not 
affected at all in the studied sucrose concentration range due to the high RI of 
polystyrene of 1.59 (Figure 6-5B) which again illustrates the need for novel more 
representative particle standards as claimed before.1,15,20 This high RI makes an 
RI match with sucrose solutions impossible due to the solubility limit of sucrose 
and the viscosity limit for LO and MFI. 
Protein particles (HSA (heating) or IgG A (stirring)) were suspended in sucrose 
solutions of varying concentration and analyzed in the same way as the particle 
standards. To exclude direct effects of the high sucrose concentration, i.e. 
dissolution or generation of particles, two types of control experiments were 
performed: (1) Redilution control: high concentration sucrose samples with 
particles were diluted back to a lower sucrose concentration with water and the 
measured particle concentration was compared to the concentration measured in 
a particle sample directly prepared at the lower sucrose concentration. (2) 
Incubation control: particle concentrations were monitored before and after 
incubation of the protein particles in a solution of high sucrose concentration for 
one hour at room temperature. Both controls (1) and (2) showed no significant 
changes in the particle levels.  
For these protein samples, significantly more particles were detected by MFI as 
compared to LO, which is in accordance with the literature.10,11,21 The measured 
(“apparent”) concentration of HSA particles (heating) (Figure 6-5C) and IgG A 
particles (stirring) (Figure 6-5D) was significantly reduced at high sucrose 
concentrations in both techniques. This is due to the increased RI of the 
surrounding formulation and consequently decreased RI difference between 
particles and liquid. Particle counts by LO decreased nearly linearly for both 
particle types and showed significant differences to the initial particle 
concentration (at 0% sucrose) already at a sucrose concentration of 5% for HSA 
particles (heating) (Figure 6-5C) and 10% for IgG A particles (stirring) (Figure 
6-5D). These sucrose concentrations of 5-10% are often found in (marketed) 
formulations of therapeutic proteins. Particle counts by MFI also decreased 
significantly with increasing sucrose concentration. However, the MFI system 
seemed to be less affected by the decreased RI difference than LO as the relative 
decrease in particle concentration was lower. Reasons for this might be (1) the 
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different measurement principle and set-up including a lower wavelength LED 
(470 nm) in MFI compared to a higher wavelength laser (670 nm) in LO; and (2) 
the “optimize illumination” process in MFI which allows the system to set the 
sensitivity according to the optical properties of the respective liquid.12,23 
Strikingly, again, in both techniques, protein particles became “invisible” at the 
RI match of 1.41 similar to silica particles. 
The transparency of protein particles shown as the intensity minimum (mean of 
the complete particle population of 2-6 µm) generated from MFI images 
increased linearly (R2>0.99) with increasing sucrose concentration (Figure 6-6). 
This can also be seen in the MFI images (Figure 6-6) and explains the decrease 
in MFI particle counts with increasing RI of the formulation. In LO, “shadows” of 
the particles are projected on a light-sensitive area at the detector and the 
particle size is calculated proportional to the area of the shadow. Therefore, it 
can be assumed that increased light transmission caused by decreased RI 
differences, as described above in the context of the RI determination method, 
led to the decrease in LO counts. Similarly to the RI determination method it can 
be expected that particles “reappear” when the RI of the formulation is further 
increased exceeding the RI match point. However, those experiments were not 
performed due to the viscosity limit for LO and MFI. 
 
Figure 6-6: Increase in intensity minimum values from MFI (shown as the mean of the 
complete particle population of 2-6 µm) depending on the sucrose concentration of the 
solution and representative images of 10 µm particles from MFI. The additional x-axis 
shows the RI of the respective solutions. Error bars represent standard deviations from 
triplicate samples (dilutions were prepared in triplicates). 
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We propose the following mechanism for the phenomenon of subvisible particles 
becoming “invisible”: With increasing RI of the formulation, the particles get 
more difficult to detect by light-based techniques as the particle contour becomes 
blurred (also observed in MFI images of 5 µm silica particles, Figure 6-7A). For 
particles of uniform size and shape, this leads to a constant decrease in the 
apparent particle size for both LO and MFI as observed for 5 µm silica particle 
standards (Figure 6-7A). Nevertheless, in the case of 5 µm silica particle 
standards, the particles are still counted accurately as the decrease in size does 
not reach the detection limit of the systems until 40% sucrose with LO and 45% 
sucrose with MFI. Those particles only become invisible at the RI match. In the 
case of 2 µm silica particle standards, the particles become “invisible” at lower RI 
as the particle size decreases below the detection limit before the RI of particles 
and formulation match (Figure 6-7B). In the case of protein particles, particles 
become partly “invisible” at lower sucrose concentrations due to the polydisperse 
size distribution and the presence of smaller particles (Figure 6-2). These small 
particles “shrink” below the detection limit of the systems already at only slightly 
increased RI values, whereas larger particles are still detected and only become 
“invisible” when the refractive indices match. Additionally, the stronger RI 
influence on protein particles compared to silica particles is probably also due to 
other factors such as the irregular shape and surface structure, higher surface 
roughness and the lower compactness of protein particles which hamper the 
detection by light-based systems.21 
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Figure 6-7: (A) Mean particle size of 5 µm silica particle standards determined by LO and 
MFI in sucrose solutions of varying concentration. Stars (*) indicate data points of 
significantly smaller particle size compared to the initial size (ANOVA, p < 0.05). 
Representative images from MFI show the softening contours of the imaged particles 
with increasing RI. (B) Particle counts of 2 µm silica particle standards determined by LO 
and MFI for a fixed particle concentration in sucrose solutions of varying concentration. 
Stars (*) indicate data points differing significantly from the initial concentration 
(ANOVA, p < 0.05). The additional x-axis shows the RI of the respective solutions. 
 
Another formulation parameter that can affect RI is protein concentration. 
Pharmaceutically relevant protein concentrations cover a range from below 
1 mg/mL up to about 200 mg/mL or even higher. Thus, the influence of RI on 
protein particle analysis was further evaluated with high protein concentration. 
Significant differences in the concentration of HSA particles (heating) were 
observed by LO at 100 mg/mL HSA concentration (Figure 6-8A) or 50 mg/mL 
HSA combined with 5% sucrose (Figure 6-8B). Both conditions represent 
common formulation conditions. 
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Figure 6-8: Particle counts of HSA particles (heating) at a fixed concentration determined 
by LO and MFI in formulations of (A) HSA and (B) HSA and sucrose. The additional x-axis 
shows the RI of the respective solutions. Stars (*) indicate data points differing 
significantly from the initial concentration (ANOVA, p < 0.05). Error bars represent 
standard deviations from triplicate samples (dilutions were prepared in triplicates). 
 
A high protein concentration is pharmaceutically relevant especially for 
subcutaneous administration, for example Simponi® (golimumab) and Cimzia® 
(certolizumab) are formulated at 100 mg/mL and 200 mg/mL, respectively.38,39 
Also formulations with lower protein concentration but with excipients increasing 
the RI are represented by our model solutions such as Humira® (50 mg/mL 
adalimumab and 1.2% mannitol)40 and Enbrel® (50 mg/mL etanercept and 1% 
sucrose).41 For both Humira® and Enbrel® an RI of 1.35 was determined by Abbé 
refractometry which corresponds to the RI of formulations containing 100 mg/mL 
HSA or 50 mg/mL HSA with 5% sucrose. For example, the original etanercept 
formulation was analyzed undiluted and in several dilutions in the formulation 
buffer by LO and MFI (Figure 6-9). Clearly more particles (calculated back to the 
original concentration) were detected in diluted formulations of lower protein 
concentration for both LO and MFI. These results indicate that mainly LO, but 
also MFI might not detect the real particle load of a sample, but might instead 
underestimate subvisible particle numbers due to a low RI difference between 
particles and formulation. 
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Figure 6-9: Particle counts in expired prefilled syringes of Enbrel® (etanercept) measured 
undiluted (50 mg/mL) and diluted in the appropriate formulation buffer by LO and MFI. 
The error bar for 1 mg/mL represents the standard deviation from a duplicate sample 
(dilution was prepared in duplicate). Formulations at 2 mg/mL, 5 mg/mL, and 50 mg/mL 
were analyzed only n=1 due to limited material availability. 
 
To understand whether the obtained data are prone to error due to detection 
problems caused by the formulation RI we suggest two possible ways to cope 
with the influence of high formulation RI when using light-based techniques:     
(i) use of PTFE particles for the evaluation of the “invisible particle effect” in LO, 
(ii) use of alternative (light-independent) measurement principles. 
3.4 PTFE particles for the evaluation of the “invisible 
particles effect” in LO 
To address the question whether the RI of the formulation potentially influences 
the outcome of light-based subvisible particle detection methods, the formulation 
of interest can be tested for the “invisible particles effect” using PTFE particles. 
These polymeric particles in suspension show similar optical properties as protein 
particles (Figure 6-3) and can be spiked as a highly-concentrated suspension into 
the formulation of interest.  
As shown in Figure 6-10A, the measured (“apparent”) concentration of PTFE 
particles by LO and MFI was influenced by the RI of the surrounding formulation. 
Decreases in PTFE particle concentration by LO were already observed at only 
5% sucrose. The relative apparent particle concentrations determined by LO 
compared to the real concentration in the sample were very similar for protein 
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particles (e.g. 87%, 82%, and 58% for HSA particles and 97%, 89%, and 60% 
for IgG particles in 5%, 10%, and 20% sucrose, Figure 6-5C,D) and PTFE 
particles (88%, 72%, and 61%, Figure 6-10A). The apparent increase of the 
PTFE particle concentration in LO at 40% sucrose is probably due to the lower 
and more polydisperse RI of PTFE (RI 1.35-1.3830,31) as compared to protein (RI 
1.41). As the RI of 40% sucrose (RI 1.40) exceeds the RI of the particles, 
detection is facilitated when compared to 30% sucrose solution (RI 1.38) and 
particles “reappear”, due to the increase of light scattering after the RI match 
point (Figure 6-4). With MFI, the PTFE concentration was also affected by the RI 
of the sucrose solution as particle counts decreased until 10-20% sucrose. The 
apparent increase in PTFE particle concentration after the RI match was observed 
at lower sucrose concentrations compared to LO. The measured particle 
concentration at 40% sucrose was even higher than the initial concentration in 
water, presumably because of the better optical contrast of PTFE in 40% sucrose 
as compared to PTFE in water which is due to the low RI of PTFE. 
The utility of using PTFE particles was confirmed by LO and MFI analysis of a 
PTFE particle suspension in a model protein formulation containing 50 mg/mL 
HSA and 5% sucrose (Figure 6-10B). PTFE particles were even more sensitive 
towards the “invisible particles effect” than protein particles. The relative 
apparent particle concentration by LO in the formulation containing 50 mg/mL 
HSA and 5% sucrose compared to the concentration in water was clearly lower 
for PTFE particles (53%, Figure 6-10B) as compared to HSA particles (76%, 
Figure 6-8B). With MFI, the apparent concentration of PTFE particles decreased 
to 70% in 50 mg/mL HSA and 5% sucrose whereas there was no significant 
effect for HSA particles. Overall, PTFE particles are recommended to test 
formulations for the “invisible particles effect” by LO, for an RI range up to 1.38. 
This range covers protein formulations with protein concentrations up to at least 
150 mg/mL IgG (RI 1.3711) or 200 mg/mL HSA and 10% sucrose (RI 1.38, own 
results).  
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Figure 6-10: (A) Particle counts of PTFE particles at a fixed concentration determined by 
LO and MFI in sucrose solutions of varying RI. The red box indicates the range in which 
PTFE particles could be used to test specific formulations for the “invisible particles 
effect”. The additional x-axis shows the RI of the respective solutions. Stars (*) indicate 
data points differing significantly from the initial concentration (ANOVA, p < 0.05). 
(B) Particle counts of PTFE determined by LO and MFI in a solution containing HSA and 
sucrose in pharmaceutically relevant concentrations for an application test of PTFE 
particles as model particles. Stars (*) indicate significant differences between data 
points (ANOVA, p < 0.05). Error bars represent standard deviations from triplicate 
samples (dilutions were prepared in triplicates). 
 
A group from the National Institute of Standards and Technology (NIST) also 
aimed to develop more proteinaceous particle standards and identified 
ethylenetetrafluoroethylene (ETFE) as a proper material.26 This supports the 
general suitability of fluorinated polymers as protein particle-like materials and 
encourages searching for potentially even better fitting candidates within this 
class of materials. 
In order to examine the formulation of interest for the “invisible particles effect” 
by means of PTFE particles, we suggest the following procedure: spike the same 
amount of a highly-concentrated PTFE particle suspension into water and into the 
formulation of interest, to achieve a final concentration similar to that expected 
in the protein formulation to be analyzed. Determine the apparent particle 
concentration of PTFE particles in both solutions by LO. A significant difference 
points towards a potential “invisible particles effect” for the analysis of protein 
particles in the formulation of interest. In this case, we recommend including 
orthogonal analytical techniques, preferably techniques with light-independent 
underlying principles such as ESZ or RMM (see below).  
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PTFE particles might furthermore serve as a protein particle surrogate material 
for the comparison of different analytical techniques or instruments. This could 
help to explain and bridge differing results for particle concentrations obtained 
from different instruments. 
3.5 Orthogonal techniques for protein particle analysis 
to cope with RI influences 
Difficulties with subvisible particle analysis due to RI influences can be addressed 
by using techniques with other underlying measurement principles. An example 
of a light-independent particle counting technique is the ESZ method (e.g. 
Coulter counter) which was originally developed for cell counting, but has 
recently also been applied for the analysis of protein particles.11,36,42-44 Drawbacks 
of ESZ are the large required sample volume and that the sample needs to be 
suspended in a conductive solution if the sample buffer does not have sufficient 
conductivity. 
Another non-optical technique for particle counting and sizing that has recently 
become commercially available is the Archimedes system. In this technique, the 
principle of RMM is applied using a suspended microchannel resonator (SMR) or 
microcantilever, which resonates mechanically and changes its frequency 
depending on the buoyant mass of particles passing the channel.17-19 The 
buoyant mass is converted to absolute mass and then to particle size based on 
the density of both particle and fluid. We evaluated RMM as an orthogonal 
technique to LO and MFI for IgG A particles (stirring) in phosphate buffer 
containing 0% or 20% sucrose and compared apparent particle concentrations in 
the overlapping size range of 1-4 µm (Figure 6-11). The IgG particle 
concentration in phosphate buffer determined by RMM was in a similar range as 
determined by LO. In 20% sucrose, significantly less particles were detected by 
LO and MFI as compared to phosphate buffer (similar as in Figure 6-5D). In 
contrast, no significant difference was found for the same conditions by RMM. 
This emphasizes the suitability of light-independent techniques for the analysis of 
particles in therapeutic protein formulations and it can be recommended that 
they be included in an analytical package. This is especially important for 
formulations containing high protein concentration and/or excipients that 
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increase the RI of the formulation such as sugars. Otherwise, by applying only 
light-based methods particle counts in therapeutic protein formulations may be 
significantly underestimated. 
 
Figure 6-11: Particle counts of IgG A particles (stirring) at a fixed concentration 
determined by LO, MFI, and RMM in pure phosphate buffer (0% sucrose) and phosphate 
buffer containing 20% sucrose in the overlapping size range between the three systems. 
Results were calculated back to the original concentration as samples were analyzed in 
different dilutions due to different concentration limits of the systems. Stars (*) indicate 
significant differences between data points (ANOVA, p < 0.05). Error bars represent 
standard deviations from triplicate samples (dilutions were prepared in triplicates) for 
MFI and LO and for a triplicate measurement for RMM. 
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4 Conclusion 
Our study showed that transparency, which is related to the RI of both particles 
and formulation, is an important parameter for protein particle analysis by light-
based techniques. A fast batch method for RI determination of protein particles 
developed in this study provided an RI of 1.41 for protein particles generated by 
heat as well as mechanical stress. We envision the use of the method for 
research purposes in the development phase to get an insight into the RI of the 
particles of a certain protein and to judge the suitability of light-based methods 
for detecting subvisible particles suspended in a specific formulation. The RI 
difference between protein particles and surrounding formulation has a strong 
influence on the performance of LO and MFI. At pharmaceutically relevant 
sucrose concentrations (5%) and protein concentrations (100 mg/mL), the 
particle concentrations were clearly underestimated by LO and MFI. An RI match 
even caused particles to become “invisible” for the system, i.e. not detectable 
anymore by LO and MFI. Therefore, increased attention is required in the 
evaluation of subvisible particle analysis in formulations of high protein 
concentration and/or sugars. To address the influence of the RI, we recommend 
two alternatives: (1) Use of PTFE particles as model particles to test specific 
formulations for an RI influence in LO, because these particles have similar 
optical properties to protein particles. (2) Include light-independent techniques, 
e.g. RMM (Archimedes), in the analytical package as RMM was not affected at all 
by increased RI in the formulation. These procedures should help to avoid 
significant underestimation of the particle concentration in therapeutic protein 
formulations due to RI influences; which is critical for both development and 
release. 
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            Chapter 7
           
Summary of the thesis 
The overall goal of this thesis was to identify and evaluate critical factors for 
protein particle analysis and to apply this knowledge for the development of 
novel standardized protein-like particles. Thorough analysis of particles in 
therapeutic protein formulations is crucial due to regulatory requirements, the 
potential immunogenicity of protein aggregates and particles, and the need for 
quality and stability control of the product. 
Chapter 1 provides a comprehensive overview of analytical methods for the 
detection and characterization of particles in therapeutic protein formulations. 
The extensive portfolio of available methods does not only offer more flexibility 
and cross-validation of results, but also brings along the difficulty how to handle 
and to interpret differing results from several analytical techniques or 
instruments. In this chapter, the underlying theory, output parameters, benefits, 
shortcomings, and illustrative examples for each technique are described. In this 
context, the necessity of method evaluation before data analysis is outlined 
which requires the development of novel more proteinaceous particle standards. 
In Chapter 2, novel techniques or instruments (Sysmex FPIA-3000 and Occhio 
FC200S+ (flow imaging microscopy), Coulter counter Multisizer 4 (electrical 
sensing zone (ESZ)), Archimedes (resonant mass measurement (RMM)), rapID 
(image directed Raman spectroscopy)) were evaluated regarding their 
performance for (protein) particle counting, sizing, or characterization. Results 
from flow imaging microscopy differed strongly depending on the applied settings 
and the used system. More established flow imaging techniques such as Micro-
Flow Imaging (MFI) or FlowCAM were regarded preferable in this case. The non-
optical particle techniques ESZ and RMM presented useful additions to the pool of 
techniques as they provided good size and count accuracy when compared to the 
established techniques dynamic light scattering (DLS) or nanoparticle tracking 
analysis (NTA). Particle identification by rapID proved to be an interesting 
approach, but with the need for further improvements. Chapter 2 showed that 
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novel techniques for particle analysis can be useful, but their strengths, 
weaknesses, and output parameters need to be evaluated thoroughly for the 
intended application. 
A prominent application in the field of particle analysis is the differentiation of 
protein particles from silicone oil droplets. The latter may especially be 
introduced into products filled in prefilled syringes which are siliconized for 
lubrication. Chapter 3 describes this critical differentiation by MFI and RMM for 
samples of artificially generated silicone oil droplets and protein particles in 
controllable defined mixtures. MFI was identified as reliable for particles with a 
size above 2 µm and with moderate droplet/particle ratios (70:30 – 30:70) when 
using the built-in software algorithm for the identification of similar particle 
images. The performance could be improved, especially for more extreme ratios 
(95:5 – 15:85), by a customized filter which was developed specifically for this 
study based on particle transparency and shape. RMM was considered as highly 
accurate for particles from 0.5 to 2 µm if the total droplet/particle concentration 
was in a statistically sufficient range. As a conclusion from this chapter, MFI and 
RMM should be applied as orthogonal techniques in combination to achieve an 
accurate and reliable differentiation of protein particles and silicone oil droplets. 
Flow imaging microscopy is of increasing importance due to extended particle 
characterization possibilities beyond sizing and counting. Therefore, regulatory 
agencies tend to include the technique into the pharmacopeias, in addition to the 
conventional technique of light obscuration (LO). However, results from flow 
imaging microscopy may vary substantially depending on the used instrument as 
observed in Chapter 2. In Chapter 4, four of the pharmaceutically most relevant 
flow imaging microscopy systems (MFI4100, MFI5200, FlowCAM VS1, and 
FlowCAM PV) were subjected to a detailed evaluation of particle quantification, 
characterization, image quality, differentiation of protein particles and silicone oil 
droplets, and handling of the systems. The FlowCAM systems provided higher 
image quality and were more flexible with respect to adjustment of settings, 
whereas the MFI systems appeared more useful for standardized applications. In 
detail, the FlowCAM VS1 was considered as the best choice for high resolution 
images, the FlowCAM PV for an accurate quantification and differentiation of 
protein particles and silicone oil droplets. The MFI systems showed their strength 
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in size and count accuracy, the MFI5200 was especially suitable for protein 
particle analysis under impaired optical conditions by an increased refractive 
index of the formulation. The results from this chapter indicate again that the 
choice of the appropriate instrument depends strongly on the output parameters 
of interest. 
Based on the knowledge on critical particle properties in different analytical 
techniques acquired in the previous chapters, a material screening for the 
development of novel standardized protein-like particles for light-based 
techniques was performed in Chapter 5. In the screening, proteinaceous (human 
serum albumin (HSA)-starch particles, spray-dried HSA, gelatin particles, and 
zein) and non-proteinaceous materials (chitosan and polytetrafluoroethylene 
(PTFE)) were assessed regarding their optical similarity to particles of therapeutic 
proteins (represented by HSA particles generated by heat stress). Based on 
numerous particle properties (size, size distribution, shape, transparency, and 
stability) gelatin and PTFE particles were considered the most promising 
materials for light-based applications. The density of protein particles, as a 
crucial particle parameter for weight-based techniques like RMM, has not been 
characterized well up to now. Thus, two novel methods based on RMM for density 
determination of pure protein and protein particles including entrapped liquid 
were developed. The methods provided a density of about 1.4 g/mL for pure 
protein (rituximab and gelatin), in congruence with theoretically calculated values 
of 1.38-1.44 g/mL. For protein particles including entrapped liquid an apparent 
density of about 1.07 g/mL was obtained for rituximab particles generated by 
heat stress. This chapter indicated that both gelatin particles and PTFE might be 
valuable in the development of standardized protein-like particles depending on 
the application purpose: gelatin particles might be suitable for both light-based 
and weight-based techniques whereas PTFE particles could be used for light-
based techniques. 
As many analytical techniques for protein particles are based on the interaction 
of the particles with light, the particle transparency plays a crucial role for 
accurate particle quantification on the one hand and the development of suitable 
standardized protein-like particles on the other hand. Chapter 6 is focused on the 
relevance of the refractive index (RI), which is closely related to transparency, 
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for particle analysis. As the RI of protein particles has been unknown until now, a 
novel method for RI determination of protein particles was developed. This 
method provided an RI of 1.41 for particles from two different therapeutic 
proteins (HSA and IgG). The relevance of the RI was then investigated by 
increasing the RI of the surrounding formulation until particles became 
“invisible”, i.e. not detectable anymore by light-based systems (in this case LO 
and MFI) at the RI match. As an increased RI is of practical significance at high 
protein concentration and/or the use of excipients such as sugars, potential 
solution strategies were also investigated in this chapter. As a result, PTFE 
particles, as identified in the material screening in Chapter 5, turned out to be 
suitable to test a specific formulation for RI effects. Furthermore, light-
independent techniques such as RMM can be beneficial in case of RI influences. 
Taken together, this study provides new insight into the analysis of particles in 
therapeutic protein formulations. It illustrates that it is crucial to not only 
comprehensively understand the techniques’ principle and limitations, but to also 
evaluate data from different techniques carefully in order to draw reliable 
conclusions. In this regard, potential candidates for the development of novel 
standardized protein-like particles identified in this study are very valuable and 
can help to improve protein particle analysis in the future. 
 
SARAH ZÖLLS                                                   APPENDIX 
i 
 
Publications and presentations associated 
with this thesis 
Review articles 
S. Zölls, R. Tantipolphan, M. Wiggenhorn, G. Winter, W. Jiskoot, W. Friess, 
A. Hawe: “Particles in therapeutic protein formulations, part 1: overview of 
analytical methods”; J Pharm Sci 101(3):914-935 (2012) 
 
Book chapters 
A. Hawe, S. Zölls, A. Freitag, J. F. Carpenter: “Subvisible and visible particle 
analysis in biopharmaceutical research and development”, in Biophysical 
characterization of proteins in developing biopharmaceuticals, Elsevier, editors: 
D. Houde, S. Berkowitz (submitted) 
 
Research articles 
S. Zölls, M. Gregoritza, R. Tantipolphan, M. Wiggenhorn, G. Winter, W. Friess, 
A. Hawe: “How subvisible particles become invisible – relevance of the refractive 
index for protein particle analysis”; J Pharm Sci 102(5):1434-1446 (2013) 
D. Weinbuch*, S. Zölls*, M. Wiggenhorn, W. Friess, G. Winter, W. Jiskoot, 
A. Hawe: “Micro-Flow Imaging and resonant mass measurement (Archimedes) – 
complementary methods to quantitatively differentiate protein particles and 
silicone oil droplets”; J Pharm Sci 102(7):2152-2165 (2013); *joint first authors 
S. Zölls*, D. Weinbuch*, M. Wiggenhorn, G. Winter, W. Friess, W. Jiskoot, 
A. Hawe: “Flow imaging microscopy for protein particle analysis – a comparative 
evaluation of four different analytical instruments”; The AAPS Journal (accepted); 
*joint first authors 
 
Oral presentations 
S. Zölls: “Micro-Flow Imaging for protein particles – getting more than just 
numbers”. Protein Simple User Meeting, Basel, CH, July 3-4, 2012 
APPENDIX                                                                                               SARAH ZÖLLS 
ii 
 
Poster presentations 
S. Zölls, D. Weinbuch, M. Wiggenhorn, G. Winter, W. Friess, W. Jiskoot, 
A. Hawe: “Comparative evaluation of four different flow imaging microscopy 
instruments for protein particle analysis”; National Biotech Conference, San 
Diego, CA, May 20-22, 2013 
S. Zölls, D. Weinbuch, M. Wiggenhorn, G. Winter, W. Friess, W. Jiskoot, 
A. Hawe: “Micro-Flow Imaging and resonant mass measurement (Archimedes) 
for the differentiation of silicone oil droplets and protein particles”; PepTalk, Palm 
Springs, CA, January 21-25, 2013; and National Biotech Conference, San Diego, 
CA, May 20-22, 2013 
S. Zölls, D. Weinbuch, W. Friess, A. Hawe: “Differentiation of silicone oil droplets 
and protein particles by MFI and RMM”; Controlled Release Society (CRS) 
German Local Chapter Meeting, Ludwigshafen, Germany, March 21-22, 2013 
S. Zölls, R. Tantipolphan, M. Wiggenhorn, G. Winter, W. Friess, A. Hawe: 
“Evaluation of Archimedes and Coulter counter for the analysis of (protein) 
particles”; National Biotech Conference, San Diego, CA, May 21-22, 2012 
S. Zölls, M. Gregoritza, R. Tantipolphan, M. Wiggenhorn, G. Winter, W. Friess, 
A. Hawe: “How subvisible particles get invisible - Relevance of refractive index 
for protein particle analysis”; PEGS Protein engineering summit, Boston, MA, 
April 30 – May 3, 2012; and National Biotech Conference, San Diego, CA, May 
21-22, 2012 
S. Zölls, R. Tantipolphan, M. Wiggenhorn, G. Winter, W. Friess, A. Hawe: 
“Comparative analysis of subvisible particles induced by freeze-thawing, stirring 
and heating of an IgG antibody”; Colorado Protein Stability Conference, 
Breckenridge, CO, July 19-21, 2011; and National Biotech Conference, San 
Francisco, CA, May 16-18, 2011 
S. Mickisch, R. Tantipolphan, M. Wiggenhorn, W. Friess, G. Winter, A. Hawe: 
“Subvisible particles in a monoclonal antibody formulation analyzed by 
nanoparticle tracking analysis and Micro-Flow Imaging”; National Biotech 
Conference, San Francisco, CA, May 16-19, 2010; and Workshop on protein 
aggregation and immunogenicity, Breckenridge, CO, July 20-22, 2010 
SARAH ZÖLLS                                                   APPENDIX 
iii 
 
Curriculum vitae 
SARAH ZÖLLS, GEB. MICKISCH 
 
PERSONAL DETAILS 
Date of birth:  23.04.1984               
Place of birth:  Starnberg             
Nationality:   German 
 
EDUCATION 
05/2010 - 06/2013  PhD studies       
   Coriolis Pharma, Martinsried    
   Supervisor: Dr. Andrea Hawe    
   in collaboration with Department of Pharmacy,  
   Pharmaceutical Technology and Biopharmaceutics, 
   Ludwig-Maximilians-Universität München  
   Supervisor: Prof. Dr. Wolfgang Frieß 
10/2009 - 04/2010  Research project      
   Max Planck Institute of Biochemistry   
   Supervisor: Prof. Dr. F.-Ulrich Hartl 
10/2007 – 09/2009 Studies of Pharmaceutical Sciences (M.Sc.)  
   Ludwig-Maximilians-Universität München  
09/2007 – 04/2008  Research stay      
   Oncology Research Institute, Greenville, SC, USA 
   Supervisor: Prof. Dr. Xianzhong Yu 
10/2004 – 08/2007 Studies of Pharmaceutical Sciences (B.Sc.)  
   Ludwig-Maximilians-Universität München  
10/2003 – 07/2004 Studies of Pharmacy     
   Ludwig-Maximilians-Universität München  
09/1994 – 07/2003  Highschool, graduation with “Abitur”   
   Gymnasium Starnberg 
